Amikacin is a semi-synthetic aminoglycoside antibiotic, derived from kanamycin A. It is effective against a wide range of gram-negative bacteria, including those resistant to other aminoglycosides. Amikacin is synthesized by chemical modification of kanamycin A, involving the addition of a 4-amino-2-hydroxybutyric acid (AHBA) group. Its mechanism of action involves binding to the 16S ribosomal RNA of bacterial ribosomes, inhibiting protein synthesis and leading to bacterial death. Amikacin is commonly used to treat serious infections caused by gram-negative bacteria, such as pneumonia, sepsis, and urinary tract infections. It is often administered intravenously or intramuscularly. Amikacin is an important antibiotic due to its broad-spectrum activity and its effectiveness against multidrug-resistant bacteria. It is also studied for its potential to treat other diseases, such as tuberculosis and cancer. Its importance lies in its effectiveness against a broad range of gram-negative bacteria, including those resistant to other aminoglycosides, making it a valuable therapeutic option for serious infections. Research on amikacin focuses on its potential to treat other diseases, such as tuberculosis and cancer, as well as exploring new ways to improve its efficacy and reduce its side effects.'
(R)-3-hydroxybutyrylcarnitine : An O-hydroxybutyryl-L-carnitine in which the acyl group is specified as 3-hydroxybutyryl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 90659885 |
| CHEBI ID | 84842 |
| MeSH ID | M0000903 |
| PubMed CID | 16307093 |
| CHEMBL ID | 3393145 |
| SCHEMBL ID | 17938602 |
| MeSH ID | M0000903 |
| PubMed CID | 37768 |
| CHEMBL ID | 177 |
| CHEBI ID | 2637 |
| SCHEMBL ID | 2985 |
| MeSH ID | M0000903 |
| Synonym |
|---|
| o-3-hydroxybutanoyl-(r)-carnitine |
| CHEBI:84842 |
| hydroxybutyrylcarnitine |
| 3-hydroxybutyryl-l-carnitine |
| (3r)-3-[(3-hydroxybutanoyl)oxy]-4-(trimethylazaniumyl)butanoate |
| (r)-3-hydroxybutyrylcarnitine |
| 875668-57-8 |
| Q27158110 |
| DTXSID701334829 |
| (3r)-3-((3-hydroxybutanoyl)oxy)-4-(trimethylammonio)butanoate |
| chembl3393145 , |
| bdbm50059083 |
| AKOS007999700 |
| S7365 |
| HY-15848 |
| adiporon , |
| c27h28n2o3 |
| AM85966 |
| 924416-43-3 |
| acetamide,2-(4-benzoylphenoxy)-n-[1-(phenylmethyl)-4-piperidinyl]- |
| 2-(4-benzoylphenoxy)-n-(1-benzyl-4-piperidinyl)acetamide |
| AN-465/43506510 |
| 2-(4-benzoylphenoxy)-n-(1-benzylpiperidin-4-yl)acetamide |
| EX-A283 |
| sc-396658 , |
| SCHEMBL17938602 |
| HMS3653C18 |
| NCGC00370758-10 |
| 2-(4-benzoylphenoxy)-n-[1-(phenylmethyl)-4-piperidinyl]acetamide |
| SW219831-1 |
| FT-0700407 |
| Z32352521 |
| AS-35052 |
| mfcd08271060 |
| BCP08895 |
| 2-(4-benzoylphenoxy)-n-(1-(phenylmethyl)-4-piperidinyl)acetamide |
| acetamide, 2-(4-benzoylphenoxy)-n-(1-(phenylmethyl)-4-piperidinyl)- |
| ND7UVH6GKJ , |
| SB17384 |
| CCG-268984 |
| SY103513 |
| ZLB41643 |
| unii-nd7uvh6gkj |
| EN300-80366 |
| AC-35903 |
| bay 41-6551 |
| CHEMBL177 |
| potentox |
| o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->4)-o-(6-amino-6-deoxy-alpha-d-glucopyranosyl-(1->6))-n(3)-(4-amino-l-2-hydroxybutyryl)-2-deoxy-l-streptamine |
| amikacine |
| amikacinum |
| CHEBI:2637 , |
| (2s)-4-amino-n-[(1r,2s,3s,4r,5s)-5-amino-2-(3-amino-3-deoxy-alpha-d-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-d-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide |
| amikacina |
| 1-n-(l(-)-gamma-amino-alpha-hydroxybutyryl)kanamycin a |
| (2s)-4-amino-n-{(1r,2s,3s,4r,5s)-5-amino-2-[(3-amino-3-deoxy-alpha-d-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-d-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide |
| D02543 |
| amikacin (usp/inn) |
| BSPBIO_000609 |
| cas-37517-28-5 |
| amikin |
| NSC177001 , |
| amikin (disulfate) |
| bb-k8 |
| (2s)-4-amino-n-[(1r,2s,3s,4r,5s)-5-amino-2-[(2s,3r,4s,5s,6r)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-4-[(2r,3r,4s,5s,6r)-6-(aminomethyl)-3,4,5-trihydroxy-tetrahydropyran-2-yl]oxy-3-hydroxy-cyclohexyl]-2-hydroxy-butanamide |
| o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1->6)-o-[6-amino-6-deoxy-.alpha.-d-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-d-streptamine |
| AMK , |
| BPBIO1_000671 |
| PRESTWICK3_000395 |
| AB00513828 |
| 37517-28-5 |
| amikacin |
| C06820 |
| NCGC00093350-02 |
| DB00479 |
| nsc-177001 |
| NCGC00093350-03 |
| amikacinum [inn-latin] |
| mikavir |
| d-streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-6)-o-(6-amino-6-deoxy-alpha-d-glucopyranosyl-(1-4))-n(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (s)- |
| amikacine [inn-french] |
| kaminax |
| d-streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->6)-o-(6-amino-6-deoxy-alpha-d-glucopyranosyl-(1->4))-n(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (s)- |
| d-streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-6)-o-(6-amino-6-deoxy-alpha-d-glucopyranosyl-(1-4))-n1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (s)- |
| o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(6-amino-6-deoxy-alpha-d-glucopyranosyl-(1-6))-n(sup 3)-(4-amino-l-2-hydroxybutyryl)-2-deoxy-l-streptamine |
| amiglyde-v |
| amikacina [inn-spanish] |
| amikavet |
| arikace |
| hsdb 3583 |
| lukadin |
| bb-k 8 |
| nsc 177001 |
| einecs 253-538-5 |
| amicacin |
| antibiotic bb-k 8 |
| STK039706 |
| (2s)-4-amino-n-[(1r,2s,3s,4r,5s)-5-amino-2-[(2s,3r,4s,5s,6r)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2r,3r,4s,5s,6r)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide |
| amukin |
| A823716 |
| dtxsid3022586 , |
| dtxcid002586 |
| tox21_111201 |
| amikacin base |
| amikacin dihydrate |
| AKOS005383276 |
| d-streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1.fwdarw.6)-o-(6-amino-6-deoxy-alpha-d-glucopyranosyl-(1.fwdarw.4))-n1-((2s)-4-amino-2-hydroxy-1-oxobutyl)-2-deoxy- |
| bay41-6551 |
| 84319sgc3c , |
| amikacillin |
| amikozit |
| amikacin [usp:inn:ban] |
| unii-84319sgc3c |
| mat2501 |
| n1-[(s)-4-amino-2-hydroxybutyryl]kanamycin a |
| amikacin (free base) |
| (2s)-n-[(1r,2s,3s,4r,5s)-4-[(2r,3r,4s,5s,6r)-6-(aminomethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5-azanyl-2-[(2s,3r,4s,5s,6r)-4-azanyl-6-(hydroxymethyl)-3,5-bis(oxidanyl)oxan-2-yl]oxy-3-oxidanyl-cyclohexyl]-4-azanyl-2-oxidanyl-butanamide |
| AKN , |
| amikacin [jan] |
| amikacin [mart.] |
| amikacinum [who-ip latin] |
| d-streptamine, o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1->6)-o-(6-amino-6-deoxy-.alpha.-d-glucopyranosyl-(1->4))-n(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (s)- |
| o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(6-amino-6-deoxy-.alpha.-d-glucopyranosyl-(1->6))-n(sup 3)-(4-amino-l-2-hydroxybutyryl)-2-deoxy-l-streptamine |
| amikacin [usp monograph] |
| amikacin [ep monograph] |
| amikacin [inn] |
| amikacin [usp-rs] |
| amikacin [mi] |
| amikacin [who-ip] |
| amikacin [hsdb] |
| amikacin [vandf] |
| amikacin [who-dd] |
| HY-B0509A |
| SCHEMBL2985 |
| tox21_111201_1 |
| W-106531 |
| amikacin, antibiotic for culture media use only |
| d-streptamine, o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1->6)-o-[6-amino-6-deoxy-.alpha.-d-glucopyranosyl-(1->4)]-n1-[(2s)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy- |
| AB00513828_06 |
| bdbm50237603 |
| mfcd00883675 |
| (2s)-4-amino-n-[(1r,2s,3s,4r,5s)-5-amino-2-{[(2s,3r,4s,5s,6r)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-{[(2r,3r,4s,5s,6r)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide |
| (2s)-n-[(1r,2s,3s,4r,5s)-4-[(2r,3r,4s,5s,6r)-6-(aminomethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5-azanyl-2-[(2s,3r,4s,5s ,6r)-4-azanyl-6-(hydroxymethyl)-3,5-bis(oxidanyl)oxan-2-yl]oxy-3-oxidanyl-cyclohexyl]-4-azanyl-2-oxidanyl-butanamide |
| (s)-4-amino-n-((1r,2s,3s,4r,5s)-5-amino-2-(((2s,3r,4s,5s,6r)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-4-(((2r,3r,4s,5s,6r)-6-(aminomethyl)-3,4,5-trihydroxytetrahydro-2h-pyran-2-yl)oxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide |
| nktr-061 |
| ,6r)-4-azanyl-6-(hydroxymethyl)-3,5-bis(oxidanyl)oxan-2-yl]oxy-3-oxidanyl-cyclohexyl]-4-azanyl-2-oxidanyl-butanamide |
| (2s)-n-[(1r,2s,3s,4r,5s)-4-[(2r,3r,4s,5s,6r)-6-(aminomethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5-azanyl-2-[(2s,3r,4s,5s |
| (s)-4-amino-n-((1r,2s,3s,4r,5s)-5-amino-2-((2s,3r,4s,5s,6r)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)-4-((2r,3r,4s,5s,6r)-6-(aminomethyl)-3,4,5-trihydroxytetrahydro-2h-pyran-2-yloxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide |
| amikacin,(s) |
| Q408529 |
| arikayce liposomal |
| gtpl10894 |
| amikacin; 6-o-(3-amino-3-deoxy-?-d-glucopyranosyl)-4-o-(6-amino-6-deoxy-?-d-glucopyranosyl)-1-n-[(2s)-4-amino-2-hydroxybutanoyl]-2-deoxy-d-streptamine |
| 37517-28-5 (free base) |
| amikacin free base |
| SR-01000722004-6 |
| AS-76985 |
| EN300-7481440 |
| at03 - amikacin |
| td1 - therapeutic drug mixture |
| o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->4)-o-(6-amino-6-deoxy-alpha-d-glucopyranosyl-(1->6))-n(sup 3)-(4-amino-l-2-hydroxybutyryl)-2-deoxy-l-streptamine |
| amikacin (usp monograph) |
| d06ax12 |
| amikacin (ep monograph) |
| amikacinum (inn-latin) |
| j01gb06 |
| amikacinum (latin) |
| amikacine (inn-french) |
| amikacin (usp:inn:ban) |
| amikacin (usp-rs) |
| amikacina (inn-spanish) |
| amikacin (mart.) |
| s01aa21 |
Amikacin (AK) is an aminoglycoside that is widely used to treat life-threatening Gram-negative infections, especially in intensive care units. It is a first-line drug that must be evaluated when performing an antimycobacterial susceptibility test for Mycobacterium avium complex.
Amikacin has a very narrow therapeutic range and can cause very serious side effects such as nephrotoxicity and ototoxicity. Amikac in with Imipenem has a synergistic effect.
Amikacin has a very narrow therapeutic range and can cause very serious side effects such as nephrotoxicity and ototoxicity. It has the similar antibacterial spectrum as gentamicin, dibekacin or tobramycin, but its antibacterial activity is generally weakest among these four drugs.
Amikacin was chosen because of its unique rapid and high mycobacterial killing capacity. It does cause nephrotoxicity and ototoxicity; however there is no conclusive evidence that these toxicities differ from those caused by other major aminoglycosides.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Amikacin plays a key role in the treatment of severe hospital-acquired infections with Gram-negative bacteria. " | ( Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses. Illamola, SM; Sherwin, CM; van Hasselt, JGC, 2018) | 2.21 |
| "Mean amikacin clearance was lower (0.48 to 0.59 ml/kg/min, P <0.001) in infants co-treated with ibuprofen." | ( The impact of ibuprofen on renal clearance in preterm infants is independent of the gestational age. Allegaert, K; Cossey, V; de Hoon, J; Debeer, A; Devlieger, H; Langhendries, JP; Van Overmeire, B, 2005) | 0.78 |
| "Amikacin was chosen because of its unique rapid and high mycobacterial killing capacity." | ( Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice. Bakker-Woudenberg, IA; de Steenwinkel, JE; Schiffelers, RM; Ten Kate, MT; van Agtmael, MA; van Vianen, W; Verbrugh, HA, 2007) | 1.06 |
| "Amikacin does cause nephrotoxicity and ototoxicity; however there is no conclusive evidence that these toxicities differ from those caused by other major aminoglycosides." | ( Antimicrobial spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate. Ho, PW; Pien, FD, 1981) | 1.21 |
| "Amikacin, because of its activity against infections caused by Pseudomonas, Serratia, and other frequently resistant bacteria, as well as its ability to achieve high blood and tissue levels, provides a significant advantage over other aminoglycoside agents in hospitalized urologic patients with suspected nosocomial infections." | ( Overview of first-line amikacin therapy for urologic infections. Carson, CC; Paulson, DF; Rudd, C, 1985) | 1.3 |
Amikacin treatment duration modified the effect of the dosage on the risk of hearing loss, increasing this risk as the duration increased. In amikacIn-treated animals, deterioration was evident in the threshold and tuning properties of cortical neurons, particularly in those cells whose input originated in damaged cochlear regions.
Amikacin ODD is as safe and effective as the MDD regimen. The toxic threshold doses were found to be within the range of human therapeutic dosages.Experiments with rabbits demonstrated no toxic effects on the retina after vitrectomy.
Amikacin requires pharmacodynamic targets of peak serum concentration (Cmax) of 8-10 times the minimal inhibitory concentration, corresponding to a target Cmax of 60-80 mg/L for the less susceptible bacteria.
The stability of aminoglycosides gentamicin, tobramycin, and amikacin stored in combination with carbenicillin, piperacillin, cefotaxime, and moxalactam was evaluated at four temperatures (25, 4, -8, and -70 degrees C) over a 3-week period. The in vitro bactericidal interactions of three new extended-spectrum cephalosporins were compared against 40 recent nosocomial bloodstream Enterobacteriaceae isolates.
| Excerpt | Reference | Relevance |
|---|---|---|
| " The aim of this study was to characterize the metabolites of AdipoRon in rat and human liver microsomes using ultra-high performance liquid chromatography combined with Q-Exactive Orbitrap tandem mass spectrometry (UPLC-Q-Exactive-Orbitrap-MS) together with data processing techniques including extracted ion chromatograms and a mass defect filter." | ( Characterization of the metabolite of AdipoRon in rat and human liver microsomes by ultra-high-performance liquid chromatography combined with Q-Exactive Orbitrap tandem mass spectrometry. Ge, Y; Li, X; Liu, Q; Yu, Y; Zhang, Y, 2019) | 0.51 |
| "The in vitro effects of Bay k 4999 in combination with gentamicin, tobramycin, amikacin sisomicin and netilmicin in bacteriostatic (MIC) and bactericidal (MBC) concentrations were compared using the checkerboard dilution technique against 20 different strains of Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and indole-positive-negative Proteus species." | ( In vitro efficacy of Bay k 4999, a new ureido-penicillin, in combination with aminoglycosides against Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Proteus strains. Daschner, FD; Langmaack, H; Steffens, A, 1979) | 0.49 |
| " Tobramycin was the most effective aminoglycoside when used in combination with beta-lactam antibiotics." | ( In vitro activity of cefamandole, cefoxitin, cefuroxime, and carbenicillin, alone and in combination with aminoglycosides against Serratia marcescens. Bartlett, M; Crane, JK; Griffin, PS; Miller, MA; Yousuf, M, 1979) | 0.26 |
| "Continuous infusions of gentamicin, amikacin or sisomicin combined with carbenicillin were compared in a randomized study in the treatment of 572 febrile episodes in 281 patients with cancer." | ( A randomized comparative trial of three aminoglycosides--comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Bodey, GP; Keating, MJ; Rodriguez, V; Valdivieso, M, 1979) | 0.75 |
| "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection." | ( TLC G-65 in combination with other agents in the therapy of Mycobacterium avium infection in beige mice. Cynamon, MH; Klemens, SP; Swenson, CE, 1992) | 0.28 |
| " In this report, we investigated the therapeutic effect of G-CSF alone and in combination with Amikacin (20 mg/kg) against experimental urinary tract infection induced by Pseudomonas aeruginosa in diabetic mice." | ( [Study of the increasing effect of therapeutic efficacy of amikacin in combination with human granulocyte-colony stimulating factor (G-CSF) against experimental urinary tract infection in diabetic mice]. Hirose, T; Kumamoto, Y; Tanaka, N; Yokoo, A, 1991) | 0.74 |
| "The post-antibiotic effect (PAE) of amikacin alone and in combination with ceftazidime, ceftriaxone and piperacillin was studied for two strains each of Pseudomonas aeruginosa and Serratia marcescens using a bioluminescent assay of bacterial ATP." | ( Synergic post-antibiotic effect of amikacin in combination with beta-lactam antibiotics on gram-negative bacteria. Hanberger, H; Isaksson, B; Maller, R; Nilsson, LE; Nilsson, M, 1991) | 0.83 |
| " When clarithromycin was tested against three MAC strains in combination with another drug, it showed a synergistic effect only when combined with rifampicin." | ( In vitro activity of clarithromycin alone or in combination with other antimicrobial agents against Mycobacterium avium-intracellulare. Complex strains isolated from AIDS patients. De Gregoris, P; Fattorini, L; Hu, CQ; Iona, E; Mascellino, MT; Orefici, G; Santoro, C, 1991) | 0.28 |
| " The PAE of amikacin in combination with 32 mg/l piperacillin on Ps." | ( The postantibiotic effect of amikacin alone and in combination with piperacillin on gram-negative bacteria. Hanberger, H; Isaksson, B; Maller, R; Nilsson, LE; Nilsson, M, 1990) | 0.95 |
| "The effect of amikacin and two new macrolides (roxithromycin and azithromycin) used either alone or in combination with recombinant tumor necrosis factor (TNF) to inhibit or kill Mycobacterium avium complex in human macrophages was examined in vitro." | ( Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex. Bermudez, LE; Young, LS, 1988) | 1 |
| "The in vivo activity of amikacin, used alone or in combination with rifabutin or clofazimine or both, was assessed in the treatment of early and established Mycobacterium avium complex infections in beige mice." | ( In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. Gangadharam, PR; Iseman, MD; Kesavalu, L; Perumal, VK; Podapati, NR, 1988) | 0.91 |
| " We conclude that ceftazidime should be given in combination with a conventional full course of an aminoglycoside (amikacin) when used for the empirical treatment of gram-negative bacteremia in cancer patients with granulocytopenia." | ( Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. Calandra, T; Gaya, H; Glauser, MP; Klastersky, J; Meunier, F; Zinner, SH, 1987) | 0.73 |
| " A trial of ceftazidime (3 g/day) administered alone or combined with amikacin or vancomycin is currently in progress in two medical centres." | ( [Antibiotic therapy protocol using ceftazidime 3g/day alone or in combination with vancomycin or amikacin. In febrile episodes in neutropenic patients]. Ajchenbaum, F; Baume, D; Chiche, D; Delmer, A; Fitoussi, F; Marie, JP; Pico, JL; Richet, H; Rio, B; Tancrède, C, 1988) | 0.73 |
| "The antibacterial activity of imipenem combined with norfloxacin, ciprofloxacin, or ofloxacin against 43 gram-positive cocci and 53 aerobic gram-negative rods compared to results obtained with the combination of imipenem with amikacin." | ( In vitro antibacterial activity of imipenem in combination with newer quinolone derivatives. Gulden, H; Kern, W; Kurrle, E; Vanek, E, 1988) | 0.46 |
| "We report the excellent therapeutic response obtained with amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of 15 patients with actinomycotic mycetoma who had a poor response to the traditional pharmacologic agents and/or in whom important organs such as lungs, spinal cord, and bone were involved." | ( Amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic mycetoma. Gonzalez, J; Ocampo, J; Sauceda, E; Welsh, O, 1987) | 1.96 |
| "One hundred febrile episodes in neutropenic (PMN less than 500/mm3) patients were treated with Timentin alone or in combination with amikacin." | ( A prospective randomized study comparing the efficacy of Timentin alone or in combination with amikacin in the treatment of febrile neutropenic patients. Bru, JP; Hollard, D; Leautet, JB; Legrand, C; Michallet, M; Micoud, M; Sotto, JJ; Stahl, JP; Swierz, P, 1986) | 0.69 |
| "The in vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against 50 Pseudomonas aeruginosa strains was studied by the broth dilution method and the time-kill curve method." | ( In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa. Watanakunakorn, C, 1983) | 0.71 |
| "The in vitro bactericidal interactions of three new extended-spectrum cephalosporins (ceftriaxone, ceftizoxime, or ceftazidime) in combination with gentamicin or amikacin were compared against 40 recent nosocomial bloodstream Enterobacteriaceae isolates by the timed-kill curve technique." | ( Enhanced in vitro bactericidal activity of amikacin or gentamicin combined with three new extended-spectrum cephalosporins against cephalothin-resistant members of the family Enterobacteriaceae. Bayer, AS; Eisenstadt, R; Morrison, JO, 1984) | 0.73 |
| "The in vitro activities of imipenem (formerly imipemide, N-formimidoyl thienamycin, or MK0787) and amikacin in combination with cefotaxime, trimethoprim-sulfamethoxazole, and each other were tested against 26 Nocardia asteroides strains." | ( Synergism of imipenem and amikacin in combination with other antibiotics against Nocardia asteroides. Aulicino, TM; Gombert, ME, 1983) | 0.78 |
| "Serum bactericidal activity (SBA) was studied in vitro after intravenous administration of cefoperazone alone or in combination with mezlocillin or amikacin to human volunteers." | ( Comparative study of the serum bactericidal activity of cefoperazone alone and in combination with amikacin or mezlocillin against gram-negative bacilli and Staphylococcus aureus. Klastersky, J; Lagast, H; Standiford, H; Viollier, A, ) | 0.55 |
| "The MIC and MBC activity of mezlocillin alone and in combination with two concentrations of ceftizoxime, moxalactam, and amikacin and a single concentration of cefoxitin was studied in a broth microdilution partial checkerboard against 472 strains of aerobic gram-negative and gram-positive bacteria." | ( In vitro activities of ureidopenicillins alone and in combination with amikacin and three cephalosporin antibiotics. Gerding, DN; Moody, JA; Peterson, LR, 1984) | 0.71 |
| "The in vitro synergistic activity of aztreonam in combination with piperacillin, moxalactam, cefotaxime, cefoperazone, and amikacin was examined against multiply resistant isolates of the family Enterobacteriaceae and Pseudomonas aeruginosa." | ( In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli. Buesing, MA; Jorgensen, JH, 1984) | 0.71 |
| "The stability of the aminoglycosides gentamicin, tobramycin, and amikacin stored in combination with carbenicillin, piperacillin, cefotaxime, and moxalactam was evaluated at four temperatures (25, 4, -8, and -70 degrees C) over a 3-week period." | ( Stability of gentamicin, tobramycin, and amikacin in combination with four beta-lactam antibiotics. Glew, RH; Pavuk, RA, 1983) | 0.77 |
| "The antibacterial in vitro activity of piperacillin and tazobactam (in a concentration ratio of 8/1) was studied in combination with netilmicin or amikacin by a microtiter checkerboard assay against 162 strains of Enterobacteriaceae." | ( [In vitro antibacterial activity of piperacillin-tazobactam in combination with netilmicin or amikacin against Enterobacteriaceae resistant to amoxicillin]. Chamard-Neuwirth, C; Cordin, X; Duez, JM; Kazmierczak, A; Pechinot, A; Siebor, E, 1995) | 0.71 |
| "The in vitro activity of vancomycin and teicoplanin (fourfold the MBC), alone and in combination with amikacin (16 mg/l) or rifampin (1 mg/l), against Staphylococcus epidermidis (slime-producing and non slime-producing strains) biofilms on different plastic catheters was evaluated." | ( Activity of glycopeptides in combination with amikacin or rifampin against Staphylococcus epidermidis biofilms on plastic catheters. Pascual, A; Perea, EJ; Ramirez de Arellano, E, 1994) | 0.76 |
| " These results indicate that IPM/CS alone produces of good response in moderate to severe respiratory infections while IPM/CS combined with AMK is useful in intractable respiratory infections." | ( [Imipenem/cilastatin sodium alone or combined with amikacin sulfate in respiratory infections]. Ichikawa, Y; Ishibashi, T; Oizumi, K; Takamoto, M; Tamaru, N; Tanaka, H; Tokunaga, N; Toyoshima, H; Watanabe, K; Yoshida, M, 1994) | 0.54 |
| " Imipenem was administered as monotherapy (simulated 1-g bolus every 8 or every 12 h) and in combination with amikacin (7." | ( Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model. Lamp, KC; McGrath, BJ; Rybak, MJ, 1993) | 0.72 |
| " malmoense isolates to a number of antibacterial drugs as well as their possible synergistic interactions when each of them was combined with ethambutol." | ( Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. Hjelm, U; Hoffner, SE; Källenius, G, 1993) | 0.29 |
| " The efficacy and safety of meropenem was compared with that of ceftazidime (alone or in combination with amikacin) in 153 patients with septicaemia who were enrolled into identical, prospective, randomised studies." | ( Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin. Sjursen, H; Solberg, CO, 1995) | 0.71 |
| "The in-vitro activities of various antibiotics, either alone or in combination with amikacin were assessed in clinical isolates of Pseudomonas aeruginosa." | ( In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. Gerçeker, AA; Gürler, B, 1995) | 0.75 |
| " The aim of the present study was to evaluate the in vitro bactericidal activity of the new broad spectrum cephalosporins cefepime (FEP) and cefpirome (CPO) alone or in combination with amikacin (AKN), gentamicin (GTN) or ciprofloxacin (CIP) against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae producing a derepressed cephalosporinase." | ( [Kinetics of bactericidal activity of cefepime and cefpirome alone or combined with gentamicin, amikacin or ciprofloxacin against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae hyperproductive in cephalosporinase]. Elkhaïli, H; Jehl, F; Kamili, N; Linger, L; Monteil, H; Pompei, D, 1996) | 0.7 |
| "The in vitro activity of trovafloxacin alone and in combination with ceftazidime, meropenem, and amikacin was studied by determining the minimal inhibitory concentrations (MICs) for 111 gram-negative and 71 gram-positive bacteria." | ( In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin. Milatovic, D; Wallrauch, C, 1996) | 0.74 |
| "Forty critically ill adult patients with severe Gram-negative infection were treated with once-daily amikacin combined with ceftazidime." | ( Efficacy and safety of once-daily amikacin in combination with ceftazidime in critically ill adults with severe gram-negative infections. Abu-Aisha, H; al-Zeer, AH; Dahmash, NS; Fayed, DF; Huraib, SO; Shibl, AM, 1996) | 0.79 |
| "The in vitro activity of fosfomycin in combination with ceftazidime, imipenem, amikacin, or ciprofloxacin was studied by an agar plate checkerboard method against 40 clinical isolates of Pseudomonas aeruginosa with various antibiotic resistance profiles." | ( In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Quentin, C; Tessier, F, 1997) | 0.76 |
| "The action of two glycopeptides (vancomycin and teicoplanin) alone or in combination with amikacin or fusidic acid has been studied against 10 non-repetitive strains of methicillin-resistant Staphylococcus." | ( Effect of vancomycin and teicoplanin alone or in combination with fusidic acid or amikacin against methicillin-resistant staphylococci. Barbiery, P; Courcol, RJ; Roussel-Delvallez, M; Wallet, F, 1997) | 0.74 |
| " The 8 h SBTs for dosing schedule containing meropenem combined with amikacin were 1:4 and 1:16 after 30 min short infusion and continuous infusion respectively." | ( [In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model]. Elkhaïli, H; Jehl, F; Levêque, D; Linger, L; Monteil, H; Niedergang, S; Peter, JD; Pompei, D; Salmon, J; Salmon, Y; Thierry, RC, 1997) | 0.83 |
| "The antibacterial activities of human regimens of cefepime, ceftazidime, and imipenem alone or in combination with amikacin against an isogenic pair of Enterobacter cloacae strains (wild type and its corresponding derepressed cephalosporinase mutant) were compared by using our nonlethal model of pneumonia with 180 immunocompetent rats." | ( Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains. Hidri, N; Jacolot, A; Leotard, S; Mimoz, O; Nordmann, P; Petitjean, O; Samii, K, 1998) | 0.74 |
| "In a randomized trial conducted in 35 centers, we compared the clinical efficacy and safety of piperacillin plus tazobactam (TAZ) alone (monotherapy [MT]) versus those of TAZ combined with amikacin (AMK) (combined therapy [CT]) for the treatment of severe generalized peritonitis (SGP)." | ( Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group. Carbon, C; Carlet, J; Dupont, H, 2000) | 0.5 |
| "Ceftazidime and amikacin were administered in a Pseudomonas aeruginosa rabbit endocarditis model using computer-controlled intravenous (iv) infusion pumps to simulate human serum concentrations for the following regimens: continuous (constant rate) infusion of 4, 6 or 8 g of ceftazidime over 24 h or intermittent dosing of 2 g every 8 h either alone or in combination with amikacin (15 mg/kg once daily)." | ( In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. Baron, D; Bugnon, D; Caillon, J; Dube, L; Kergueris, MF; Le Conte, P; Navas, D; Potel, G; Robaux, MA, 2001) | 0.87 |
| "The in-vitro activities of various antibiotics, either alone or in combination with amikacin were assessed using clinical isolates of Pseudomonas aeruginosa." | ( In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. Gerçeker, AA; Karakoç, B, 2001) | 0.77 |
| ") in combination with amikacin (15 mg/kg/o." | ( Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study. Akan, H; Akova, M; Cetinkaya, Y; Erman, M; Ferhanoğlu, B; Köksal, I; Korten, V; Unal, S; Uzun, O, 2001) | 0.87 |
| "To investigate the phamacokinetics and serum bactericidal activities (SBAs) of trovafloxacin, cefepime and amikacin alone and trovafloxacin in combination with cefepime or amikacin, so that the most favorable combination with trovafloxacin can be determined." | ( Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers. Borner, K; Brodersen, B; Koeppe, P; Lode, H; Lubasch, A; Ziege, S, 2003) | 0.76 |
| " However, the maximal concentration of cefepime was significantly lower when it was used in combination with trovafloxacin." | ( Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers. Borner, K; Brodersen, B; Koeppe, P; Lode, H; Lubasch, A; Ziege, S, 2003) | 0.55 |
| " aeruginosa, the bactericidal activity of cepefime alone was higher than that of the combination with trovafloxacin." | ( Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers. Borner, K; Brodersen, B; Koeppe, P; Lode, H; Lubasch, A; Ziege, S, 2003) | 0.55 |
| "To investigate the characteristics of bacteriology and the drug resistance in the patients with chronic obstructive disease (COPD) combined with pneumonia at our respiratory intensive care unit(RICU) in 2001." | ( [Characteristics of bacteriology and drug sensitivity in patients with COPD combined with pneumonia]. Xiang, XD; Yang, H; Yi, ZM, 2003) | 0.32 |
| "The sputum of 543 patients with COPD combined with pneumonia was collected with a regular method, the bacteria were cultured, and then the drug sensitivity was analyzed with K-B method." | ( [Characteristics of bacteriology and drug sensitivity in patients with COPD combined with pneumonia]. Xiang, XD; Yang, H; Yi, ZM, 2003) | 0.32 |
| "The bacteria in the patients with COPD combined with pneumonia at RICU of the hospital in 2001 are mainly made up of G- bacillus and secondarily of G+ bacteria which are sensitive to imipenem, amikacin, and ceftazidime." | ( [Characteristics of bacteriology and drug sensitivity in patients with COPD combined with pneumonia]. Xiang, XD; Yang, H; Yi, ZM, 2003) | 0.51 |
| "Summary We report a case of protothecosis in an 18-year-old female student caused by Prototheca zopfii successfully treated with amikacin combined with tetracyclines." | ( Protothecosis successfully treated with amikacin combined with tetracyclines. Liu, W; Lv, G; Shen, Y; Wu, S; Zhao, J, 2004) | 0.8 |
| "A guinea-pig pneumonia model involving imipenem-susceptible and imipenem-resistant strains of Acinetobacter baumannii was developed to assess the in-vitro and in-vivo activities of imipenem, alone or in combination with amikacin, and the pharmacokinetic and pharmacodynamic parameters." | ( Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Bernabeu-Wittel, M; García-Curiel, A; Ibáñez-Martínez, J; Jiménez-Mejías, ME; Pachón, J; Pachón-Ibáñez, ME; Pichardo, C, 2005) | 0.73 |
| "The aim of this study was to evaluate the ability of levofloxacin and ciprofloxacin alone and in combination with either ceftazidime, cefepime, imipenem, piperacillin-tazobactam or amikacin to select for antibiotic-resistant mutants of Pseudomonas aeruginosa and Acinetobacter spp." | ( In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. De Vecchi, E; Drago, L; Gismondo, MR; Nicola, L; Tocalli, L, 2005) | 0.72 |
| " For multi-step studies, MICs were determined after five serial passages on antibiotic-gradient plates containing each antibiotic alone or in combination with levofloxacin or ciprofloxacin." | ( In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. De Vecchi, E; Drago, L; Gismondo, MR; Nicola, L; Tocalli, L, 2005) | 0.52 |
| " The following problems were investigated: is the treatment of serious bacterial infections with cheap standard antibiotics [SAT] or other antibiotics therapy [OAT] combined with amikacin safe and effective? What are the direct costs? How can reduction in costs be achieved? Prospective, randomized, single-blind study was performed in the group of 152 patients, admitted from 1 January to 31 July 2000, treated with amikacin combined with aminopenicillin/amoxicillin [SAT] versus other antibiotic therapy [OAT]." | ( Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I. Kusowska, J, ) | 0.57 |
| " The following problems were investigated: is the treatment of serious bacterial infections with cheap standard antibiotics [SAT] or other antibiotics therapy [OAT] combined with amikacin safe and effective? What are the direct costs? How can reduction in costs be achieved? Prospective, randomized, single-blind study was performed in the group of 152 patients, admitted from 1 January to 31 July 2000, treated with amikacin combined with aminopenicillin/amoxicillin [SAT] versus other antibiotic therapy [OAT]." | ( Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II. Kusowska, J, ) | 0.57 |
| "A two-step gradient liquid chromatographic method combined with pulsed electrochemical detection is described for the determination of amikacin and its impurities." | ( Improved reversed-phase liquid chromatographic method combined with pulsed electrochemical detection for the analysis of amikacin. Adams, E; Hoogmartens, J; Li, B; Zawilla, NH, 2007) | 0.75 |
| "The activities of tigecycline alone and in combination with other antimicrobials are not well defined for carbapenem-intermediate or -resistant Acinetobacter baumannii (CIRA)." | ( In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Noskin, GA; Obias, A; Postelnick, MJ; Qi, C; Scheetz, MH; Warren, JR; Zembower, T, 2007) | 0.34 |
| "In this study the bactericidal effect of the N-terminal fragment of the frog skin peptide esculentin-1b [Esc(1-18)] in combination with clinically used antimicrobial agents was evaluated against Stenotrophomonas maltophilia, either in standard conditions (phosphate buffer) or in the presence of human serum." | ( In vitro bactericidal activity of the N-terminal fragment of the frog peptide esculentin-1b (Esc 1-18) in combination with conventional antibiotics against Stenotrophomonas maltophilia. Barnini, S; Barra, D; Batoni, G; Brancatisano, FL; Campa, M; Capria, AL; Di Luca, M; Esin, S; Maisetta, G; Mangoni, ML; Pichierri, G, 2009) | 0.35 |
| "This study evaluated the activity of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli co-producing extended-spectrum β-lactamases and acquired AmpC β-lactamases." | ( Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Hur, J; Kim, HS; Lee, KM; Park, MJ; Park, MS; Song, W; Woo, H; Yim, H, 2011) | 0.84 |
| " One hundred forty-eight cases received levofloxacin and 137 received amikacin, both in combination with ceftazidime." | ( Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. Bompolaki, I; Bozionelou, V; Falagas, ME; Kalpadaki, C; Karageorgopoulos, DE; Koutsounaki, E; Mitsikostas, P; Samonis, G; Sgouros, J; Taktikou, V, 2012) | 0.84 |
| " We evaluated the effects of four carbapenems given as monotherapies or in combination with amikacin on the level of gastrointestinal colonisation by Candida albicans in a previously established mouse model." | ( Effects of carbapenems and their combination with amikacin on murine gut colonisation by Candida albicans. Dimopoulou, D; Galanakis, E; Kofteridis, DP; Maraki, S; Ntaoukakis, M; Samonis, G; Sarchianaki, E; Spathopoulou, T, 2013) | 0.86 |
| "The aim of this study was to evaluate the in vitro activity of doripenem (DOR) alone and in combination with a variety of commonly used anti-Acinetobacter chemotherapeutic agents against 22 primary multidrug-resistant (MDR) Acinetobacter baumannii isolates (including 17 isolates that were resistant to DOR) from Intensive Care Unit patients." | ( In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection. Bordi, E; Capone, A; D'Arezzo, S; Di Caro, A; Mazzarelli, A; Petrosillo, N; Principe, L, 2013) | 0.39 |
| "To determine the effect of regional limb perfusion (RLP) with amikacin sulfate alone and in combination with ticarcillin/clavulanate on synovial fluid concentration and antimicrobial activity of amikacin." | ( Accumulation of amikacin in synovial fluid after regional limb perfusion of amikacin sulfate alone and in combination with ticarcillin/clavulanate in horses. Fubini, SL; Schwark, WS; Watts, AE; Zantingh, AJ, 2014) | 0.99 |
| " Gentamicin, amikacin or vancomycin was combined with disodium EDTA or l-arginine for 24 h to reproduce the antibiotic lock therapy (ALT) approach." | ( In vitro activity of gentamicin, vancomycin or amikacin combined with EDTA or l-arginine as lock therapy against a wide spectrum of biofilm-forming clinical strains isolated from catheter-related infections. Beloin, C; Ghigo, JM; Lebeaux, D; Leflon-Guibout, V, 2015) | 1.04 |
| " However, the effects of D-AAs combined with common antibiotics on biofilms have rarely been studied." | ( The effects of D-Tyrosine combined with amikacin on the biofilms of Pseudomonas aeruginosa. Chen, L; Koronfel, A; Liu, H; Luo, Z; She, P; Wu, Y; Zou, Y, 2015) | 0.68 |
| " We report a case of metastatic endophthalmitis combined with subretinal abscess with successful visual outcome after treatment." | ( Metastatic endophthalmitis combined with subretinal abscess in a patient with diabetes mellitus--a case report. Peng, KL; Tsai, TH, 2015) | 0.42 |
| " We investigated the activity of various antibiotics in combination with polymyxin B using time-kill studies (TKS)." | ( In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B. Cai, Y; Chan, EC; Hong, Y; Hsu, LY; Koh, TH; Kwa, AL; Lee, W; Lim, TP; Sasikala, S; Tan, TT; Tan, TY; Teo, J, 2016) | 0.43 |
| "Carbapenem-resistant Acinetobacter baumannii clinical isolates (n=23) were investigated for carbapenem resistance mechanisms and in vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin." | ( In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates. Chatsuwan, T; Singkham-In, U, 2018) | 0.92 |
| "Erythromycin combined with budesonide may reduce inflammation and modify fibrosis progression in TS after tracheal injury." | ( Erythromycin combined with corticosteroid reduced inflammation and modified trauma-induced tracheal stenosis in a rabbit model. Changchun, H; Enyuan, Q; Guangnan, L; Jinghua, G; Lei, Z; Lihua, L; Luoman, G; Mingpeng, X; Wentao, L; Xiaoyan, M; Yu, L, ) | 0.13 |
| "Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE)." | ( Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin. Burgess, DS; Clark, JA; Kulengowski, B, 2019) | 2.21 |
| " Raman and IR spectroscopy combined with DFT calculations conducted to a complete vibrational characterization of the molecule, with the assignment of the vibrational modes." | ( IR, Raman and SERS analysis of amikacin combined with DFT-based calculations. Baia, M; Balan, C; Pop, LC, 2019) | 0.8 |
| "5 g q8h dose, respectively, in combination with 69 mg/L amikacin, corresponding to the free peak plasma concentration." | ( In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. Adamou, P; Antoniadou, A; Damala, M; Deliolanis, I; Fountoulis, K; Galani, I; Galani, L; Giamarellou, H; Karaiskos, I; Karantani, I; Kirikou, H; Kodonaki, A; Maraki, S; Markopoulou, M; Papadogeorgaki, E; Papoutsaki, V; Petinaki, E; Prifti, E; Souli, M; Tsiplakou, S; Vagiakou, E, 2020) | 1.04 |
| " In combination with amikacin, a synergistic interaction at 24 h was observed against 85." | ( In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. Adamou, P; Antoniadou, A; Damala, M; Deliolanis, I; Fountoulis, K; Galani, I; Galani, L; Giamarellou, H; Karaiskos, I; Karantani, I; Kirikou, H; Kodonaki, A; Maraki, S; Markopoulou, M; Papadogeorgaki, E; Papoutsaki, V; Petinaki, E; Prifti, E; Souli, M; Tsiplakou, S; Vagiakou, E, 2020) | 1.11 |
| " However, the synergistic effects of tigecycline in combination with other antibiotics including colistin or amikacin remain unclear." | ( In Vitro Activities of Tigecycline in Combination with Amikacin or Colistin Against Carbapenem-Resistant Acinetobacter baumannii. Feng, H; He, L; Wu, H; Xu, P; Zhang, H, 2021) | 1.08 |
| " We measured 191 pairwise drug combination effects among 22 antibacterials and identified 71 synergistic pairs, 54 antagonistic pairs, and 66 potentiator-antibiotic pairs." | ( Novel Synergies and Isolate Specificities in the Drug Interaction Landscape of Mycobacterium abscessus. Aldridge, BB; Degefu, YN; Klickstein, J; Larkins-Ford, J; Leus, PA; Maurer, FP; Poonawala, H; Smith, TC; Stone, D; Thorpe, CM; Van, N, 2023) | 0.91 |
| " Some studies have demonstrated promising results of IgG in combination with antimicrobial preparations against bacterial infections, in which the direct action of IgG has restored the immune system balance." | ( In vitro evaluation of human intravenous immunoglobulin in combination with antimicrobials and human serum against multidrug-resistant isolates of Acinetobacter baumannii. Alves, LC; Bezerra Cavalcanti, CL; Brayner, FA; da Silva, EM; de Araújo, AR; de Freitas, CF; de Lima, FCG; do Nascimento, AV; Oliveira Júnior, JB; Sandes, JM; Veras, DL, 2023) | 0.91 |
Amikacin was well absorbed from the site of intramuscular injection. The absorption rate constant decreased from 1.5 to 1.3.
The pharmacokinetics/pharmacodynamics (PK/PD) of amikacin in critically ill patients undergoing continuous venovenous hemodiafiltration (CVVHDF) are poorly described, and appropriate dosing is unclear in this patient population. 48 patients, aged 80 +/- 5 years, with estimated creatinine clearance (eCCR) of 48 +/- 15 ml/mn, received amkacin initial dosage of 13.5 mg/kg bwt i.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Time-related changes in the serum and muscle ACC profiles were demonstrated that were not affected by the CLA supplement at the dosage used in the present study." | ( Acylcarnitine profiles in serum and muscle of dairy cows receiving conjugated linoleic acids or a control fat supplement during early lactation. Adamski, J; Dänicke, S; Prehn, C; Rehage, J; Sadri, H; Saremi, B; Sauerwein, H; Yang, Y, 2019) | 0.51 |
| " In the second group, the dosage of each antibiotic necessary to induce apnea is sought." | ( [Neuromuscular inhibition of new aminoglycoside antibiotics]. Baltar, I; Esplugues, J; Marti, JL; Orts, A, 1979) | 0.26 |
| " The maximum concentrations of the two cytotoxic drugs were chosen to be twice the known peak plasma levels of commonly employed dosage schedules." | ( Effect of two cancer chemotherapeutic agents on the antibacterial activity of three antimicrobial agents. Moody, MR; Morris, MJ; Moyé, LA; Schimpff, SC; Wiernik, PH; Young, VM, 1978) | 0.26 |
| " This variation in penetration reflected individual differences in each dosage group and the increase in percent penetration that was observed during therapy." | ( Comparison of four aminoglycoside antibiotics in the therapy of experimental E. coli meningitis. Mandaleris, CD; Sande, MA; Strausbaugh, LJ, 1977) | 0.26 |
| " The recommended 12-hourly dosage regimen has also proved useful in medium- to long-term management of refractory pulmonary infections." | ( Clinical experience with amikacin, a new aminoglycoside antibiotic. De Kock, MA; Theron, FP, 1977) | 0.56 |
| " Our data indicate that low dosage amikacin sulfate is satisfactory in the treatment of complicated urinary tract infections." | ( Treatment of complicated urinary tract infections with amikacin: comparison of low and high dosage. Harrison, LH, 1977) | 0.78 |
| " Intramuscular dosage schedules were calculated, based on the sensitivity of the different bacterial strains and the duration of effective serum drug concentrations." | ( Comparative clinical pharmacology of amikacin and kanamycin in dairy calves. Ziv, G, 1977) | 0.53 |
| " Despite a uniform dosing protocol, a wide range of netilmicin serum levels was obtained." | ( Clinical evaluation of netilmicin therapy in serious infections. Fu, KP; Jahre, JA; Neu, HC, 1979) | 0.26 |
| " Ototoxicity, highly correlated with a duration of greater than 19 days and a total dosage of greater than 25 g of amikacin sulfate, occurred in four patients (5." | ( Empiric therapy for infections in granulocytopenic cancer patients: continuous infusion of amikacin plus cephalothin. Curtis, JE; Feld, R; Hasselback, R; Messner, HA; Tuffnell, PG, 1979) | 0.69 |
| " Separate in vitro experiments with gentamicin, however, revealed an inverse dose-response relationship with chemotactic suppression." | ( Abnormal neutrophil chemotaxis and random migration induced by aminoglycoside antibiotics. Chang, CT; Evans, HE; Glass, L; Khan, AJ; Khan, P; Nair, SR, 1979) | 0.26 |
| " Drug dosage was altered to keep serum levels 1 h after administration between 5 and 10 mug/ml (gentamicin or tobramycin) or 20 and 40 mug/ml (amikacin)." | ( Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. Lietman, PS; Lipsky, JJ; Smith, CR, 1979) | 0.46 |
| " A dosage regimen as a function of the pharmacokinetic parameters is established for patients with terminal renal impairment which guarantees safe and efficient concentrations of the antibiotic." | ( Pharmacokinetics of amikacin (BB-K8) in patients undergoing hemodialysis. Dominguez-Gil, A; Lanao, JM; Sanchez Tomero, JA; Tabernero, JM, 1979) | 0.58 |
| " Pharmacists, in consultation with the infectious diseases service, made recommendations for alternative antibiotic therapy or dosage regimens, provided drug education to prescribing physicians and nurses, and aided in monitoring efficacy and toxicity of therapy." | ( Aminoglycoside use monitored by clinical pharmaceutical services. Barriere, SL; Conte, JE, 1979) | 0.26 |
| " Dosing intervals during 1 or 2 and 3 or 4 days of therapy were studied with serum samples collected before and at the end of the infusion and serially to the end of the dosing interval." | ( Multiple-dose amikacin kinetics in pediatric oncology patients. Cleary, T; Frankel, LS; Kohl, S; Kramer, WG; Pickering, LK, 1979) | 0.62 |
| " The influence of dosage and renal function on serum levels and their relevance to ototoxicity are discussed." | ( Suggestions for monitoring patients during treatment with aminoglycoside antibiotics. Lerner, SA; Matz, GJ, ) | 0.13 |
| " There were 10 animals in each dosage group." | ( [Comparative ototoxicity of aminoglycoside antibiotics in a guinea pig model (author's transl)]. Brummett, RE, 1978) | 0.26 |
| " A linear relation between concentrations in the perilymph and dosage of gentamicin was ascertained." | ( [Pharmacokinetical, histological, and histochemical investigation on the ototoxicity of gentamicin, tobramycin, and amikacin (author's transl)]. Federspil, P; Schätzle, W; Tiesler, E, 1977) | 0.47 |
| "5; 5; 10; 20; 100 and 500 mg/kg/day; dosage interval: 12 h) over a period of 5 days." | ( [Amikacin and kanamycin. Comparative experimental studies on nephrotoxicity]. Sack, K; Züllich, B, 1978) | 1.17 |
| " Dose-response data demonstrating linear recovery are included for all four aminoglycosides as well as a comparison of the GLC method with the microbiological method for the assay of gentamicin and amikacin." | ( Gas-liquid chromatographic method for the assay of aminoglycoside antibiotics in serum. Gorbach, SL; Mayhew, JW, 1978) | 0.45 |
| "Netilmicin, gentamicin, tobramycin, amikacin, kanamycin, streptomycin, and sisomicin were given daily for 15 days to groups of rats at three dosage levels corresponding to 10, 15, or 25 times the dose recommended for humans on a weight basis." | ( Comparative nephrotoxicity of aminoglycoside antibiotics in rats. Bloch, R; Costello, R; Luft, FC; Maxwell, DR; Sloan, RS; Yum, MN, 1978) | 0.53 |
| " This more rapid elimination necessitated a shorter dosing interval (every 6 hours), resulting in an increased daily dose (30 mg/kg/day)." | ( The necessity of increased doses of amikacin in burn patients. Sawchuk, RJ; Strate, RG; Zaske, DE, 1978) | 0.53 |
| " The pharmacokinetic parameters in the computer program were used to generate a new aminoglycoside dosing chart." | ( Amikacin serum concentrations: prediction of levels and dosage guidelines. Hull, JH; Sarubbi, FA, 1978) | 1.7 |
| " The dosage was 125." | ( [Amikacin in urinary tract infections with so-called problem pathogens]. Hofstetter, A; Staehler, G, 1976) | 1.17 |
| " Gentamicin, sisomicin and amikacin are useful against Serratia infections; but in each case, a higher dosage is needed." | ( Comparative evaluation of five aminoglycosides for treatment. Köhler, M; Naumann, P; Reintjens, E; Rosin, H, 1976) | 0.55 |
| " The pharmacokinetic data were used to make dosage regimen recommendations for the treatment of patients undergoing intermittent hemodialysis or peritoneal dialysis." | ( Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. Colding, H; Jensen, H; Kampmann, JP; Regeur, L, 1977) | 0.58 |
| " Depending upon the dosage of the administered drug, Amikacin (150 mg per kg body weight daily, corresponding to 10 times an average recommended human dose) caused pronounced outer hair cell damage even 1 day after the treatment was stopped." | ( Comparative surface studies of ototoxic effects of various aminoglycoside antibiotics on the organ of Corti in the guinea pig. A scanning electron microscopic study. Theopold, HM, ) | 0.38 |
| "Amikacin was used in 77 treatment courses at a dosage of >/=7." | ( Ototoxicity of amikacin. Black, RE; Hewitt, WL; Lau, WK; Weinstein, RJ; Young, LS, 1976) | 2.05 |
| " A linear relation between concentrations in the perilymph and the dosage of gentamicin was ascertained." | ( Pharmacokinetics and ototoxicity of gentamicin, tobramycin, and amikacin. Federspil, P; Schätzle, W; Tiesler, E, 1976) | 0.49 |
| " The calculated half-life values may be used for development of appropriate dosage schedules for patients with various degrees of renal function." | ( Pharmacokinetics of amikacin in patients with renal insufficiency: relation of half-life and creatinine clearance. Baert, L; Boelaert, J; Daneels, R; Hallynck, T; Pijck, J; Soep, H, 1976) | 0.58 |
| " Knowledge of these relations may aid in adjustment of the dosage of amikacin in patients with impaired renal function, especially when such information is used in conjunction with serum assays of amikacin." | ( Pharmacokinetics of amikacin in patients with impaired renal function. Gavan, TL; Hall, PM; McHenry, MC; Vidt, DG; Wagner, JG, 1976) | 0.81 |
| " A tentative dosage schedule was prepared for patients with various degrees of impaired renal function on the basis of average half-life values." | ( Pharmacokinetics of amikacin for treatment of urinary tract infections in patients with reduced renal function. Demers, HG; Höffler, D; Koeppe, P, 1976) | 0.58 |
| " The prophylactic effect upon ototoxicity of the administration of dimercaptopropanol or of dividing up the daily dosage was examined." | ( [Ototoxicity of the aminoglycoside antibiotics (author's transl)]. Federspil, P, 1976) | 0.26 |
| "Thirty children over the age of one month were treated with amikacin (BBK8), a new aminoglycoside derived from kanamycin A, with three intramuscular dosage schedules." | ( Amikacin (BBK8) in infections due to gram-negative organisms in children over the age of one month. Agudelo, NH; de Vidal, EL; Ramirez, JI; Trujillo, H; Uribe, A, 1976) | 1.94 |
| "Indications, side effects, dosage and several pharmacokinetic properties of gentamicin, tobramycin, sisomicin, kanamycin, amikacin, and streptomycin are delt with in the first part." | ( [Aminoglycoside antibiotics from clinical viewpoint]. Lüthy, R, 1975) | 0.46 |
| " A dose-response experiment was performed with clarithromycin at 50, 100, 200, or 300 mg/kg of body weight administered daily by gavage to mice infected with approximately 10(7) viable MAC." | ( Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Cynamon, MH; DeStefano, MS; Klemens, SP, 1992) | 0.28 |
| " The population values may be employed, in addition to those supplied with the software, to adapt dosage regimens of amikacin in ICU patients." | ( Population pharmacokinetic parameters for Bayesian monitoring of amikacin therapy in intensive care unit patients. Debord, J; Favereau, JP; Gay, C; Gay, R; Lachatre, G; Voultoury, JC, 1992) | 0.73 |
| " The software is menu driven to provide a very user-friendly tool for analysing pharmacokinetic data and for designing dosage regimens." | ( APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Brown, AC; Huggins, ML; Iliadis, A, 1992) | 0.28 |
| " Cefepime and amikacin can be coadministered to patients with normal renal function by using the standard recommended dosing regimens." | ( Lack of pharmacokinetic interaction between cefepime and amikacin in humans. Barbhaiya, RH; Knupp, CA; Pfeffer, M; Pittman, KA, 1992) | 0.89 |
| " Dosage of AMK was individualized based upon the therapeutic drug monitoring method, and that of PIPC was adjusted depending upon the creatinine clearance of a patient." | ( [Protective effect by piperacillin against renal impairment caused by amikacin]. Goto, M; Iwayama, N; Izuhara, Y; Kusafuka, H; Maeda, K; Obayashi, T; Sezaki, R; Yoshida, H, 1992) | 0.52 |
| " Once-daily dosing of amikacin produced greater initial killing than thrice daily dosing (P less than ." | ( Amikacin, ceftazidime, and flucloxacillin against suspended and adherent Pseudomonas aeruginosa and Staphylococcus epidermidis in an in vitro model of infection. Blaser, J; Vergères, P, 1992) | 2.04 |
| "Amikacin's pharmacokinetics and dosage requirements were studied in 98 patients receiving treatment for gram-negative infections." | ( Individualizing amikacin regimens: accurate method to achieve therapeutic concentrations. Cipolle, RJ; Kohls, PR; Rotschafer, JC; Strate, RG; Zaske, DE, 1991) | 2.07 |
| " All patients needed increased dosing requirements for amikacin to maintain therapeutic serum levels." | ( Increased dosing requirements for amikacin in burned children. Fant, WK; Kopcha, RG; Warden, GD, 1991) | 0.81 |
| " In conclusion od amikacin dosing resulted in a higher cure and less nephrotoxicity than conventional bd dosing." | ( A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. Kobilski, S; Lipman, J; Marik, PE; Scribante, J, 1991) | 0.85 |
| " Thus, it appears possible to adjust the aminoglycoside dosage by taking into account 8 patient's factors, until the amikacin plasma concentration, time data are available." | ( Correlations between aminoglycoside pharmacokinetic parameters and patient's factors: from statement to implication for individual dosage design. Firsov, AA; Nasonov, VN, 1991) | 0.49 |
| "A variety of in-vitro and animal studies were performed to define the pharmacodynamic characteristics of amikacin against Gram-negative bacilli and to determine the impact of the dosing regimen on therapeutic efficacy." | ( Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. Craig, WA; Ebert, SC; Redington, J, 1991) | 0.82 |
| " Administration of dosage regimens based on predicted pharmacokinetic parameters yielded subtherapeutic amikacin concentrations in serum in our patients." | ( Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy. Davis, RL; Lehmann, D; Neidhart, J; Stidley, CA, 1991) | 1.94 |
| "The serum concentrations and safety of single daily dosing of amikacin were studied in 16 episodes of fever and granulocytopenia in children undergoing bone marrow transplantation." | ( Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. Barretta, MA; Boni, L; Castagnola, E; Dudley, M; Ferrea, G; Lanino, E; Loy, A; Moroni, C; Somenzi, M; Viscoli, C, 1991) | 0.77 |
| " There were no significant differences between the two dosage regimens regarding efficacy and safety." | ( Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. Scandinavian Amikacin Once Daily Study Group. Ahrne, H; Eilard, T; Eriksson, I; Lausen, I; Maller, R, 1991) | 0.59 |
| " To identify measures that might prevent aminoglycoside nephrotoxicity, we investigated the influence of various dosage regimens on the renal cortical accumulation of amikacin and tobramycin in man." | ( Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. De Broe, ME; Verbist, L; Verpooten, GA, 1991) | 0.72 |
| " In conclusion, these very sensitive tests of nephro- and oto-toxicity suggest that od dosing of amikacin or netilmicin is, if anything, safer than bd or tid dosing." | ( Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. Tulkens, PM, 1991) | 0.71 |
| " In addition the serum amikacin levels in 200 patients randomized to receive a once- or twice-daily dosing regimen are reported." | ( The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens. Havlik, I; Lipman, J; Marik, PE; Monteagudo, FS, 1991) | 0.9 |
| " In summary, a once-daily dosing regimen of amikacin 15 mg/kg is practical and probably efficacious and safe in severely infected patients." | ( Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. Beaucaire, G; Beuscart, C; Caillaux, M; Chidiac, C; Karp, P; Leroy, O, 1991) | 0.78 |
| "The pharmacodynamics of amikacin given as a single daily dose was compared with standard divided dosing in an in-vitro model of infection." | ( Single daily dosing of amikacin in an in-vitro model. Dudley, MN; Zinner, SH, 1991) | 0.9 |
| "5 mg/kg bd) regimen (group A) was compared with a once-daily dosage (15 mg/kg) schedule (group B)." | ( Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. Giamarellou, H; Moschovakis, E; Petrikkos, G; Sfikakis, P; Vavouraki, E; Voutsinas, D; Yiallouros, K, 1991) | 0.55 |
| " To study this we exposed guinea pigs to continuously infused amikacin at four different dosing rates under conditions parallel to those used in our previous study which related ototoxicity to total plasma area under the concentration-time curve regardless of the level in plasma." | ( Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration. Bayne, A; Beaubien, AR; Carrier, K; Crossfield, G; Downes, M; Henri, R; Hodgen, M; Ormsby, E, 1991) | 0.88 |
| " They are the following: consideration of the structure of the antibiotic use, improvement of infection diagnosis, the use of computers in epidemiological supervision of antibiotic resistance, the use of "old" antibiotics in new dosage forms, pharmacokinetic monitoring." | ( [Ways of increasing the effectiveness of antibacterial therapy in newborns]. Strachunskiĭ, LS, 1991) | 0.28 |
| " Measuring serum amikacin concentrations and adjusting dosage regimens are necessary to achieve desired peak and trough serum concentrations." | ( Amikacin pharmacokinetics: wide interpatient variation in 98 patients. Kohls, PR; Strate, RG; Zaske, DE, 1991) | 2.06 |
| " In contrast, with a high-dose regimen of amikacin (40 mg/kg every eight hours), supra-MBC drug levels were calculated throughout the entire vegetation for at least 50 percent of the dosing interval." | ( Intravegetation antimicrobial distribution in aortic endocarditis analyzed by computer-generated model. Implications for treatment. Bayer, AS; Borrelli, RL; Crowell, D; Nast, CC; Norman, DC, 1990) | 0.54 |
| " Antibiotic concentrations were those obtained in vivo at the valley (4 micrograms/ml) and the peak (20 micrograms/ml) with a dosage of 5 mg/kg." | ( [In vitro bactericidal rate of amikacin at concentrations realizable in vivo]. de Rautlin de la Roy, Y; Grignon, B; Grollier, G, 1990) | 0.57 |
| " The phenomenon has implications for effective initial dosing with aminoglycoside antibiotics." | ( The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. Daikos, GL; Jackson, GG; Lolans, VT, 1990) | 0.28 |
| " Knowledge of synergistic PAE could have clinical implications for optimal dosing schedules during combination antimicrobial chemotherapy." | ( The postantibiotic effect of amikacin alone and in combination with piperacillin on gram-negative bacteria. Hanberger, H; Isaksson, B; Maller, R; Nilsson, LE; Nilsson, M, 1990) | 0.57 |
| " Microtiter checkerboard technique was compared with standard killing curve method and with killing curves obtained in kinetic in vitro models mimicking single or multiple dosing regimens according to human pharmacokinetics." | ( Interactions of antimicrobial combinations in vitro: the relativity of synergism. Blaser, J, 1990) | 0.28 |
| "Antibiotic therapy is directed against bacteria responsible for infectious pathology which are able to resist treatment mainly when the dosage is misadapted." | ( A new approach to optimal antibiotic dosage regimen by coupling pharmacokinetics and killing curve parameters. Dellamonica, P; Drugeon, HB; Etesse, H; Garraffo, R; Lapalus, P, 1990) | 0.28 |
| "Once-daily dosing of amikacin is a novel therapy regimen which seems pharmacokinetically appropriate for the primary group of patients considered for aminoglycoside therapy." | ( Amikacin once daily: a new dosing regimen based on drug pharmacokinetics. Emanuelsson, BM; Isaksson, B; Maller, R; Nilsson, L, 1990) | 2.04 |
| "The effect of the dosing schedule on aminoglycoside ototoxicity was investigated in the guinea pig." | ( Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin. Bagger-Sjöbäck, D; Harada, Y; Hirakawa, K; Nikaido, M; Nishida, I; Takumida, M, 1990) | 0.5 |
| " Thus, it appeared possible to adjust the aminoglycoside dosage by taking into account 8 PFs before the TDM data were available." | ( [Individualization of the amikacin administration regimen on the basis of the relationship between its pharmacokinetics and the patient's status]. Firsov, AA; Murav'eva, SA; Nasonov, VN; Portnoĭ, IuA; Savitskaia, KI, 1990) | 0.58 |
| " However, late evening samples should also be tested whenever dosage modifications are considered so that continuous therapeutic serum concentrations can be ensured." | ( Circadian variation in serum amikacin levels. Bodey, GP; Elting, L; Fainstein, V; Rosenbaum, B, 1990) | 0.57 |
| " Serum amikacin concentrations were determined at three times during an 8 or 12 h dosing interval." | ( Pharmacokinetics of amikacin in critically ill neonatal foals treated for presumed or confirmed sepsis. Adland-Davenport, P; Brown, MP; Derendorf, HC; Robinson, JD, 1990) | 1.06 |
| "To complement a study on aminoglycoside dosing regimen and ototoxicity in the guinea pig, we designed an experiment to examine: (1) the effect of dosing regimen on guinea pig pharmacokinetic parameters, and (2) possible differential accumulation after repeated intramuscular administrations of netilmicin and amikacin (150 mg/kg/day) for 7 days by 1 or 3 daily injections." | ( Aminoglycoside dosing regimen and pharmacokinetic parameters in the guinea pig. Bamonte, F; Dionisotti, S; Kramer, WG; Leung, P; Ongini, E, 1990) | 0.45 |
| " Amikacin was also tested at 225 mg/kg/day with each dosing regimen." | ( Relation of dosing regimen to aminoglycoside ototoxicity: evaluation of auditory damage in the guinea pig. Arpini, A; Bamonte, F; Dionisotti, S; Gamba, M; Melone, G; Ongini, E, 1990) | 1.19 |
| " These pharmacokinetic data were used to calculate a new dosage schedule for preterm infants." | ( Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Chance, GW; Kenyon, CF; Knoppert, DC; Lee, SK; Vandenberghe, HM, 1990) | 1.72 |
| " After dosing intramuscularly the peak concentration (23." | ( Comparative pharmacokinetics of amikacin sulphate in calves and sheep. Carli, S; Madonna, M; Montesissa, C; Said-Faqi, A; Sonzogni, O, 1990) | 0.56 |
| " Despite the wide range of dosing durations required to achieve drug ototoxicity (2-24 days), the full development of both high and low frequency hearing loss was invariably found to be delayed with respect to the time of drug removal." | ( Delay in hearing loss following drug administration. A consistent feature of amikacin ototoxicity. Bayne, A; Beaubien, AR; Carrier, K; Cauchy, MJ; Desjardins, S; Henri, R; Hodgen, M; Ormsby, E; Salley, J; St Pierre, A, ) | 0.36 |
| " Netilmicin failed to affect either the vestibular or the acoustic apparatus in the animal groups receiving the two dosing regimens." | ( The impact of different dosing regimens of the aminoglycosides netilmicin and amikacin on vestibulotoxicity in the guinea pig. Dionisotti, S; Draicchio, F; Errico, P; Ferraresi, A; Pettorossi, VE, 1990) | 0.51 |
| " Drug-localization studies demonstrated that significant fractions of the total dosage were associated with the red-cell membrane." | ( The effects of antibiotics on hemolytic behavior of red cells. Lijana, RC; Williams, MC, 1986) | 0.27 |
| "A Bayesian approach was developed to determine an amikacin dosage regimen to achieve the desired plasma concentrations for each patient." | ( Application of Bayesian estimation for the prediction of an appropriate dosage regimen of amikacin. Cano, JP; Dellamonica, P; Garraffo, R; Iliadis, A; Lapalus, P, 1989) | 0.75 |
| "An assessment of the dosage regimens prescribed for potentially nephrotoxic antibiotics (amikacin, gentamicin, tobramycin, and vancomycin) was undertaken on surgical intensive care unit patients." | ( Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. Crotchett, J; Fischer, RP; Miller-Crotchett, P; Reed, RL; Wu, AH, 1989) | 0.5 |
| " On the basis of this study a new neonatal dosage schedule is proposed." | ( [Comparative study of the administration of amikacin by intramuscular and intravenous routes in neonatal resuscitation]. Avril, JL; Betremieux, P; Deramoudt-Dutrus, V; Le Marec, B; Lefrançois, C; Malledant, Y, 1989) | 0.54 |
| "We compared the therapeutic outcome in patients with normal renal function managed with either individualized pharmacokinetic (PK) dosing or standard (every 12 h) dosing of amikacin." | ( Individualized pharmacokinetic versus standard dosing of amikacin: a comparison of therapeutic outcomes. Casner, P; Dillon, KR; Dougherty, SH; Polly, S, 1989) | 0.72 |
| "We compared the nephrotoxic interaction between cisplatin (CP) and amikacin (AM) in young and adult rats, using different dosage combinations." | ( Potentiated nephrotoxicity of cisplatin when combined with amikacin comparing young and adult rats. Jongejan, HT; Molenaar, JC; Provoost, AP, 1989) | 0.76 |
| " Total dose or total AUC estimates of the drug exposure required to produce ototoxicity in 50% of the animals (ED50s) were not significantly different over an eight-fold range of dosing rates or plasma concentrations." | ( Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels. Bayne, A; Beaubien, AR; Carrier, K; Cauchy, MJ; Desjardins, S; Henri, R; Hodgen, M; Ormsby, E; Salley, J; St Pierre, A, ) | 0.5 |
| "5 mg/kg every 12 hours, permitted to establish a dosage related to PCA." | ( [Posology of amikacin in newborn infants, adapted to the postconceptional age]. Drugeon, B; Mouzard, A; Rigal, E; Rozé, JC; Tohier, C, 1989) | 0.65 |
| " We prospectively studied prophylactic amikacin and clindamycin in 150 abdominal trauma patients requiring laparotomy, analyzing the effects of duration of coverage, dosing interval, and dose." | ( Prophylactic antibiotics in trauma: the hazards of underdosing. Ericsson, CD; Fischer, RP; Hunt, C; Miller-Crotchett, P; Reed, L; Rowlands, BJ, 1989) | 0.55 |
| " In conclusion, if it could be necessary to use habekacin and to prefer this aminoglycoside to gentamicin from an antibacterial activity point of view it is necessary to keep in mind that this drug is potentially nephrotoxic and that the dosage had to be strictly respected." | ( [Habekacin: a new aminoglycoside. Study of nephrotoxicity in rats in comparison with gentamicin, netilmicin and amikacin]. Fillastre, JP; Morin, JP; Olier, B; Thomas, N, 1988) | 0.49 |
| "5 X 10(8) cfu/ml), either amikacin, ticarcillin, ceftazidime, amikacin-ticarcillin, amikacin-ceftazidime, or ticarcillin-ceftazidime was administered at dosing intervals that mimicked the serum concentrations of the drugs found in humans after therapeutic doses." | ( Pseudomonas peritonitis in neutropenic rats treated with amikacin, ceftazidime and ticarcillin, alone and in combination. Nightingale, CH; Quintiliani, R; Shyu, WC, 1987) | 0.82 |
| " The dosage was 5 to 12." | ( Kinetic parameters of amikacin in cystic fibrosis children. Autret, E; Grenier, B; Marchand, S; Thompson, R, ) | 0.45 |
| "This article reviews the clinical pharmacokinetics, clinical toxicity and cost-effectiveness analysis of aminoglycosides and of dosing services for aminoglycosides." | ( Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services. Bailie, GR; Mathews, A, 1987) | 0.27 |
| " The dosage regimen led to plasma concentrations of pefloxacin and amikacin within their therapeutic range." | ( Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. Auzepy, P; Pezzano, M; Richard, C; Singlas, E; Sultan, E, 1988) | 0.79 |
| " After G and N, the creatinine clearance of the neonates was decreased according to the dosage given to the mother." | ( In utero aminoglycosides-induced nephrotoxicity in rat neonates. Billerey, C; Coulon, G; Faucourt, A; Mallié, JP; Morin, JP, 1988) | 0.27 |
| " A recommended dosage of 10 mg/kg, q 8 h can be expected to provide a therapeutic serum concentration of amikacin with a mean steady-state concentration of 14 micrograms/ml." | ( Pharmacokinetics of amikacin in cats. Hatch, RC; Jernigan, AD; Wilson, RC, 1988) | 0.81 |
| " Although amikacin was cleared more effectively during HD compared to the interdialysis period, the small amount of drug removed suggests that routine supplemental dosing of amikacin after HD may not be necessary." | ( Hemodialysis of amikacin in critically ill patients. Armstrong, DK; Dasta, JF; Garner, WL; Hodgman, T; Reilley, TE; Visconti, JA, 1988) | 1.02 |
| " Pharmacokinetics should underlie the rational use of drugs and when a therapeutic range is known, the achievement of safe and effective target concentrations may be assured by a dosage regimen computed for a given administration schedule." | ( Dynamical dosage regimen calculations in linear pharmacokinetics. Bruno, R; Cano, JP; Iliadis, A, 1988) | 0.27 |
| "Individualized dosage regimens have recently been recommended for patients treated with aminoglycoside antibiotics." | ( Individualized aminoglycoside dosage regimens in patients with cystic fibrosis. Delage, G; Desautels, L; Lamarre, A; Lapierre, JG; Lasalle, R; Legault, S; Masson, P; Spier, S, 1988) | 0.27 |
| " As a result, amikacin dosing regimens developed in able-bodied humans may demonstrate diminished efficacy when extrapolated uncritically to these patients." | ( Amikacin pharmacokinetics in patients with spinal cord injury. Brunnemann, SR; Eltorai, IM; Gordon, SK; Segal, JL, 1988) | 2.08 |
| " It should be emphasized, however, that the standard dosage of aminoglycosides in patients with cystic fibrosis frequently results in serum concentrations that are lower than anticipated because of a relatively larger volume of drug distribution and a greater urinary excretion rate." | ( Aminoglycoside toxicity in infants and children. McCracken, GH, 1986) | 0.27 |
| " Every 2 days and at least 5 times during therapy, ODMF serum levels were determined (peak and trough levels) for dosage adjustment." | ( [Clinical and bacteriological study of O-demethylfortimicin A sulfate in urinary infection]. Bergogne-Bérézin, E; Delcercq, D; Prokocimer, P; Serieys, C, 1986) | 0.27 |
| " A graded dose-response effect was found between an increasing maximal peak concentration/MIC ratio and clinical response." | ( Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Lietman, PS; Moore, RD; Smith, CR, 1987) | 0.27 |
| " The purpose of this study was to determine if the two assay methods were comparable and would provide the same estimates for pharmacokinetic parameters and dosage recommendations." | ( Observed differences in amikacin pharmacokinetic parameters and dosage recommendations determined by enzyme immunoassay and fluorescence polarization immunoassay. Bleske, BE; Larson, TA; Rotschafer, JC, 1987) | 0.58 |
| " The mean dosage of vancomycin was higher for the auditory impairment group than for the unimpaired group." | ( Auditory brainstem response in young burn-wound patients treated with ototoxic drugs. Gary, LB; Hall, JW; Herndon, DN; Winkler, JB, 1986) | 0.27 |
| " Shapes of plasma concentration curves after multiple administrations of HAPA-B were very similar to those after single administrations at all dosage levels tested." | ( [Studies on the metabolic fate of isepamicin sulfate (HAPA-B). V. Plasma concentrations of HAPA-B in dogs after multiple administrations]. Endo, S; Morishita, M; Nakanishi, D; Sakai, A; Shirai, M; Somiya, Y; Suzuki, T, 1987) | 0.27 |
| " The procedure may be used for routine sanitary inspection of ambient air for every of the above antibiotics in the absence of the other in production of the substances and their dosage forms." | ( [Spectrophotometric determination of amikacin and sisomicin in the air using the Hantzsch reaction]. Churagulova, NK, 1987) | 0.55 |
| " Calculations of optimum doses and dosing intervals were based on individual parameters." | ( Evaluation of a Bayesian method of amikacin dosing in intensive care unit patients with normal or impaired renal function. Bruder, N; Cano, JP; Francois, G; Granthil, C; Lacarelle, B; Manelli, JC, 1987) | 0.55 |
| " Equivalent antibiotic dosing was based on the time rat serum antibiotic levels were above the minimal bactericidal concentration for the challenge organism." | ( Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats. Johnson, DE; Thompson, B, 1986) | 0.51 |
| " To control the development of aminoglycoside resistance in hospitals, it may be necessary to restrict the use of more than the one drug to which resistance is developing; to use the antibiotic at the right dosage and, when necessary, in a combination that may prevent the emergence of resistant organisms and plasmids; and to develop measures to control bacterial and R factor transmission." | ( Strategies in aminoglycoside use and impact upon resistance. Acar, JF; Bleriot, JP; Goldstein, FW; Menard, R, 1986) | 0.27 |
| " Since drug uptake kinetics determine the extent of cortical concentrations achieved, dosing strategies may affect cortical accumulation of aminoglycosides." | ( Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity. De Broe, ME; Giuliano, RA; Verpooten, GA, 1986) | 0.27 |
| " When older patients are treated, adjustments in dosing should be based on estimates of kidney function." | ( Management of sepsis in the elderly. Holloway, WJ, 1986) | 0.27 |
| " according to a variable dosage regimen." | ( Pharmacokinetics of amikacin in cystic fibrosis: a study of bronchial diffusion. Autret, E; Breteau, M; Grenier, B; Marchand, S, 1986) | 0.59 |
| "The influence of three different dosage schedules on kidney cortical accumulation of aminoglycosides was studied in rats." | ( The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. De Broe, ME; Giuliano, RA; Verpooten, GA, 1986) | 0.27 |
| " Ceftazidime was given intravenously at the dosage of 100-150 mg/kg/day." | ( Ceftazidime in the therapy of pseudomonal meningitis. Andreoni, M; Concia, E; Fiori, G; Marone, P; Maserati, R; Minoli, L; Suter, F, 1985) | 0.27 |
| "Six healthy pony foals, from 2 to 11 days of age, were given a single IM injection of amikacin sulfate (250 mg/ml) at a dosage rate of 7 mg/kg of body weight." | ( Pharmacokinetics of amikacin in pony foals after a single intramuscular injection. Beal, C; Brown, MP; Gronwall, RR; Martinez, DS, 1986) | 0.82 |
| " The pharmacokinetic profile showed serum levels sufficient to provide good antimicrobial activity throughout the dosing interval." | ( Moxalactam and piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients. de Jongh, C; Drusano, GL; Joshi, J; Moody, MR; Newman, K; Schimpff, SC; Wharton, R, ) | 0.13 |
| " The dosage determination in the dialysis patients receiving these drugs is discussed." | ( Effect of peritoneal dialysis on serum concentrations of three drugs commonly used in pediatric patients. Chow-Tung, E; John, EG; Lau, AH; Vidyasagar, D, 1985) | 0.27 |
| " Drug concentrations in plasma were found to be threefold higher in anesthetized animals, whereas drug levels in perilymph were the same in both groups at similar dosing rates." | ( Effect of pentobarbital anesthesia on amikacin concentrations in plasma and perilymph and evaluation of multiple sampling in perilymph of guinea pigs. Beaubien, AR; Cauchy, MJ; Desjardins-Giasson, S, 1985) | 0.54 |
| "6 mg/kg twice daily and, for the more serious life-threatening infections, dosing three times a day." | ( Pharmacokinetics of amikacin in the horse following intravenous and intramuscular administration. Orsini, JA; Park, M; Rourke, JE; Soma, LR, 1985) | 0.59 |
| " For dogs with normal renal function, an amikacin dosage of 10 mg/kg (IM or subcutaneously) is recommended every 8 hours for treatment of systemic infections, and every 12 hours for treatment of urinary tract infections caused by susceptible bacteria." | ( Clinical pharmacokinetics of amikacin in dogs. Baggot, JD; Chatfield, RC; Ling, GV, 1985) | 0.83 |
| " Expressed as a percentage of the injected amount, the uptake decreased as the aminoglycoside dosage increased." | ( Nephrotoxicity of aminoglycosides in young and adult rats. Adejuyigbe, O; Provoost, AP; Wolff, ED, 1985) | 0.27 |
| " These measurements confirmed the dosage of 5 micrograms per kg repeated every 8 hours in patients with normal renal function." | ( [Serial measurement of serum levels of amikacin. Value in therapy]. Charrel, CT; François, G; Gouin, F; Granthil, C; Martin, C; Savin, B, 1981) | 0.53 |
| " So, because of the risk of ototoxicity, the dosage should be reduced to 10 mg per kg-1 per 24 h-1, with measurements of the serum peak level and the level just before the following injection." | ( [Kinetics of multiple-dose amikacin in the newborn infant]. Camboulives, J; Charrel, C; Olivesi, A; Unal, D, 1981) | 0.56 |
| " Concurrently, physicians were instructed in the proper use and dosage of gentamicin via lectures and dosing nomograms provided by the clinical pharmacist." | ( Effect of aminoglycoside-use restrictions on drug cost. DeTorres, OH; White, RE, 1984) | 0.27 |
| "Six mares were given 5 IM injections (at 12-hour intervals between doses) of amikacin sulfate at a dosage of 7 mg/kg of body weight." | ( Amikacin sulfate in mares: pharmacokinetics and body fluid and endometrial concentrations after repeated intramuscular administration. Beal, C; Brown, MP; Curry, SH; Embertson, RM; Gronwall, RR; Mayhew, IG, 1984) | 1.94 |
| " Amikacin levels in plasma and perilymph were measured in guinea pigs after continuous intravenous infusion at four different dosing rates." | ( Correlation of amikacin concentrations in perilymph and plasma of continuously infused guinea pigs. Beaubien, AR; Desjardins-Giasson, S, 1984) | 1.53 |
| " Although this colorimetric method is not expected to be stability-indicating, it is convenient and should be useful in content uniformity determinations for pharmaceutical dosage forms (e." | ( Colorimetric determination of gentamicin, kanamycin, tobramycin, and amikacin aminoglycosides with 2,4-dinitrofluorobenzene. Ryan, JA, 1984) | 0.5 |
| " The daily dosage of cefoperazone ranged from 2 to 4 gm in two equally divided doses, and the daily dosage of amikacin ranged from 900 to 1,000 mg in two equally divided doses." | ( Comparative study of cefoperazone and amikacin. Chang, ST; Chung, ES; Whang, CW, 1984) | 0.75 |
| " She recovered after surgical drainage of the abscesses and prolonged treatment with intravenous amikacin and high dosage cotrimoxazole and sulphadimidine." | ( Abdominal nocardiosis in a Sudanese girl. Dickson, JA; Duerden, BI; Milner, RD; Salfield, SA, 1983) | 0.48 |
| "A spectrophotometric assay method for the quantitative determination of amikacin, kanamycin, neomycin, and tobramycin in pharmaceutical dosage forms has been developed." | ( Quantitation of amikacin, kanamycin, neomycin, and tobramycin in pharmaceutical dosage forms using the Hantzsch reaction. Gunter, JM; Gupta, VD; Stewart, KR, 1983) | 0.84 |
| " An intravenous drip infusion of AMK in adequate dosage would be beneficial to use against some infectious diseases of otorhinolaryngologic field." | ( [Clinical evaluation of ototoxicity associated with intravenous drip infusion of amikacin]. Hanamure, Y; Hashimoto, M; Iida, F; Kiyota, R; Kurono, Y; Maeyama, T; Ogawa, K; Ohhori, Y, 1983) | 0.49 |
| "The authors describe the use of a microcomputer to evaluate an existing dosage regimen and to determine a new regimen and steady-state peak and trough levels for four aminoglycoside antibiotics--amikacin, gentamicin, kanamycin, and tobramycin." | ( Aminoglycoside pharmacokinetics on a microcomputer. Buchanan, EC; Kaka, JS, 1983) | 0.46 |
| "To determine an adequate dosage of amikacin, a pharmacokinetic model was used based on lean body mass (LBM), age and serum creatinine." | ( Clinical application of amikacin dosage based upon lean body mass in patients with different renal function. Fieren, MW; Goessens, WH; Michel, MF; Wagenvoort, JH, 1984) | 0.85 |
| "The capabilities of two pharmacokinetic amikacin dosing methods were evaluated and compared with the standard amikacin dosage recommended by the manufacturer." | ( Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients. Britten, J; Caplan, E; deJongh, CA; Finley, RS; Fortner, CL; Newman, KA; Schimpff, SC; Wade, JC; Wiernik, PH, 1982) | 0.78 |
| " When the dosage was adjusted according to the patient's weight and serum creatinine, some nephrotoxicity occurred, possibly due to drug accumulation." | ( Netilmicin treatment of complicated urinary tract infections. Baumueller, A; Frimodt-Møller, N; Hoyme, U; Lau, C; Madsen, PO; Maigaard, S; Nielsen, OS; Welling, PG, 1980) | 0.26 |
| " Although intermittent injections can result in higher levels of aminoglycosides within the bronchial secretions, such levels cannot be maintained for prolonged periods unless the dosage is increased." | ( Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of bronchopulmonary infections due to gram-negative bacteria. Klastersky, J; Mombelli, G; Thys, JP, ) | 0.13 |
| "Serum amikacin concentrations were compared in infected renal transplant recipients that were compared in infected renal transplant recipients that were dosed using a creatinine-based nomogram (group I) or an individual computer-assisted pharmacokinetic dosing method (group II)." | ( Aminoglycoside dosing in renal transplant patients. Comparison of nomogram and individualized pharmacokinetic methods in patients with shifting renal function. Canafax, DM; Peterson, PK; Simmons, RL; Tofte, RW, 1982) | 0.75 |
| " Most of the cefoxitin-sensitive mycobacteria were inhibited by concentrations which can be easily attained in serum on standard dosage schedules." | ( In vitro susceptibility of mycobacteria species other than Mycobacterium tuberculosis to amikacin, cephalosporins and cefoxitin. Haas, H; Michel, J; Sacks, TG, 1982) | 0.49 |
| "576 serum levels at peak and before the next dosage (end level) were determined during clinical treatment conditions using radioimmunoassay in 131 patients treated with tobramycin or amikacin because of life-threatening infections." | ( [Control of serum levels of tobramycin and amikacin during clinical routine treatment conditions (author's transl)]. Daschner, F; Eiermann, T; Langmaack, H; Stark, GB, 1982) | 0.72 |
| " A dosage regimen for administration of the antibiotic is proposed for this kind of patient on the basis of desired peak and trough serum levels obtained throughout treatment." | ( Disposition kinetics of amikacin in patients with renal impairment after intramuscular administration. Dominguez-Gil, A; Lanao, JM; Molina, HD; Tabernero, JM, 1982) | 0.57 |
| " This rate change apparently is a physical phenomenon due to differing dosing volumes at different doses and attendant changes in the surface area to volume ratio at the injection site." | ( Effect of dosing volume on intramuscular absorption rate of aminoglycosides. Pfeffer, M; Van Harken, DR, 1981) | 0.26 |
| " There were no statistical differences between the gentamicin- and amikacin-treated patients in age, sex, weight, base-line creatinine clearance, concurrent cephalosporins or diuretics, treatment duration, site of infection, normalized (amikacin/gentamicin dosing ratio of 3:1) total dose, mortality, or tissue accumulation." | ( Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients. Cerra, FB; French, MA; Plaut, ME; Schentag, JJ, 1981) | 1.94 |
| " Some high-dose studies in rats have also suggested that the slope of the nephrotoxicity dose-response curve of netilmicin was less steep than the slopes of other aminoglycosides." | ( Nonparallel nephrotoxicity dose-response curves of aminoglycosides. Barnett, D; Christensen, EF; Gordon, LL; Hottendorf, GH; Madissoo, H, 1981) | 0.26 |
| " From thie equation, the dosage interval is modified to maintain the serum concentrations of the antibiotic within the therapeutic interval." | ( Pharmacokinetics of amikacin in children with normal and impaired renal function. Crespo, M; Dominguez-Gil, A; Dominguez-Gil, AA; Lanao, JM; Málaga, S; Santos, F, 1981) | 0.59 |
| " In the last of the 10 patients included in the survey, the evolution of the plasma concentrations of the antibiotic were studied while the patient was undergoing a multiple dosage regimen with the aim of determining the accumulation of Amikacin in the ascitic fluid." | ( The influence of ascites on the pharmacokinetics of amikacin. Diez, JL; Dominguez-Gil, A; Lanao, JM; Macias, JG; Nieto, MJ, 1980) | 0.69 |
| " Presently available computer-based dosage recommendations inadequately take into account the individual variability of the patient." | ( Basis for an adequate dosage of aminoglycoside antibiotics. Lüthy, R, 1980) | 0.26 |
| "The recommended neonatal dosage regime for amikacin of 15 mg/kg/day was found to be unsatisfactory in four neonates and a loading dose of 10 mg/kg did not improve levels in two further newborns with normal renal function." | ( Evaluation of amikacin dosage regimes in the low and very low birthweight newborn. Cookson, B; Leung, T; Tripp, J; Williams, JD, 1980) | 0.88 |
| " Furthermore, many of these assessments have used only one or two dose levels and have not described a dose-response comparison among antibiotics." | ( Comparative low-dose nephrotoxicities of gentamicin, tobramycin, and amikacin. Gordon, LL; Hottendorf, GH, 1980) | 0.5 |
| " Thus, monitoring of serum creatinine and aminoglycoside levels is recommended, especially for those with renal failure, in order to maintain an optimal dosage between toxic and noneffective serum aminoglycoside levels." | ( Pharmacokinetics of amikacin, netilmicin and tobramycin in children with chronic renal failure. Emre, S; Eti, S; Nayir, A; Sirin, A; Yeşilbek, T, ) | 0.45 |
| " A data set previously used to relate the incidence of amikacin ototoxicity to dosing rates and blood concentrations was re-examined to assess the toxicodynamics of amikacin in terms of decibels of hearing loss across dosing rate, hearing frequency and time following drug exposure." | ( Toxicodynamics and toxicokinetics of amikacin in the guinea pig cochlea. Beaubien, AR; Karpinski, K; Ormsby, E, 1995) | 0.81 |
| "During once-daily dosing regimens of aminoglycosides, administration of large single doses results in high peak levels and low 24-h trough levels." | ( Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Blaser, J; Cometta, A; Fatio, R; Follath, F; Glauser, M; König, C, 1995) | 0.56 |
| " In 4 of the patients with initial SC < 20 micrograms/ml, dosage was adjusted and thereafter therapeutic value was obtained (SC 24." | ( Determination of plasma concentrations of amikacin in patients of an intensive care unit. Abelha, F; Menezes, MR; Pimentel, FL; Sá, LV; Trigo, MA, 1995) | 0.56 |
| " Amikacin elimination by this approach should be taken into consideration for designing a dosage schedule during the treatment." | ( Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis. Fujita, H; Ikeda, Y; Ishii, M; Kihara, M; Masumori, S; Shibata, K; Shionoiri, H; Shiratori, K; Takagi, N; Umemura, S, 1995) | 1.46 |
| "Abbott Laboratories has developed a new software package (Abbottbase pharmacokinetic system or PKS package) that employs the principles of pharmacokinetics to assist clinical pharmacologists and clinicians in designing dosage regimens." | ( Abbott PKS system: a new version for applied pharmacokinetics including Bayesian estimation. Catalin, J; Durand, A; Gauthier, T; Guder, F; Lacarelle, B; Pisano, P; Villard, PH, 1994) | 0.29 |
| "Many dosing methods (nomogram, pharmacokinetic methods, Bayesian methods) can be used for the individualization of amikacin dosing." | ( Predictive performance of two software packages (USC*PACK PC and Abbott PKS system) for the individualization of amikacin dosage in intensive care unit patients. Catalin, J; Durand, A; Gauthier, T; Lacarelle, B; Marre, F; Villard, PH, 1994) | 0.71 |
| " A method has been designed to compute dosage regimens in order to maintain a constant steady-state average plasma concentration of 8 mg." | ( Pharmacokinetics and dosage regimens of amikacin in intensive care unit patients. Debord, J; Favereau, JP; Gay, R; Lachatre, G; Voultoury, JC, 1994) | 0.56 |
| " Individualized drug dosage regimens have made such therapy possible even in patients with impaired renal function." | ( Computation of drug concentrations in endocardial vegetations in patients during antibiotic therapy. Barbaut, X; Brazier, JL; Chuzeville, M; Confesson, MA; el Brouzi, M; Ivanoff, N; Jelliffe, RW; Maire, P; Pivot, C; Vergnaud, JM, 1994) | 0.29 |
| "Recording the times of dosage administration and serum sampling by trained personnel resulted in significantly greater adherence to the protocol of therapeutic drug monitoring and in significantly greater precision in the achievement of desired serum concentration goals of aminoglycoside therapy than when relatively untrained personnel recorded it as a comparatively unemphasized part of their job." | ( Prediction of future serum concentrations with Bayesian fitted pharmacokinetic models: results with data collected by nurses versus trained pharmacy residents. Breant, V; Charpiat, B; Jelliffe, R; Maire, P; Pivot-Dumarest, C, 1994) | 0.29 |
| "The efficiencies of two dosage schedules of amikacin (2 x 10 mg/kg of body weight per 24 h and 1 x 20 mg/kg/24 h intramuscularly for 5 days) against Pseudomonas aeruginosa sepsis in rabbits were compared." | ( Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin. Atanasova, I; Markova, B; Staneva, M; Terziivanov, D, 1994) | 0.77 |
| " 48 patients, aged 80 +/- 5 years, with estimated creatinine clearance (eCCR) of 48 +/- 15 ml/mn, received amikacin initial dosage of 13." | ( [Adaptive control of therapeutics using amikacin in very old patients: retrospective analysis of efficacy and toxicity]. Cogoluenhes, V; Confesson, MA; Courpron, P; Druguet, M; Grillot, M; Jelliffe, RW; Maire, PH; Pivot, C, 1994) | 0.77 |
| " It may be important to take account of the PAE when designing dosing regimens." | ( Postantibiotic effect of aminoglycosides on staphylococci. Isaksson, B; Maller, R; Nilsson, LE; Nilsson, M, 1993) | 0.29 |
| "Aminoglycosides (AG) are excellent antibiotics against gram-negative bacilli infections, but their use implies potential ototoxicity and nephrotoxicity if an excessive dosage is prescribed." | ( [Surveillance of therapy with aminoglycosides at a specialized hospital]. Aguilar-Orozco, G; Córdova-Rodríguez, C; León-Hernández, AC; Macías-Hernández, AE; Muñoz-Barrett, JM; Olivares-Durán, EM, ) | 0.13 |
| "The pharmacodynamic effects of extended imipenem dosing intervals were studied against two strains of Pseudomonas aeruginosa (ATCC 27853 and an imipenem-resistant mutant, 27853R) in an in vitro model of infection." | ( Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model. Lamp, KC; McGrath, BJ; Rybak, MJ, 1993) | 0.5 |
| "We conducted a randomized trial with ceftazidine alone or associated with amikacin or vancomycin to investigate the efficacy of the daily 3 g dosage of ceftazidime and the efficacy of monotherapy with ceftazidime and to determine if vancomycin should be added empirically." | ( Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial. Andremont, A; Chiche, D; Guiguet, M; Hayat, M; Lagrange, P; Lapierre, V; Marie, JP; Pico, JL; Richet, H; Tancrede, C, 1993) | 0.52 |
| " The pharmacokinetic data were used to calculate dosage schedules that would maintain the plasma amikacin concentrations in individual foals within a target range of > or = 15 micrograms/ml but < 30 micrograms/ml for peak values and < or = 3 micrograms/ml for trough values." | ( Clinical pharmacokinetics of amikacin in hypoxic premature foals. Conlon, PD; Green, SL, 1993) | 0.79 |
| " The efficacy of both dosage regimens was very good with a satisfactory clinical response in 90% of the patients." | ( Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group. Ahrne, H; Holmen, C; Lausen, I; Maller, R; Nilsson, LE; Smedjegård, J, 1993) | 0.59 |
| "To compare the efficacy and toxicity of single daily dosing of amikacin and ceftriaxone with that of multiple daily dosing of amikacin and ceftazidime for febrile episodes in patients with cancer and granulocytopenia." | ( Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the Eu , 1993) | 0.78 |
| "Single daily dosing of amikacin and ceftriaxone was as effective and no more toxic than multiple daily dosing of amikacin and ceftazidime for the empiric therapy of infection in patients with cancer and granulocytopenia." | ( Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the Eu , 1993) | 0.85 |
| " An intramuscular amikacin dosage of 15 to 20 mg/kg body weight either two or three times per day is recommended for treatment of infections caused by susceptible bacteria." | ( Pharmacokinetic properties of gentamicin and amikacin in the cockatiel. Ramsay, EC; Vulliet, R, ) | 0.72 |
| "Burn patients have altered aminoglycoside pharmacokinetics, which often result in subtherapeutic serum concentrations when these drugs are administered by conventional dosing (CD) methods." | ( Aminoglycoside dosing in burn patients using first-dose pharmacokinetics. Harper, DJ; Hollingsed, TC; Jennings, JP; Morris, SE; Saffle, JR, 1993) | 0.29 |
| "A once-daily dosage regimen has been recently recommended in the use of aminoglycoside antibiotics since they induce a postantibiotic effect." | ( Circadian variation in amikacin clearance and its effects on efficacy and toxicity in mice with and without immunosuppression. Hosokawa, H; Mifune, K; Nakamura, K; Nakano, S; Nyu, S, 1993) | 0.6 |
| " In all cases a 1-g dose of ceftazidime was administered; for amikacin, the dosage regimen was adjusted according to the patient's amikacin levels (250 to 750 mg)." | ( Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. Bouvet, O; Bressolle, F; de la Coussaye, JE; Eledjam, JJ; Fabre, D; Galtier, M; Kinowski, JM; Saissi, G, 1993) | 0.81 |
| " Therefore, in adult patients with a wide range of infections requiring aminoglycoside therapy, once-daily dosing with isepamicin is as effective as twice- daily dosing with amikacin." | ( Overview of the efficacy of isepamicin in the adult core clinical trial programme. Carbon, C, 1995) | 0.48 |
| "5 mg/kg of body weight twice daily or amikacin the same dosage regimen for the treatment of various infections in neutropenic and non-neutropenic paediatric patients were compared in a prospective randomised trial." | ( A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients. Principi, N; Viganò, A, 1995) | 0.83 |
| "In the past few decades aminoglycosides have usually been administered as multiple daily dosing regimens." | ( [Dosing aminoglycosides once a day]. Blaser, J, 1996) | 0.29 |
| "Once-daily dosage of aminoglycosides is currently under consideration." | ( In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model. Baron, D; Bugnon, D; Caillon, J; Drugeon, H; Kergueris, MF; Le Conte, P; Potel, G; Xiong, YQ, 1996) | 0.51 |
| " Teicoplanin was given intravenously at a dosage of 6 mg/kg of body weight at 0, 12, and 24 h and once a day thereafter." | ( Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Biard, O; Casassus, P; Guillevin, L; Lortholary, O; Padoin, C; Petitjean, O; Rizzo, N; Tod, M, 1996) | 0.29 |
| " After inoculation of the bacteria, the following intramuscular dosage regimens were carried out to test the antimicrobial effects: injection with 20 mg/kg of amikacin sulfate every 9 hr for 72 hr, injection with 20 mg/kg every 18 hr for 72 hr, injection with 20 mg/kg every 36 hr for 72 hr, and injection with 10 mg/kg every 12 hr for 72 hr." | ( Antimicrobial effects of amikacin therapy on experimentally induced Salmonella typhimurium infection in fowls. Hiramune, T; Itoh, N; Kikuchi, N, 1996) | 0.79 |
| " These data show synergistic bactericidal activity of both new extended cephalosporins combined with AKN, GTN or CIP at concentrations achievable in biological fluid with adaptative dosage regimen." | ( [Kinetics of bactericidal activity of cefepime and cefpirome alone or combined with gentamicin, amikacin or ciprofloxacin against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae hyperproductive in cephalosporinase]. Elkhaïli, H; Jehl, F; Kamili, N; Linger, L; Monteil, H; Pompei, D, 1996) | 0.51 |
| "Once daily amikacin dosing schedule rather divided doses every 8 or 12 hours has the potential to provide a more convenient dosing interval, reduced pharmacy and nursing time for preparation and administration." | ( [New modalities of administration of amikacin: economic point of view of a hospital pharmacist]. Charpiat, B; Tissier, G, 1996) | 0.96 |
| "The pharmacokinetics of Amikacin were studied in 56 febrile episodes for 45 patients with severe neutropenia while using the USC*Pack PC Clinical Programs for adaptive control of their dosage regimens [223 drug levels]." | ( [Assessment of pharmacokinetic parameters of amikacin in a group of neutropenic patients in onco-hematology]. Deweerdt, C; Maire, P; Pivot-Dumarest, C; Roux, D; Sorensen, P; Troncy, J, 1996) | 0.86 |
| "A randomized clinical trial was performed in children with cancer, fever and neutropenia, to evaluate the efficacy of amikacin once daily versus thrice daily dosing plus carbenicillin in both groups." | ( [Amikacin in single daily doses in children with fever]. Bernaldez-Ríos, R; Díaz-Bensussen, S; Díaz-Peña, R; Díaz-Ponce, H; Miranda-Novales, MG; Rivera-Márquez, H; Solórzano-Santos, F, ) | 1.25 |
| " The dosage was adjusted during therapy for 57% of the patients because of low levels, and for 43% of the patients because of toxic levels." | ( Aminoglycoside prescription, therapeutic monitoring and nephrotoxicity at a university hospital in Saudi Arabia. Bahnassy, AA; Eltahawy, AT, 1996) | 0.29 |
| " These data confirm the induction of aminoglycoside adaptive resistance in vivo and further support the advantages of once-daily aminoglycoside dosing regimens in the treatment of serious pseudomonal infections." | ( Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model. Baron, D; Bayer, AS; Caillon, J; Drugeon, H; Kergueris, MF; Potel, G; Xiong, YQ, 1997) | 0.3 |
| " Because the frequency of Pseudomonas aeruginosa is low in many centers, there is a rationale to test other antibiotic regimens that provide appropriate antibacterial coverage with the advantage of reduced dosing frequency, such as once daily ceftriaxone plus amikacin." | ( Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Chil Charnas, R; Lüthi, AR; Ruch, W, 1997) | 0.77 |
| " Consideration of hemodynamic response and vital support measures, in addition to other previously described covariates, can be of great value in the design of initial dosing regimens." | ( Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Castañeda-Hernández, G; Lugo, G, 1997) | 0.52 |
| " For the six dosage regimens used in this study, the killing activities were similar and resulted in at least 4 log decrease at 6 h after drug exposure." | ( [In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model]. Elkhaïli, H; Jehl, F; Levêque, D; Linger, L; Monteil, H; Niedergang, S; Peter, JD; Pompei, D; Salmon, J; Salmon, Y; Thierry, RC, 1997) | 0.59 |
| " aeruginosa, the CPO-AG combination is bactericidal at concentrations achievable with standard dosing regimens in man." | ( [Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance]. Canis, F; Cavallo, JD; Husson, MO, 1997) | 0.3 |
| "This investigation aimed to compare the efficacy and toxicity of two amikacin dosing regimens in seriously ill paediatric surgical patients." | ( A comparison of two amikacin dosing regimens in paediatric surgical patients. Botha, JH; Forsyth, NB; Hadley, GP, 1997) | 0.86 |
| "5 ml of amikacin encapsulated in lipid particle-based sustained-release dosage form." | ( Local treatment of prosthetic vascular graft infection with multivesicular liposome-encapsulated amikacin. Chen, JC; Furman, GM; Huh, J; Kafie, F; King, B; Malki, C; Wilson, SE, 1998) | 0.95 |
| "The disposition kinetics, urinary excretion and dosage regimen of amikacin after a single intravenous administration of 10 mg/kg was investigated in six cross-bred bovine calves." | ( The disposition kinetics, urinary excretion and dosage regimen of amikacin in cross-bred bovine calves. Saini, SP; Srivastava, AK, 1998) | 0.77 |
| "To derive pharmacokinetic data for 3 amikacin dosing regimens in guinea pigs and to determine whether the antibacterial activity of 15 mg/kg of body weight given twice daily is equivalent to administering the drug more frequently." | ( Comparison of amikacin dosing regimens in neutropenic guinea pigs with Escherichia coli infection. McClure, JT; Rosin, E, 1998) | 0.93 |
| "Aminoglycoside dosing regimen with high peak concentration and long drug-free interval is as efficacious as divided dose regimens." | ( Comparison of amikacin dosing regimens in neutropenic guinea pigs with Escherichia coli infection. McClure, JT; Rosin, E, 1998) | 0.66 |
| " The efficacy of both dosage regimens was very good with a satisfactory clinical response in 90." | ( Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections. Georgiou, A; Halkiadaki, D; Houpas, P; Karachalios, GN; Karachaliou, I; Papalimneou, V; Tziviskou, E, 1998) | 0.54 |
| " Predicted steady-state tissue concentrations for twice weekly dosing were >100 microg/g." | ( Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome). Fielding, RM; Lewis, RO; Moon-McDermott, L, 1998) | 0.56 |
| " The long tissue half-lives suggest liposomal amikacin is sequestered within tissues, and that an extended dosing interval is appropriate for chronic or prophylactic therapy with this formulation." | ( Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome). Fielding, RM; Lewis, RO; Moon-McDermott, L, 1998) | 0.82 |
| "24) microgram/ml with twice and single daily dosage schedules, respectively." | ( Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients. Ben Arush, MW; Elhasid, R; Krivoy, N; Postovsky, S, ) | 0.43 |
| " Blood cultures were taken before initiating empirical treatment: a) carbenicillin (400 mg/kg/day) plus amikacin (21 mg/kg/day) (Cb/ak), and b) ceftazidime (100 mg/kg/day), plus amikacin at the same dosage (Cz/ak)." | ( Empirical antimicrobial therapy in pediatric patients with neutropenia and fever. Risk factors for treatment failure. Belmont-Martinez, L; Bernaldez-Rios, R; Miranda-Novales, MG; Penagos-Paniagua, M; Solorzano-Santos, F; Villasis-Keever, MA, 1998) | 0.51 |
| " To develop appropriate dosing regimens for low-clearance liposomal amikacin, we studied the pharmacokinetics of liposomal amikacin in plasma, the level of exposure of plasma to free amikacin, and urinary excretion of amikacin after the administration of single-dose (20 mg/kg of body weight) and repeated-dose (20 mg/kg eight times at 48-h intervals) regimens in rhesus monkeys." | ( Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey. Fielding, RM; Horner, MJ; Lewis, RO; Moon-McDermott, L, 1999) | 0.8 |
| " The oxacillin-alone dosage represents a subtherapeutic regimen against the infecting strain in the endocarditis model (L." | ( Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses. Bayer, AS; Kupferwasser, LI; Xiong, YQ; Zack, PM, 1999) | 0.58 |
| "In fullterm neonatal patients, once daily dosing of amikacin is no more toxic than the twice daily regimen." | ( Once versus twice daily amikacin in neonates: prospective study on toxicity. Bartel, PR; Kotze, A; Sommers, DK, 1999) | 0.86 |
| " This synergistic PAE of amikacin with ceftazidime has a significant effect on designing optimal dosage regimens." | ( Postantibiotic effect of a combination of antimicrobial agents on pseudomonas aeruginosa. Mandal, A; Mishra, B; Sood, P, ) | 0.43 |
| "Ceftazidime and amikacin were administered in a Pseudomonas aeruginosa rabbit endocarditis model using computer-controlled intravenous (iv) infusion pumps to simulate human serum concentrations for the following regimens: continuous (constant rate) infusion of 4, 6 or 8 g of ceftazidime over 24 h or intermittent dosing of 2 g every 8 h either alone or in combination with amikacin (15 mg/kg once daily)." | ( In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. Baron, D; Bugnon, D; Caillon, J; Dube, L; Kergueris, MF; Le Conte, P; Navas, D; Potel, G; Robaux, MA, 2001) | 0.87 |
| "This study was undertaken in micropigs (i) to compare serum levels achieved by equal bolus dosages of two antibiotics (amikacin and vancomycin) administered through an intratibial needle, an intraosseous implantable device and central IV routes to determine whether standard parenteral dosing guidelines for antibiotics may be applied without modification for IO injection, and (ii) to show the efficiency of the implantable device over a prolonged period, as a permanent access to intraosseous space." | ( Pharmacokinetic longitudinal studies of antibiotics administered via a permanent intraosseous device in micropigs. Barberi-Heyob, M; Chastagner, P; Lascombes, P; Lozniewski, A; Merlin, JL; Merthes, PM, 2001) | 0.52 |
| " Therefore, it can be used for the population pharmacokinetic analysis and individualization of dosage regimen." | ( Population pharmacokinetic analysis of amikacin and validation on neonates using Monte Carlo method. Liang, WQ; Pan, CM; Wang, J; Wu, JJ, 2000) | 0.58 |
| " However, dosage regimens are not well defined in this group of patients because of a wide inter-individual pharmacokinetic variability." | ( Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models. Aulagner, G; Bleyzac, N; Boutroy, MJ; Jelliffe, RW; Labaune, JM; Maire, P; Putet, G, 2001) | 0.61 |
| " Dosage regimens of amikacin and other aminoglycosides should be revised in newborns with high GA." | ( Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. Aulagner, G; Bleyzac, N; Corvaisier, S; Jelliffe, RW; Labaune, JM; Maire, P; Putet, G; Varnier, V, 2001) | 0.92 |
| " Although low-clearance liposomes increased the safety, potency and dosing interval of amikacin in these models, all aminoglycosides, including liposomal amikacin, were only bactericidal in the presence of bacillary metabolism and growth." | ( The activity of low-clearance liposomal amikacin in experimental murine tuberculosis. Adler-Moore, J; Dhillon, J; Fielding, R; Goodall, RL; Mitchison, D, 2001) | 0.8 |
| "There remain concerns about the safety of once-daily dosing of aminoglycosides (AGs) in the elderly." | ( Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. Hite, Y; Kopyt, M; Raveh, D; Rudensky, B; Sonnenblick, M; Yinnon, AM, 2002) | 0.31 |
| " They received amikacin initial dosage of 17." | ( [Efficacy and toxicity of aminoglycoside therapy in the elderly: combined effect of both once-daily regimen and therapeutic drug monitoring]. Bourhis, Y; Coudray, S; Druguet, M; Ducher, M; Foltz, F; Maire, P; Rougier, F, 2002) | 0.67 |
| " The validation of this technique as adapted to the Dimension RXL HM has allowed its use for routine dosage adjustment of amikacin and netilmicin." | ( [Evaluation of Emit netilmicin and amikacin assays on Dimension RXL HM (Dade Behring) open channels]. Baltassat, P; Berny, C; Manchon, M; Mialon, A; Vételé, F, ) | 0.61 |
| " A simulation program assessed the influences of the dosage regimens on the occurrence of nephrotoxicity." | ( Aminoglycoside nephrotoxicity: modeling, simulation, and control. Claude, D; Corvaisier, S; Ducher, M; Jelliffe, R; Maire, P; Maurin, M; Rougier, F; Sedoglavic, A, 2003) | 0.32 |
| "To evaluate whether individualized pharmacokinetic dosing of aminoglycosides can reduce nephrotoxicity and improve the outcome of patients with gram-negative sepsis." | ( Pharmacokinetic dosing of aminoglycosides: a controlled trial. Alkan, M; Almog, Y; Bartal, C; Danon, A; Reisenberg, K; Schlaeffer, F; Sidi, A; Smoliakov, R, 2003) | 0.32 |
| " In the study group (pharmacokinetic dosing) of 43 patients, plasma aminoglycoside levels were determined 1 hour after initiation of drug infusion and 8 to 16 hours later to estimate the elimination half-life and volume of distribution, from which the subsequent dosage schedule was calculated." | ( Pharmacokinetic dosing of aminoglycosides: a controlled trial. Alkan, M; Almog, Y; Bartal, C; Danon, A; Reisenberg, K; Schlaeffer, F; Sidi, A; Smoliakov, R, 2003) | 0.32 |
| "These results suggest that individualized pharmacokinetic dosing of aminoglycosides reduces the incidence of nephrotoxicity and allows the use of greater doses of aminoglycosides." | ( Pharmacokinetic dosing of aminoglycosides: a controlled trial. Alkan, M; Almog, Y; Bartal, C; Danon, A; Reisenberg, K; Schlaeffer, F; Sidi, A; Smoliakov, R, 2003) | 0.32 |
| "The model is a powerful tool to represent and describe the influence of the dosage regimen on aminoglycoside nephrotoxicity." | ( Aminoglycoside dosages and nephrotoxicity: quantitative relationships. Claude, D; Corvaisier, S; Ducher, M; Jelliffe, R; Maire, P; Maurin, M; Rougier, F, 2003) | 0.32 |
| " In clinical use, the choice of the dosage regimen is not clear-cut, and both expected efficacy and expected toxicity must be taken into account in order to obtain an overall optimisation of each patient's therapy." | ( Aminoglycoside dosages and nephrotoxicity: quantitative relationships. Claude, D; Corvaisier, S; Ducher, M; Jelliffe, R; Maire, P; Maurin, M; Rougier, F, 2003) | 0.32 |
| " These data show that surprisingly excessive blood levels of amikacin are likely in infants < or = 1,000 gm and may also occur in larger infants using currently recommended dosage schedules." | ( Recommended amikacin doses in newborns often produce excessive serum levels. Cassady, G; Dworsky, ME; Philips, JB; Satterwhite, C, 1982) | 0.88 |
| "The aim of this study was to assess the pharmacokinetics of individualized amikacin single-dosage regimens targeting low peak serum concentrations in a population of intensive care unit (ICU) patients, and to describe the outcomes associated with this dosing strategy." | ( A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes. Adamidou, M; Bacopoulou, F; Markantonis, SL; Pavlou, E, 2003) | 0.86 |
| "Amikacin dosage individualization with low peak target concentrations was successful for the 36 ICU patients." | ( A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes. Adamidou, M; Bacopoulou, F; Markantonis, SL; Pavlou, E, 2003) | 2.08 |
| "28 mg/kg at shorter dosage interval (t) of 8 hr may be useful in case of normal goats whereas lower doses (D* of 13." | ( Effect of fever on pharmacokinetics and dosage regimen of intramuscularly administered amikacin in goats. Agrawal, AK; Jayachandran, C; Singh, SD, 2001) | 0.53 |
| " High-dose, extended-interval dosing regimens of amikacin in neonatal foals appear rational, although clinical use remains to be confirmed." | ( Pharmacokinetics of a high dose of amikacin administered at extended intervals to neonatal foals. Magdesian, KG; Mihalyi, J; Wilson, WD, 2004) | 0.85 |
| "To develop a simplified amikacin dosage regimen for nosocomial infections in preterm infants including a loading dose in order to achieve therapeutic Maximum Serum Concentrations early in the course of therapy." | ( Evaluation of an amikacin loading dose for nosocomial infections in very low birthweight infants. Berger, A; Gludovatz, P; Haiden, N; Heinze, G; Kretzer, V; Pollak, A, 2004) | 0.97 |
| "The new amikacin dosing protocol yielded targeted peak and trough concentrations in a high percentage of very low birthweight infants with nosocomial infection after the first week of life." | ( Evaluation of an amikacin loading dose for nosocomial infections in very low birthweight infants. Berger, A; Gludovatz, P; Haiden, N; Heinze, G; Kretzer, V; Pollak, A, 2004) | 1.1 |
| " This study compared the incidences of toxicities associated with 2 recommended dosing regimens." | ( Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Berning, SE; Cook, JL; Curran-Everett, D; Goble, M; Huitt, GA; Iseman, MD; Nitta, AT; Peloquin, CA; Simone, PM, 2004) | 0.32 |
| " Dosage regimens were designed to target a maximal plasma concentration 8-10 times the minimum inhibitory concentrations of the pathogen and to reduce the risk of aminoglycoside toxicity." | ( Comparison of amikacin pharmacokinetics in a killer whale (Orcinus orca) and a beluga whale (Delphinapterus leucas). Huff, D; KuKanich, B; Papich, M; Stoskopf, M, 2004) | 0.68 |
| " Although the lesions disappeared with the combined administration of clarithromycin and amikacin for 3 months in most cases, five out of 25 patients (20%) showed residual lesions at the end of treatment, and had to be treated with a higher dosage of clarithromycin or alternative antibiotics based on sensitivity tests." | ( Iatrogenic Mycobacterium abscessus infection associated with acupuncture: clinical manifestations and its treatment. Kim, WJ; Oh, CH; Ryu, HJ; Song, HJ, 2005) | 0.55 |
| " Dosage or duration of aminoglycosides use did not relate to SNHL." | ( Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure. Cheung, PY; Etches, PC; Peliowski, A; Robertson, CM; Tyebkhan, JM, 2006) | 0.33 |
| "Patients were allocated to receive, in addition to ceftriaxone sodium, amikacin sulfate, and metronidazole, molgramostim in a daily dosage of 3 microg/kg for 4 days (group 1) or placebo (group 2)." | ( Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. Arch, J; González, QH; Hinojosa, C; Medina-Franco, H; Orozco, H; Pantoja, JP; Sifuentes-Osornio, J; Vargas-Vorackova, F; Vilatoba, M, 2006) | 0.57 |
| "The objective of this article was to determine the current practice on amikacin dosing and monitoring in spinal cord injury patients from spinal cord physicians and experts." | ( Amikacin dosing and monitoring in spinal cord injury patients: variation in clinical practice between spinal injury units and differences in experts' recommendations. Almog, Y; Buczynski, AZ; Cannon, J; Jayawardena, V; Markantonis, SL; Peloquin, C; Soni, BM; Vaidyanathan, S; Vidal, J; Wyndaele, JJ, 2006) | 2.01 |
| " PK profiles and in vivo killing effects of the combination at different dosing ratios were studied." | ( Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model. Chan, E; Duan, W; Srikumar, S; Zhou, S, 2006) | 0.54 |
| " The dosing ratio of 12." | ( Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model. Chan, E; Duan, W; Srikumar, S; Zhou, S, 2006) | 0.54 |
| " Typical once-daily dosing (ODD) of 15 mg/kg amikacin (AMK) in burn patients does not always produce peak concentrations (C(max)) reaching the therapeutic objective of six to eight times the minimal inhibitory concentration (MIC)." | ( Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Breden, A; Chabanon, G; Coley, N; Conil, JM; Georges, B; Houin, G; Lavit, M; Saivin, S; Samii, K; Segonds, C; Seguin, T, 2006) | 1 |
| " Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process." | ( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A, ) | 0.13 |
| " A blood-crystalloid mixture dosed with amikacin was pumped from a reservoir through a hemofiltration circuit and back to the reservoir." | ( Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Choi, GY; Gomersall, CD; Ip, M; Joynt, GM; Tan, PE; Tian, Q, 2008) | 0.97 |
| " Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population." | ( An evaluation of amikacin nephrotoxicity in the hematology/oncology population. Kiel, PJ; Lo, M; Patel, GP; Stockwell, D, ) | 0.47 |
| " A hollow-fiber infection model (HFIM) simulating various clinical (fluctuating concentrations over time) dosing exposures was used to selectively validate our quantitative assessment of the combined killing effect." | ( Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Chang, KT; Hou, JG; Kwa, AL; Ledesma, KR; Lim, TP; Nikolaou, M; Prince, RA; Quinn, JP; Tam, VH, 2008) | 0.35 |
| " The dosage regimen of amikacin is regularly modified according to the patient's glomerular filtration rate (GFR)." | ( Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin. Halacova, M; Kotaska, K; Kukacka, J; Kuzelova, M; Prusa, R; Ticha, J; Vavrova, V, 2008) | 0.87 |
| "To facilitate optimal dosing regimen design, we previously developed a mathematical model using time-kill study data to predict the responses of Pseudomonas aeruginosa to various pharmacokinetic profiles of meropenem and levofloxacin." | ( Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Kabbara, S; Ledesma, KR; Lim, TP; Nikolaou, M; Tam, VH; Vo, G, 2008) | 0.35 |
| " To date, the use of these formulas in determining drug dosage and estimating drug elimination has not been thoroughly investigated." | ( Modification of Diet in Renal Disease and modified Cockcroft-Gault formulas in predicting aminoglycoside elimination. Bookstaver, PB; Johnson, JW; McCoy, TP; Stewart, D; Williamson, JC, 2008) | 0.35 |
| "The 6-variable MDRD performs better than the CG(m) formula in predicting aminoglycoside clearance and may be considered as a tool in aminoglycoside dosing recommendations." | ( Modification of Diet in Renal Disease and modified Cockcroft-Gault formulas in predicting aminoglycoside elimination. Bookstaver, PB; Johnson, JW; McCoy, TP; Stewart, D; Williamson, JC, 2008) | 0.35 |
| " Cl and t(1/2) are influenced by development, and this must be taken into consideration when planning a dosage regimen with aminoglycosides in the neonate." | ( Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Pacifici, GM, 2009) | 0.35 |
| " To develop an alternative dosing strategy for amikacin in neonates." | ( Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Broadbent, RS; Medlicott, NJ; Reith, DM; Sherwin, CM; Svahn, S; Van der Linden, A, 2009) | 0.91 |
| " Simulations were performed to develop a new dosing strategy." | ( Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Broadbent, RS; Medlicott, NJ; Reith, DM; Sherwin, CM; Svahn, S; Van der Linden, A, 2009) | 0.66 |
| " Following the logistic regression analysis of treatment failure, new amikacin target concentrations were estimated and used in development of an alternative dosing strategy." | ( Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Broadbent, RS; Medlicott, NJ; Reith, DM; Sherwin, CM; Svahn, S; Van der Linden, A, 2009) | 0.89 |
| "Simulation of a new dosing regimen yielded the following recommendations: 15 mg/kg at 36-h intervals, 14 mg/kg at 24-h intervals and 15 mg/kg at 24-h intervals for neonates < or = 28 weeks, 29-36 weeks and > or = 37 weeks postmenstrual age respectively." | ( Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Broadbent, RS; Medlicott, NJ; Reith, DM; Sherwin, CM; Svahn, S; Van der Linden, A, 2009) | 0.66 |
| " This variability is almost ignored in adult standard dosage regimens since only the weight is used in the dose calculation." | ( [Amikacin pharmacokinetics in adults: a variability that question the dose calculation based on weight]. Bourguignon, L; Burdin de Saint Martin, J; Ducher, M; Gérard, C; Goutelle, S; Guillermet, A; Maire, P, ) | 1.04 |
| "The aim of this study was to evaluate the reliability for dosage individualization and Bayesian adaptive control of several literature-retrieved amikacin population pharmacokinetic models in patients who were critically ill." | ( Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients. Ardanuy, R; Domínguez-Gil, A; Lanao, JM; Mar Fernández de Gatta, MD; Moreno, SR; Victoria Calvo, M, 2009) | 0.8 |
| "Only a single amikacin serum level seemed necessary to diminish the influence of population model on dosage individualization." | ( Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients. Ardanuy, R; Domínguez-Gil, A; Lanao, JM; Mar Fernández de Gatta, MD; Moreno, SR; Victoria Calvo, M, 2009) | 0.96 |
| " Single daily dosing with GM, regardless of the total daily dose, produced less nephrotoxicity than multiple dosing." | ( A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function. Sweileh, WM, 2009) | 0.6 |
| "7% were at inefficient rates, even when the recommended aminoglycoside dosage for was given." | ( [Monitoring aminoglycosides in an Intensive Care Unit]. Buguet-Brown, ML; Commandeur, D; Danguy des Déserts, M; Drouillard, I; Eyrieux, S; Giacardi, C; Le Noël, A; Nguyen, VB, 2010) | 0.36 |
| "The study aims to develop empirical models able to predict the pharmacokinetics (PK) of four beta-lactams using the amikacin (AMK) therapeutic drug monitoring (TDM), in order to optimize their dosage regimens." | ( Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. Cumps, J; Delattre, IK; Dugernier, T; Jacobs, F; Laterre, PF; Musuamba, FT; Spapen, H; Taccone, FS; Verbeeck, RK; Vincent, JL; Wallemacq, PE; Wittebole, X, 2010) | 0.77 |
| " Subsequently, a neutropenic murine pneumonia model with simulated clinical dosing exposures was used to validate our quantitative assessment of combined killing." | ( Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. Hou, J; Ledesma, KR; Prince, RA; Singh, R; Tam, VH; Yuan, Z, 2010) | 0.36 |
| " There is obviously a need to change the dosing regimen in terms of those with extended intervals, particularly for neonates of the lowest gestational age, along with pharmacokinetic measurements." | ( [Aminoglycoside trough levels in neonates]. Bozinović-Prekajski, N; Pejović, B; Ranković-Janevski, M, ) | 0.13 |
| "019) than those with the genes chromosomally encoded, which is most likely due to increased gene dosage provided by the higher copy number of associated plasmids." | ( Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan. Chang, FY; Chen, TL; Fung, CP; Hsueh, PR; Ko, WC; Kuo, SC; Lee, YT; Siu, LK, 2010) | 0.36 |
| " High dosage of aminoglycosides combined with CVVHDF may represent a valuable therapeutic option for infection due to multiresistant pathogens." | ( Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Fagnoul, D; Jacobs, F; Layeux, B; Taccone, FS; Vincent, JL, 2010) | 1.8 |
| " twice daily dosing of amikacin in neonates with suspected or proven sepsis and report on the drug's pharmacokinetics in these subjects." | ( The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. Abdel-Hady, E; Awad, H; El Hamamsy, M; Hedaya, M, 2011) | 0.93 |
| "A complex CDS advisor to provide guidance on initial dosing and monitoring of aminoglycoside orders, using both traditional-dosing and extended-interval-dosing strategies, was integrated into a computerized prescriber-order-entry (CPOE) system and compared with a control group whose aminoglycoside orders were closely monitored by pharmacists." | ( Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin. Cox, ZL; McCoy, JA; Nelsen, CL; Peterson, JF; Waitman, LR, 2011) | 0.59 |
| "An advisor for aminoglycoside dosing and monitoring integrated into a CPOE system significantly improved selection of initial doses and intervals and resulted in an improvement in the rate of trough serum drug concentrations at goal compared with standard provider dosing." | ( Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin. Cox, ZL; McCoy, JA; Nelsen, CL; Peterson, JF; Waitman, LR, 2011) | 0.59 |
| "The population pharmacokinetic model developed in this study may be used as a basis for finding optimal amikacin dosing in a Korean patient population without a significant bias." | ( Population pharmacokinetics of amikacin in a Korean clinical population. Ahn, BS; Jang, SB; Kim, HK; Kim, JH; Lee, YJ; Park, K; Park, MS; Song, YG, 2011) | 0.87 |
| " The aim of this study was to evaluate two AMK dosage regimens in comparison with standard therapy with regard to efficacy in achieving adequate plasma levels as well as safety." | ( Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Castro, J; Cornejo, R; Gálvez, R; Illanes, V; Kosche, J; Llanos, O; Luengo, C; Romero, C; Tobar, E, 2011) | 0.68 |
| "The aim of the study was to quantitatively predict the clearance of three antibiotics, amikacin, vancomycin, and teicoplanin, during continuous hemodiafiltration (CHDF) and to propose their optimal dosage in patients receiving CHDF." | ( Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration. Fujita, T; Hanafusa, N; Hisaka, A; Katada, S; Noiri, E; Suzuki, H; Yahagi, N; Yamamoto, T; Yasuno, N, 2011) | 0.59 |
| " The use of cephalosporins of the III-d generation and aminoglycosides in the high dosage is one of the possible safe forms to increase the effectiveness of antibacterial therapy in the treatment of nosocominal infection in the condition of polyresistent flora." | ( [Clinical and bacteriological efficiency of two modes of ceftazidim and aminkacin dosing in patients with ventilator-associated pneumonia]. Amonova, DS; Ibadova, DN, ) | 0.13 |
| " The model was used to derive a rational dosing regimen in comparison with currently used dosing regimens for amikacin." | ( Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Allegaert, K; Danhof, M; De Cock, RF; de Hoog, M; Knibbe, CA; Schreuder, MF; Sherwin, CM; van den Anker, JN, 2012) | 0.82 |
| " This analysis illustrated clearly that the currently used dosing regimens for amikacin in reference handbooks may possibly increase the risk of toxicities and should be revised." | ( Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Allegaert, K; Danhof, M; De Cock, RF; de Hoog, M; Knibbe, CA; Schreuder, MF; Sherwin, CM; van den Anker, JN, 2012) | 0.84 |
| " Finally, the model reflects maturation of the GFR, allowing for adjustments of dosing regimens for other renally excreted drugs in preterm and term neonates." | ( Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Allegaert, K; Danhof, M; De Cock, RF; de Hoog, M; Knibbe, CA; Schreuder, MF; Sherwin, CM; van den Anker, JN, 2012) | 0.61 |
| " Our guidelines include precise indications (severe sepsis, shock, drug resistance), dosing regimens (once-daily 20 mg/kg/day amikacin, 5 mg/kg/day gentamicin), durations of treatment, drug monitoring timing, and target C(max) concentrations (40 mg/l amikacin, 20 mg/l gentamicin)." | ( Therapeutic drug monitoring of aminoglycosides in acute myeloid leukaemia patients. Alfandari, S; Allorge, D; Berthon, C; Blondiaux, N; Cliquennois, E; Gay, J; Herbaux, C; Mareville, J; Pasquier, F, 2012) | 0.59 |
| " However, the optimal aminoglycoside or the optimal dosage remains uncertain." | ( The optimal aminoglycoside and its dosage for the treatment of severe Enterococcus faecalis infection. An experimental study in the rabbit endocarditis model. Asseray, N; Bugnon, D; Caillon, J; Dubé, L; Jacqueline, C; Potel, G, 2012) | 0.38 |
| "The study confirmed the significant link between the exposure to AMK and to β-lactams, and presented population models able to guide β-lactam dosage adjustments using renal biomarkers or TDM-related aminoglycoside data." | ( Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin. Delattre, IK; Jacobs, F; Jacqmin, P; Laterre, PF; Musuamba, FT; Taccone, FS; Verbeeck, RK; Wallemacq, P, 2012) | 0.6 |
| " Trials of new drugs and new dosing strategies are needed." | ( The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Aarnoutse, RE; Boeree, MJ; Daley, CL; Egelund, EF; Heifets, LB; Levin, A; Mouton, JW; Peloquin, CA; Totten, SE; van Ingen, J, 2012) | 0.38 |
| " The aim of this paper is to describe major approaches, methods and underlying basic foundations implemented, in clinical practice, for dosage individualization." | ( Progress in strategies for dosage regimen individualization. Benay, S; Frances, N; Iliadis, A; Marouani, H; Woloch, C, 2012) | 0.38 |
| "Peak and trough plasma concentrations and multiple serum levels in a dosage interval were measured and the latter fitted to both a one- and two-compartment model." | ( An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. Casey, E; Corrigan, OI; D'Arcy, DM; Donnelly, MB; Gowing, CM, 2012) | 0.67 |
| "The multi serum level study indicated that the one compartment model was adequate to characterize the pharmacokinetics in these patients suggesting that peak and trough plasma level data may be used to estimate individual patient pharmacokinetic parameters and to optimise individual patient dosing during treatment with CVVHDF." | ( An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. Casey, E; Corrigan, OI; D'Arcy, DM; Donnelly, MB; Gowing, CM, 2012) | 0.67 |
| " The use of pharmacokinetic parameter estimates obtained from two steady state serum-drug concentrations (peak and trough) can be used to guide individualised dosing of critically ill patients treated with CVVHDF." | ( An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. Casey, E; Corrigan, OI; D'Arcy, DM; Donnelly, MB; Gowing, CM, 2012) | 0.67 |
| "It appears necessary to use higher amikacin dosage (≥ 25 mg/kg) considering hemodynamic response of patients to sepsis." | ( Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. Ahmadi, A; Mahmoudi, L; Mohammadpour, AH; Mojtahedzadeh, M; Niknam, R, 2013) | 0.93 |
| " This population model would provide useful guidance in developing initial amikacin dosage regimens for such patients, especially using multiple model (MM) dosage design, followed by appropriate Bayesian adaptive control, to optimize amikacin dosage regimens for each individual patient." | ( Amikacin population pharmacokinetics in critically ill Kuwaiti patients. Abdul-Malek, K; Al-lanqawi, Y; Jelliffe, R; Matar, KM, 2013) | 2.06 |
| " The aminoglycoside dosage currently applied in Indonesia is derived from studies done in Caucasian populations." | ( Lack of a relationship between the serum concentration of aminoglycosides and ototoxicity in neonates. Dwijayanti, A; Louisa, M; Rundjan, L; Setiabudy, R; Simanjuntak, E; Suwento, R; Yasin, FH, 2013) | 0.39 |
| "Theoretical doses and dosing regimens allowing reaching target concentrations in this population were calculated by applying a pharmacokinetic model to 30 geriatric patients treated by amikacin." | ( Guidelines for aminoglycoside use and applicability to geriatric patients. Bourguignon, L; Leroy, B; Maire, P; Uhart, M, 2013) | 0.58 |
| " It is frequently necessary to use dosing intervals greater than 48 hours." | ( Guidelines for aminoglycoside use and applicability to geriatric patients. Bourguignon, L; Leroy, B; Maire, P; Uhart, M, 2013) | 0.39 |
| "The objectives of this study were to conduct a comparative pharmacokinetic/pharmacodynamic (PK/PD) evaluation using Monte Carlo simulation of conventional versus high-dose extended-interval dosage (HDED) regimens of amikacin (AMK) in intensive care unit (ICU) patients for an Acinetobacter baumannii infection model." | ( Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. Lanao, JM; Martín-Suárez, A; Zazo, H, 2013) | 0.97 |
| " Further pharmacodynamic studies are needed to establish the optimal dosing regimen for amikacin in paediatric burn patients." | ( Amikacin population pharmacokinetics among paediatric burn patients. Healy, D; Kagan, R; Neely, A; Sherwin, CM; Spigarelli, MG; Stockmann, C; Wead, S, 2014) | 2.07 |
| " It seems that pulmonary delivery of SLNs may improve patients' compliance due to reduction of drug side effects in kidneys and elongation of drug dosing intervals due to the sustained drug release from SLNs." | ( Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. Atyabi, F; Azarmi, S; Ghaffari, S; Jafarian, A; Kobarfard, F; Mirshojaei, SF; Varshosaz, J, 2013) | 0.72 |
| " The literature supports dosing ranges for amikacin and tobramycin of 30-35 and 7-15 mg/kg/day, respectively, given once daily, with subsequent doses determined by therapeutic drug concentration monitoring." | ( Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT, 2013) | 0.65 |
| "An amikacin maturation model can precisely reflect maturation of glomerular filtration and thus predict the dosage regimens of other renally excreted drugs by glomerular filtration in neonates." | ( Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates. Biran, V; Jacqz-Aigrain, E; Zhao, W, 2013) | 2.45 |
| " This semi-physiological approach may be used to optimize sparse data analysis and to derive individualized dosing algorithms for drugs in children." | ( A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Allegaert, K; Danhof, M; De Cock, RF; de Hoog, M; Knibbe, CA; Nielsen, EI; Sherwin, CM; van den Anker, JN, 2014) | 0.79 |
| " This article presents an outline on performing a population PK/PD study and translating these results into rational dosing regimens, with the development and prospective evaluation of PK/PD derived evidence-based dosing regimen being discussed." | ( Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. Admiraal, R; Boelens, JJ; Bredius, RG; Knibbe, CA; Tibboel, D; van Kesteren, C, 2014) | 0.4 |
| "Study results indicating improved neonatal amikacin therapy outcomes through the use of a dosage regimen tailored to population-specific pharmacokinetic parameters are presented." | ( Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates. An, SH; Gwak, HS; Kim, JY, 2014) | 0.94 |
| "In a retrospective analysis, outcomes of amikacin therapy were evaluated in two groups of Korean neonates: group 1 (n = 107), who received amikacin according to standard neonatal dosing recommendations and empirical dosing guidelines, which often resulted in a need for dosage adjustments; and group 2 (n = 74), who were treated under a revised dosage regimen derived from pharmacokinetic data on group 1 and taking into account unusually high interpatient variability in amikacin clearance among Korean newborns relative to Caucasian populations." | ( Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates. An, SH; Gwak, HS; Kim, JY, 2014) | 0.94 |
| "Relative to standard and empirical amikacin dosing, the revised dosage regimen resulted in a significantly higher percentage of neonates achieving peak concentrations within the target range of 20-30 mg/L (81." | ( Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates. An, SH; Gwak, HS; Kim, JY, 2014) | 0.95 |
| "A new amikacin dosing regimen based on the pharmacokinetic parameters of Korean neonates was effective in achieving peak and trough amikacin concentrations within the target range." | ( Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates. An, SH; Gwak, HS; Kim, JY, 2014) | 1.16 |
| "Fifteen minutes after dosing with the 300/120 mg amikacin/fosfomycin combination, tracheal aspirate amikacin concentrations±SD were 12,390±3,986 μg/g, and fosfomycin concentrations were 6,174±2,548 μg/g (n=6)." | ( A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patients. Abuan, T; Davies, A; Montgomery, AB; Tservistas, M; Vallance, S, 2014) | 0.88 |
| " It was included all patients with intravenous amikacin treatment in extended interval dosing regimen with therapeutic drug monitoring of amikacin." | ( [Influence of ethnicity on the pharmacokinetics of amikacin]. Barrantes-González, M; Conde-Estévez, D; Grau, S; Marín-Casino, M; Salas, E, 2013) | 0.9 |
| "The purpose of the study was to compare peak (Cpeak) and trough (Ctrough) amikacin levels after twice-daily (TD) or once-daily dosing (OD) in full-term neonates." | ( Pharmacokinetic variability of amikacin after once-daily and twice-daily dosing regimen in full-term neonates. Janković, B; Miljković, B; Prostran, M; Rakonjac, Z; Vučićević, K, 2014) | 0.92 |
| " Conversely paediatric studies have shown lower rates and extended interval dosing may have reduced toxicity further." | ( Aminoglycoside toxicity in neonates: something to worry about? Heath, PT; Kent, A; Sharland, M; Turner, MA, 2014) | 0.4 |
| " Unfortunately, dosing of these aminoglycosides in critically ill patients is difficult due to their altered pharmacokinetics in the critically ill and narrow therapeutic index." | ( Limited sampling strategy for estimation of amikacin optimal sampling time in critically ill adults. Ahmadi, A; Mahmoudi, L; Mohammadpour, AH; Mojtahedzdeh, M; Niknam, R, 2014) | 0.66 |
| " Results of a recent Phase II trial suggest that LAI, with the capacity for once-daily dosing and prolonged off-drug periods, may be an attractive choice of inhaled antibiotic to manage PsA lung infections in CF patients." | ( Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients. Clancy, JP; Ehsan, Z; Wetzel, JD, 2014) | 0.73 |
| " Even with new dosing regimens of 25 mg/kg, 30% of patients do not meet the pharmacodynamic target." | ( Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Bouadma, L; Chemam, S; de Montmollin, E; Gault, N; Mariotte, E; Massias, L; Mourvillier, B; Papy, E; Sonneville, R; Tubach, F; Wolff, M, 2014) | 0.7 |
| "The Cystic Fibrosis Foundation recently deemed the use of extended-interval dosing (EID) of aminoglycosides acceptable for the treatment of cystic fibrosis (CF) pulmonary exacerbations." | ( A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs. Prescott, WA, 2014) | 0.4 |
| " More than 95% of programs reported frequently or always using this dosing method." | ( A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs. Prescott, WA, 2014) | 0.4 |
| "This study indicates that the use of EID of aminoglycosides across United States adult CF programs has increased considerably since the publication of the CF pulmonary exacerbation guidelines and now appears to be the most common method for dosing aminoglycosides in adults with CF." | ( A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs. Prescott, WA, 2014) | 0.4 |
| " The dosage was dependent on the stage of chronic kidney disease (CKD)." | ( [In the search for effective and safe dose of amikacin in patients with chronic kidney disease]. Brodowska-Kania, D; Dubchak, I; Gomółka, M; Jurkiewicz, D; Niemczyk, S; Piechota, W; Rymarz, A; Szamotulska, K, 2014) | 0.66 |
| " Every two days dosage is less effective than every day dosage in patients with stage 4 CKD." | ( [In the search for effective and safe dose of amikacin in patients with chronic kidney disease]. Brodowska-Kania, D; Dubchak, I; Gomółka, M; Jurkiewicz, D; Niemczyk, S; Piechota, W; Rymarz, A; Szamotulska, K, 2014) | 0.66 |
| "This study aimed to develop optimal amikacin dosing regimens for the empirical treatment of Gram-negative bacterial sepsis in pediatric patients with burn injuries." | ( Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis. Healy, DP; Kagan, RJ; Neely, AN; Olson, J; Sherwin, CM; Spigarelli, MG; Stockmann, C; Wead, S; Yu, T, ) | 0.71 |
| "High-dose extended-interval dosage (HDED) regimen of aminoglycosides is now considered as the standard dosage strategy in sepsis." | ( Administration of higher doses of amikacin in early stages of sepsis in critically ill patients. Ahmadi, A; Ahmadvand, A; Khalili, H; Mahmoudi, L; Mojtahedzadeh, M; Najafi, A; Najmeddin, F; Sadeghi, K, 2014) | 0.68 |
| " We characterized amikacin pharmacokinetic variability in critically ill patients with ventilator-associated pneumonia (VAP) and evaluated several dosing regimens." | ( Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. Armand-Lefèvre, L; Burdet, C; Couffignal, C; Foucrier, A; Laouénan, C; Massias, L; Mentré, F; Pajot, O; Wolff, M, 2015) | 1.01 |
| "In ICU patients with VAP, classic imipenem pharmacodynamic targets are easily reached with usual dosing regimens." | ( Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia. Armand-Lefevre, L; Burdet, C; Couffignal, C; Da Silva, D; Foucrier, A; Laouénan, C; Lasocki, S; Massias, L; Mentec, H; Mentré, F; Pajot, O; Wolff, M, 2015) | 0.73 |
| " In the 50 remaining patients, a change in dosing was performed in 14 patients, leading adequate peak plasma level in 2 patients." | ( Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. Aubert, C; Barbar, S; Bastide, S; Elotmani, L; Lefrant, JY; Lloret, S; Molinari, N; Muller, L; Nucci, B; Polge, A; Pradel, G; Roberts, JA; Roger, C; Saissi, G, 2015) | 0.75 |
| " It provides useful information towards the enhancement of drug therapies, aiding in dosage control and toxicity risk management." | ( Design of a surface plasmon resonance immunoassay for therapeutic drug monitoring of amikacin. Estevez, MC; Lechuga, LM; Losoya-Leal, A; Martínez-Chapa, SO, 2015) | 0.64 |
| " Growth, maturation and environmental factors affect drug kinetics, response and dosing in pediatric patients." | ( Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children. Pfister, M; Rodieux, F; van den Anker, JN; Wilbaux, M, 2015) | 0.42 |
| " This model, in combination with the limited sampling strategy developed, can be used in daily routine to guide dosing but also to assess AUC0-24h in phase 3 studies." | ( Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. Akkerman, OW; Alffenaar, JW; de Lange, WC; Dijkstra, JA; Kosterink, JG; Proost, JH; van Altena, R; van der Werf, TS, 2015) | 0.66 |
| "Based on a previously derived population pharmacokinetic model, a novel neonatal amikacin dosing regimen was developed." | ( Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. Allegaert, K; Danhof, M; De Cock, RF; Knibbe, CA; Smits, A; Vanhaesebrouck, S, 2015) | 0.89 |
| " The method is fitted for the purpose of being a competitive alternative to the currently used method in many hospitals for AMK dosage control: fluorescence polarization immunoassay (FPIA)." | ( Fit-for-purpose chromatographic method for the determination of amikacin in human plasma for the dosage control of patients. Escuder-Gilabert, L; Ezquer-Garin, C; Lisart, RF; Martín-Biosca, Y; Medina-Hernández, MJ; Sagrado, S, 2016) | 0.67 |
| "We aimed to compare the performance of renal function and age as predictors of inter-individual variability (IIV) in clearance of amikacin in neonates through parallel development of population pharmacokinetic (PK) models and their associated impact on optimal dosing regimens." | ( Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies. Colom, H; Illamola, SM; van Hasselt, JG, 2016) | 0.89 |
| " Using stochastic simulations for both renal function or age-based dosing, we identified optimal dosing strategies that were based on attainment of optimal peak- (PCC) and trough target concentration coverage (TCC) windows associated with efficacy and toxicity." | ( Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies. Colom, H; Illamola, SM; van Hasselt, JG, 2016) | 0.69 |
| " Dosing simulations for amikacin supported the use of high dosing regimens (≥25 mg/kg) and extended intervals (36 to 48 h) for most patients when considering PK/pharmacodynamic (PD) targets of a maximum concentration in plasma (Cmax)/MIC ratio of ≥8 and a minimal concentration of ≤2." | ( Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy. Lefrant, JY; Lipman, J; Muller, L; Roberts, JA; Roger, C; Saissi, G; Wallis, SC, 2016) | 1 |
| " Although aminoglycosides are extensively used, the accurate determination of their optimal dosage is complicated by marked intra- and interindividual variability in intensive care unit patients." | ( Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies. Blin, O; Guilhaumou, R; Marsot, A; Riff, C, 2017) | 1.9 |
| " However, formal pharmacokinetic/pharmacodynamic (PK/PD) studies to identify amikacin exposures and dosing schedules that optimize Mycobacterium tuberculosis killing have not been performed." | ( Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis. Deshpande, D; Gumbo, T; Modongo, C; Pasipanodya, JG; Siyambalapitiyage Dona, CW; Srivastava, S, 2016) | 2.11 |
| " houtenae serovar and the ability to deliver effective amikacin dosage via osmotic pump to arrest osteomyelitis due to salmonellosis in a venomous snake." | ( MANAGEMENT OF OSTEOMYELITIS CAUSED BY SALMONELLA ENTERICA SUBSP. HOUTENAE IN A TAYLOR'S CANTIL (AGKISTRODON BILINEATUS TAYLORI) USING AMIKACIN DELIVERED VIA OSMOTIC PUMP. Clancy, MM; Newton, AL; Sykes, JM, 2016) | 0.89 |
| "The objectives of this study were to identify the amikacin dosage regimens and drug concentrations consistent with good outcomes and to determine the drug exposures related to nephrotoxicity and ototoxicity." | ( Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. Brown, NM; Jenkins, A; Lovering, AM; MacGowan, A; Semple, Y; Sluman, C; Thomson, AH; Wiffen, PJ, 2016) | 2.13 |
| " Measured peaks averaged 28 mg/L for twice-daily dosing and 40-45 mg/L for once-daily dosing; troughs averaged 5 and 1-2 mg/L, respectively." | ( Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. Brown, NM; Jenkins, A; Lovering, AM; MacGowan, A; Semple, Y; Sluman, C; Thomson, AH; Wiffen, PJ, 2016) | 1.88 |
| "This systematic review found little published evidence to support an optimal dosage regimen or TDM targets for amikacin therapy." | ( Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. Brown, NM; Jenkins, A; Lovering, AM; MacGowan, A; Semple, Y; Sluman, C; Thomson, AH; Wiffen, PJ, 2016) | 2.09 |
| " abscessus pulmonary disease evaluated patient background data, AMK dosage and duration, sputum conversion, clinical symptoms radiological findings, and adverse events." | ( Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series. Asakura, T; Betsuyaku, T; Fujiwara, H; Hasegawa, N; Hoshino, Y; Ishii, M; Kurashima, A; Kurosaki, A; Morimoto, K; Namkoong, H; Nishimura, T; Sugiura, H; Suzuki, S; Tanaka, H; Tasaka, S; Yagi, K; Yamada, Y, 2016) | 0.66 |
| " The pulmonary deposition of LAI was evaluated in female rats (n = 76) treated with LAI by nebulizer at 10 mg/kg of body weight per day or 90 mg/kg per day for 27 days, followed by dosing of dually labeled LAI (LAI with a lipid label plus an amikacin label) on day 28 with subsequent lung histological and amikacin analyses." | ( Pulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and Effect on Macrophage Function after Administration in Rats. Eagle, G; Gupta, R; Malinin, V; Neville, M; Perkins, WR, 2016) | 0.87 |
| " A dosing regimen has been developed and validated using pharmacometrics, considering current weight, postnatal age, perinatal asphyxia, and ibuprofen use." | ( The amikacin research program: a stepwise approach to validate dosing regimens in neonates. Allegaert, K; Kulo, A; Smits, A; van den Anker, J, 2017) | 1.01 |
| " The average age of the sample was 59 years; 88% were female; 92% were white; and 80 and 59 patients completed study drug dosing during the double-blind and open-label phases, respectively." | ( Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Addrizzo-Harris, DJ; Brown-Elliott, BA; Daley, CL; Dorgan, D; Eagle, G; Flume, PA; Griffith, DE; Gupta, R; Liu, K; McGinnis, JP; Micioni, L; Olivier, KN; Ruoss, S; Salathe, M; Wallace, RJ; Winthrop, KL, 2017) | 0.74 |
| " Currently there is no quantitative approach that can be used by clinicians to adjust dosing so that toxic drug concentrations can be brought back to levels observed with safe and efficacious therapeutic doses." | ( Facilitate Treatment Adjustment After Overdosing: Another Step Toward 21st-Century Medicine. Koch, G; Pfister, M; Schropp, J, 2017) | 0.46 |
| " The goal of this study was to examine the effects of cumulative intravenous (IV)-AG (amikacin and/or tobramycin) and/or glycopeptide (vancomycin) dosing on hearing status in patients with CF." | ( The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. Carroll, K; Cohen, DM; Cross, CP; Feeney, MP; Garinis, AC; Gold, JA; Hunter, LL; Keefe, DH; Putterman, DB; Srikanth, P; Steyger, PS, 2017) | 0.68 |
| " Dosing was calculated using two strategies: (i) total number of lifetime doses, and (ii) total number of lifetime doses while accounting for the total doses per day." | ( The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. Carroll, K; Cohen, DM; Cross, CP; Feeney, MP; Garinis, AC; Gold, JA; Hunter, LL; Keefe, DH; Putterman, DB; Srikanth, P; Steyger, PS, 2017) | 0.46 |
| "Cumulative IV-antibiotic dosing has a significant negative effect on hearing sensitivity in patients with CF, when controlling for age and gender effects." | ( The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. Carroll, K; Cohen, DM; Cross, CP; Feeney, MP; Garinis, AC; Gold, JA; Hunter, LL; Keefe, DH; Putterman, DB; Srikanth, P; Steyger, PS, 2017) | 0.46 |
| "To evaluate the pharmacokinetic parameters and toxicities of once-daily amikacin (AMK) dosing for lung disease due to Mycobacterium abscessus." | ( Once-daily dosing of amikacin for treatment of Choi, JE; Jeon, K; Jhun, BW; Kim, DH; Kim, SY; Ko, JY; Koh, WJ; Lee, H; Lee, SY; Moon, IJ; Park, HJ; Park, HY; Shin, SJ; Sohn, YM, 2017) | 1.01 |
| "This study aimed at investigating variables affecting amikacin pharmacokinetics in order to propose optimal initial dosing in critically ill adult patients treated with once-daily amikacin regimen." | ( Estimation of once-daily amikacin dose in critically ill adults. Cikánková, T; Hartinger, J; Šíma, M; Slanař, O, 2018) | 1.03 |
| " Several amikacin dosing guidelines have been proposed for treating neonates with (suspected) septicemia; however, none provide adjustments for cases of PATH." | ( Amikacin Pharmacokinetics To Optimize Dosing in Neonates with Perinatal Asphyxia Treated with Hypothermia. Allegaert, K; Cristea, S; Knibbe, CAJ; Krekels, EHJ; Kulo, A; Smits, A; van Weissenbruch, M, 2017) | 2.31 |
| " Therefore, CVVHDF dose should be taken into account when dosing amikacin." | ( Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients. Broch, MJ; Castellanos-Ortega, Á; Gordon, M; Martin-Cerezula, M; Poveda, JL; Ramírez, P; Remedios Marqués, M; Ruiz-Ramos, J; Villarreal, E, 2018) | 0.98 |
| " These results suggested that hyaluronic acid conjugation could reduce the dosage of antibiotic in treatment of intracellular bacterial infection, and further helping to alleviate the emergence of drug resistance in bacteria due to a long-term, high-dosage treatment." | ( Synthesis of hyaluronan-amikacin conjugate and its bactericidal activity against intracellular bacteria in vitro and in vivo. Duan, J; Hou, C; Li, X; Mu, H; Qiu, Y; Sun, F; Wang, D; Wang, F; Wang, Z; Yi, H, 2018) | 0.79 |
| " Therefore, convincing data are not available from the perspective of pharmacokinetics to support the fact that a dosage of 20 mg/kg of amikacin is sufficient to treat patients with ventilator-associated pneumonia (VAP)." | ( Evaluation of Epithelial Lining Fluid Concentration of Amikacin in Critically Ill Patients With Ventilator-Associated Pneumonia. Ahmadi, A; Azadbakht, S; Dianatkhah, M; Mojtahedzadeh, M; Najafi, A; Najmeddin, F; Rouini, MR; Shahrami, B; Sharifnia, H, 2020) | 1.01 |
| "Our objective was to determine the population pharmacokinetic parameters of amikacin in pediatric patients to contribute to the future development of a revised optimum dose and population-specific dosing regimens." | ( Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling. Abouelkheir, M; Alkoraishi, A; Alqahtani, S; Alsultan, A; Elsharawy, Y; Mansy, W; Osman, R, 2018) | 1.1 |
| " Pharmacokinetic/pharmacodynamic (PK/PD) simulations were performed to explore the ability of different dosage regimens to achieve the pharmacodynamic targets." | ( Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling. Abouelkheir, M; Alkoraishi, A; Alqahtani, S; Alsultan, A; Elsharawy, Y; Mansy, W; Osman, R, 2018) | 0.87 |
| "The simulation results indicated that amikacin 20 mg/kg once daily provided a higher probability of target attainment with lower toxicity than dosing three times daily." | ( Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling. Abouelkheir, M; Alkoraishi, A; Alqahtani, S; Alsultan, A; Elsharawy, Y; Mansy, W; Osman, R, 2018) | 1.14 |
| " Pediatric patients represent a particularly fragile population where adequate dosing is crucial yet challenging to achieve due significant IIV associated with developmental processes and other factors." | ( Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses. Illamola, SM; Sherwin, CM; van Hasselt, JGC, 2018) | 0.77 |
| " Local data on the pharmacokinetic/pharmacodynamic behavior of various antimicrobials in pediatrics are of great value for dosing adjustment in our pediatric population." | ( [Therapeutic monitoring of antimicrobial agents in pediatrics. Review based on Latin American experiences]. Barraza, M; Morales, J; Torres, JP; Zylbersztajn, B, ) | 0.13 |
| "To use a pre-clinical infection model to assess the antibacterial effect of human simulations of dosing with ceftolozane/tazobactam (with or without amikacin) or meropenem against Enterobacteriaceae and Pseudomonas aeruginosa." | ( Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection. Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2018) | 0.92 |
| " We performed a retrospective chart review to collect the amikacin dosing regimens, serum amikacin concentrations, blood sampling times, and patient characteristics for adults with cystic fibrosis admitted for treatment of acute pulmonary exacerbations." | ( Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. Bhakta, ZN; Carveth, H; Huynh, HQ; Illamola, SM; Liou, TG; Liu, X; Sherwin, CM; Young, DC, 2018) | 1.01 |
| " Using the final PK model, we developed a workflow for selecting optimal dosing strategies for 3 representative pediatric patient profiles." | ( Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children. Allegaert, K; De Cock, P; Healy, DP; Kagan, RJ; Liu, X; Renard, M; Sherwin, CMT; Smits, A; Wang, Y; Wead, S, 2019) | 0.83 |
| " Future investigations are needed to explore the impact of other diseases on amikacin disposition in children, and to prospectively validate the proposed dosing strategy." | ( Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children. Allegaert, K; De Cock, P; Healy, DP; Kagan, RJ; Liu, X; Renard, M; Sherwin, CMT; Smits, A; Wang, Y; Wead, S, 2019) | 1.06 |
| " The aim of this review was to search relevant pharmacokinetic (PK) and pharmacodynamic (PD) literature for the optimal dose and dosing frequency of amikacin in MDR-TB regimens trying to optimize efficacy while minimizing toxicity." | ( Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. Akkerman, OW; Alffenaar, JC; Bolhuis, MS; Ghimire, S; Simbar, N; Sturkenboom, MGG, 2018) | 2.12 |
| " Aminoglycoside dosing in CF differs from the general population due to altered pharmacokinetics." | ( Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation. Arora, V; Autry, EB; Burgess, DR; Burgess, DS; Kuhn, RJ; Nolt, VD; Pijut, KD; Williams, WC, 2019) | 1.96 |
| " Current guideline dosing recommendations of amikacin 30-35 mg/kg/day are only adequate for PsA with a MIC ≤4 mg/L." | ( Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation. Arora, V; Autry, EB; Burgess, DR; Burgess, DS; Kuhn, RJ; Nolt, VD; Pijut, KD; Williams, WC, 2019) | 2.22 |
| "Our study demonstrates the usefulness of TDM-based dosing adjustment of AG antibiotics in achieving nontoxic trough concentrations, particularly in critically ill patients, as they are prone to a renal impairment." | ( Interest of therapeutic drug monitoring of aminoglycosides administered by a monodose regimen. Aouam, K; Ben Aicha, S; Ben Fadhel, N; Ben Fredj, N; Ben Romdhane, H; Boughattas, N; Chaabane, A; Chadly, Z, 2019) | 0.51 |
| " Based on the guidelines of the American Thoracic Society, she was started on weight-based dosing of clarithromycin, levofloxacin, ethambutol, isoniazid and injection amikacin daily." | ( Pulmonary Gopalan, N; Hanna, LE; Joseph, B; Kannayan, S; Padmapriyadarsini, C; Perumal, BK; Saranathan, R; Sivaramakrishnan, GN, ) | 0.33 |
| " Patients aged 1 month to 18 years old who received amikacin, gentamicin, or vancomycin between October 2012 to March 2016 and had at least 2 serum drug concentrations done within the same dosing interval were included." | ( A Retrospective Review of the Efficiency of First-Dose Therapeutic Drug Monitoring of Gentamicin, Amikacin, and Vancomycin in the Pediatric Population. Chan, JW; Chua, JM; Chua, WBB; Lee, Q; Lim, WXS; Poh, BH; Sultana, R, 2020) | 1.03 |
| "Cyclical dosing of once-daily ALIS was noninferior to cyclical twice-daily TIS in improving lung function." | ( Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. Bilton, D; Cipolli, M; Clancy, JP; Eagle, G; Fajac, I; Galeva, I; Gupta, R; Konstan, MW; Liu, K; McGinnis, JP; Minic, P; Pressler, T; Quittner, AL; Sands, D; Solé, A, 2020) | 2 |
| " However, current dosing recommendations remain disputed (Illamola et al." | ( Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model. Marsot, A; Matouk, E; Pasche, V; Thirion, DJG, 2020) | 2 |
| " Monte Carlo simulations from the evaluated model were used to compare maximum concentration/minimum inhibitory concentration achieved with different dosing regimens." | ( Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model. Marsot, A; Matouk, E; Pasche, V; Thirion, DJG, 2020) | 2 |
| " According to these simulations, we developed the Montreal amikacin nomogram to optimize amikacin dosing regimens in patients with CF." | ( Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model. Marsot, A; Matouk, E; Pasche, V; Thirion, DJG, 2020) | 2.24 |
| "In conclusion, we developed the first nomogram to optimize initial amikacin dosing regimens in patients with CF based on this external evaluation of a recently published amikacin population PK model." | ( Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model. Marsot, A; Matouk, E; Pasche, V; Thirion, DJG, 2020) | 2.24 |
| " Probabilities of reaching targets were calculated for the dosage proposed." | ( Amikacin initial dosage in patients with hypoalbuminaemia: an interactive tool based on a population pharmacokinetic approach. Calvo, MV; Lanao, JM; Martín-Suárez, A; Pérez-Blanco, JS; Sáez Fernández, EM, 2020) | 2 |
| "To conduct a population PK analysis of amikacin data from patients with mycobacterial infections and compare predicted concentrations from standard and modified dosage guidelines with recommended target ranges." | ( Population pharmacokinetic evaluation and optimization of amikacin dosage regimens for the management of mycobacterial infections. Robb, F; Siebinga, H; Thomson, AH, 2020) | 1.07 |
| " Increasing the dosage interval for patients with CLCR <50 mL/min reduced Cmin values >2 mg/L from 34% to 25% for once-daily dosing and from 18% to 13% for TTW." | ( Population pharmacokinetic evaluation and optimization of amikacin dosage regimens for the management of mycobacterial infections. Robb, F; Siebinga, H; Thomson, AH, 2020) | 0.8 |
| "Standard amikacin dosing guidelines achieve low percentages of target concentrations for mycobacterial infections." | ( Population pharmacokinetic evaluation and optimization of amikacin dosage regimens for the management of mycobacterial infections. Robb, F; Siebinga, H; Thomson, AH, 2020) | 1.22 |
| "Patient demographics, pathology, amikacin dosing history, amikacin concentrations and Abbottbase® predicted TDM targets (area under the curve up to 24 hours, maximum concentration and trough concentration) were collected for adults receiving intravenous amikacin (2012-2017)." | ( Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing. Carland, JE; Day, RO; Lau, C; Marriott, DJE; McLeay, RC; Ryan, AC; Stocker, SL, 2021) | 1.26 |
| "Amikacin dosing and TDM practice was suboptimal compared with guidelines." | ( Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing. Carland, JE; Day, RO; Lau, C; Marriott, DJE; McLeay, RC; Ryan, AC; Stocker, SL, 2021) | 2.42 |
| " Our observations, based on combined clinical and PK data in children with oncology diagnoses, can be useful to feed dosing software programs to improve drug exposure in special populations." | ( Covariates of amikacin disposition in a large pediatric oncology cohort. Allegaert, K; Dewandel, I; Laenen, A; Renard, M; Smits, A, 2021) | 0.98 |
| " The pharmacodynamic activity of the aminoglycosides was then assessed in a dynamic one-compartment infection model over 72 h using simulated human pharmacokinetics of once-daily dosing with amikacin (15 mg/kg), gentamicin (5 mg/kg) and tobramycin (5 mg/kg)." | ( Optimizing aminoglycoside selection for KPC-producing Klebsiella pneumoniae with the aminoglycoside-modifying enzyme (AME) gene aac(6')-Ib. Bulman, ZP; Butler, DA; Hauser, AR; Huang, Y; Krapp, F; Ozer, EA; Patel, SR; Rana, AP, 2021) | 0.81 |
| "In children with cystic fibrosis (CF), the currently recommended amikacin dose ranges between 30 and 35 mg/kg/d; however, data supporting this dosing efficacy are lacking." | ( A Population Pharmacokinetic Modeling Approach to Determine the Efficacy of Intravenous Amikacin in Children with Cystic Fibrosis. Bouchet, S; Bui, S; Fayon, M; Marquet, P; Monchaud, C; Woillard, JB, 2021) | 1.08 |
| " Because amikacin undergoes renal clearance, which is immature until 1 year of age, dosing recommendations for this age group may be markedly high, warranting cautious interpretation." | ( A Population Pharmacokinetic Modeling Approach to Determine the Efficacy of Intravenous Amikacin in Children with Cystic Fibrosis. Bouchet, S; Bui, S; Fayon, M; Marquet, P; Monchaud, C; Woillard, JB, 2021) | 1.26 |
| " aeruginosa isolates (amikacin MICs 2, 8, and 64 mg/L) were exposed to simulated epithelial lining fluid exposures of nebulized amikacin with dosing regimens of 400 mg and 800 mg once- or twice-daily up to 7-days using the in vitro hollow-fiber infection model." | ( Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa. Andrews, K; Ellwood, D; Grimwood, K; Guerra-Valero, Y; Heffernan, AJ; Lipman, J; Naicker, S; Roberts, JA; Sime, FB; Wallis, S, 2021) | 1.17 |
| " aeruginosa isolates, the combined susceptibility rates (susceptible at standard dosing regimen plus susceptible at increased exposure) were highest to ceftazidime-avibactam, colistin and amikacin (≥82." | ( In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018). Piérard, D; Stone, GG, 2021) | 0.81 |
| "Using pharmacokinetic (PK) models and Bayesian methods in dosing software facilitates the analysis of individual PK data and precision dosing." | ( To Estimate or to Forecast? Lessons From a Comparative Analysis of Four Bayesian Fitting Methods Based on Nonparametric Models. Alloux, C; Bourguignon, L; Goutelle, S; Maire, P; Neely, M; Van Guilder, M, 2021) | 0.62 |
| "The monitoring of antimicrobial therapy through plasma levels makes it possible to determine the optimal dosage of antimicrobials, an essential approach in pediatrics." | ( [Impact of the vancomycin and amikacin therapeutic monitoring in the optimization of antimicrobial dose in pediatric patients]. Chávez M, P; Delpiano M, L; Fernández H, A; Hernández M, R, 2021) | 0.91 |
| " Moreover, in the elderly population, pathophysiological changes affect these pharmacokinetic variables, making it difficult to predict the appropriate dose and dosing schedule for amikacin." | ( Evaluation of amikacin dosing schedule in critically ill elderly patients with different stages of renal dysfunction. Ghaffari, S; Hadi, AM; Mojtahedzadeh, M; Najafi, A; Najmeddin, F; Rouini, MR; Shahrami, B, 2022) | 1.27 |
| "The initial dosing of amikacin in critically ill elderly patients should not be reduced, even in the context of renal impairment." | ( Evaluation of amikacin dosing schedule in critically ill elderly patients with different stages of renal dysfunction. Ghaffari, S; Hadi, AM; Mojtahedzadeh, M; Najafi, A; Najmeddin, F; Rouini, MR; Shahrami, B, 2022) | 1.4 |
| "Considering the aminoglycosides' characteristics in terms of efficacy and toxicity, multiple dosing recommendations and nomograms have been suggested over several decades." | ( Aminoglycosides' dosing and monitoring practices in critically ill patients in Quebec hospitals. Duong, A; Marsot, A; Simard, C; Thirion, DJG; Williamson, D, 2022) | 0.72 |
| "The aim of this study was to characterize the population pharmacokinetics of amikacin in elderly patients by means of nonlinear mixed effects modelling and to propose initial dosing schemes to optimize therapy based on PK/PD targets." | ( Amikacin pharmacokinetics in elderly patients with severe infections. Barcia, E; Cervero, M; García, B; Medellín-Garibay, SE; Parada, A; Romano-Aguilar, M; Romano-Moreno, S; Suárez, D, 2022) | 2.39 |
| "Initial dosing approach for amikacin was designed for elderly patients based on nonlinear mixed effects modeling to maximize the probability to attain efficacy and safety targets considering individual BMI and CrCL." | ( Amikacin pharmacokinetics in elderly patients with severe infections. Barcia, E; Cervero, M; García, B; Medellín-Garibay, SE; Parada, A; Romano-Aguilar, M; Romano-Moreno, S; Suárez, D, 2022) | 2.46 |
| " All cases received either oral clarithromycin at 500 mg twice-daily dosage or oral azithromycin at 500 mg daily." | ( Outcomes of Nontuberculous Mycobacterial Keratitis After Clear Corneal Incision Phacoemulsification Surgery: A Case Series of 6 Eyes in South Florida. Chhaya, N; Koo, EH; Miller, D; Shaik, N; Tonk, RS; Weiss, M; Zhu, A, 2022) | 0.72 |
| " To that end, the authors developed in previous work a mathematical modeling framework that can use such measurements for design of effective dosing regimens." | ( Deciphering longitudinal optical-density measurements to guide clinical dosing regimen design: A model-based approach. Eales, BM; Kesisoglou, I; Merlau, PR; Nikolaou, M; Tam, VH, 2022) | 0.72 |
| " We dosed IV MEM at 25 mg/kg every 8 h and inhaled AMK at 400 mg every 12 h." | ( Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia. Artigas, A; Battaglini, D; Bobi, J; Cabrera, R; Camprubí-Rimblas, M; Fernández-Barat, L; Ferrer-Segarra, A; Frigola, G; Kiarostami, K; Li Bassi, G; Martinez, D; Meli, A; Motos, A; Nicolau, DP; Pagliara, F; Pelosi, P; Rigol, M; Torres, A; Vila, J; Yang, H; Yang, M, 2023) | 1.34 |
| "The pharmacokinetics/pharmacodynamics (PK/PD) of amikacin in critically ill patients undergoing continuous venovenous hemodiafiltration (CVVHDF) are poorly described, and appropriate dosing is unclear in this patient population." | ( Population pharmacokinetic/pharmacodynamic evaluations of amikacin dosing in critically ill patients undergoing continuous venovenous hemodiafiltration. Li, S; Xie, F; Zhu, S, 2023) | 1.41 |
| "3), nonrisk of drug resistance (T>MIC > 60%) and risk of toxicity (trough concentration > 5 mg/l) for different dosing regimens." | ( Population pharmacokinetic/pharmacodynamic evaluations of amikacin dosing in critically ill patients undergoing continuous venovenous hemodiafiltration. Li, S; Xie, F; Zhu, S, 2023) | 1.15 |
| " The population pharmacokinetic modeling approach can aid in designing optimal dosage regimens for amikacin in neonates." | ( Predictive Performance of Population Pharmacokinetic Models for Amikacin in Term Neonates. Chaudhari, BB; Dillibatcha, J; Lewis, LE; Mallayasamy, S; Matcha, S; Moorkoth, S; Raju, AP, 2023) | 1.37 |
| " Dosing regimens were suggested for neonates using the pharmacometric simulation approach generated by the selected model." | ( Predictive Performance of Population Pharmacokinetic Models for Amikacin in Term Neonates. Chaudhari, BB; Dillibatcha, J; Lewis, LE; Mallayasamy, S; Matcha, S; Moorkoth, S; Raju, AP, 2023) | 1.15 |
| " Dosage regimens were designed to attain target therapeutic concentrations for the virtual subjects and a nomogram was developed." | ( Predictive Performance of Population Pharmacokinetic Models for Amikacin in Term Neonates. Chaudhari, BB; Dillibatcha, J; Lewis, LE; Mallayasamy, S; Matcha, S; Moorkoth, S; Raju, AP, 2023) | 1.15 |
| " A developed nomogram can assist clinicians to design an optimal dosage regimen of amikacin for term neonates." | ( Predictive Performance of Population Pharmacokinetic Models for Amikacin in Term Neonates. Chaudhari, BB; Dillibatcha, J; Lewis, LE; Mallayasamy, S; Matcha, S; Moorkoth, S; Raju, AP, 2023) | 1.37 |
| "The aim of this work was to integrate the Therapeutic Drug Monitoring (TDM) with the model-informed precision dosing (MIPD) approach, using Physiologically-based Pharmacokinetic/Pharmacodynamic (PBPK/PD) modelling and simulation, to explore the relationship between amikacin exposure and estimated glomerular filtration rate (GFR) in critically ill patients with cancer." | ( Failure to predict amikacin elimination in critically ill patients with cancer based on the estimated glomerular filtration rate: applying PBPK approach in a therapeutic drug monitoring study. Caruso, P; de Lima Moreira, F; de Souza Borges, O; Diegues, MS; E Silva, ILF; Gavazza, BV; Migotto, KC; Pinto, L; Reghini, R; Schmidt, S; Telles, JP, 2023) | 1.42 |
| " These recent clinical and population pharmacokinetics studies help improve management protocols with optimized initial dosing and infusion rules for β-lactams, vancomycin, daptomycin and amikacin; they highlight the potential benefits of therapeutic drug monitoring." | ( Advances in antibacterial treatment of adults with high-risk febrile neutropenia. Bouscary, D; Canouï, E; Charlier, C; Contejean, A; Fantin, B; Garcia-Vidal, C; Kernéis, S; Maillard, A; Parize, P, 2023) | 1.1 |
| " Few serious adverse events occurred for ALIS users; however, reduction of dosing to three times weekly was common (52%)." | ( Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease. Brown-Elliott, BA; Brunton, AE; Fuss, C; Griffith, DE; Philley, JV; Siegel, SAR; Strnad, L; Sullivan, PE; Wallace, RJ; Winthrop, KL, 2023) | 1.23 |
| " Further studies are warranted to optimize drug delivery and dosing in humans." | ( Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model. Eales, BM; Hudson, CS; Kajiji, S; Liu, X; Smith, JE; Tam, VH; Truong, LD, 2023) | 0.91 |
| Role | Description |
|---|---|
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| antibacterial drug | A drug used to treat or prevent bacterial infections. |
| nephrotoxin | A poison that interferes with the function of the kidneys. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| O-hydroxybutyryl-L-carnitine | An O-acyl-L-carnitine that is L-carnitine having a hydroxybutyryl group as the acyl substituent in which the positions of the hydroxy group is unspecified. |
| hydroxy-fatty acyl-L-carnitine | An O-acylcarnitine in which the R group is a hydroxylated fatty acyl chain. |
| alpha-D-glucoside | |
| aminoglycoside | |
| carboxamide | An amide of a carboxylic acid, having the structure RC(=O)NR2. The term is used as a suffix in systematic name formation to denote the -C(=O)NH2 group including its carbon atom. |
| amino cyclitol glycoside | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Amikacin Action Pathway | 1 | 4 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 3.0112 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| G | Vesicular stomatitis virus | Potency | 4.7724 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 0.3379 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| Interferon beta | Homo sapiens (human) | Potency | 4.7724 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 4.7724 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 4.7724 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 4.7724 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 23.7101 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 9.0743 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 0.1585 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 39.8107 | 0.0601 | 10.7453 | 37.9330 | AID492961 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.6315 | 4.4531 | 9.3000 | AID1473740 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.2000 | 5.6774 | 10.0000 | AID1473741 |
| Bile salt export pump | Homo sapiens (human) | IC50 (µMol) | 134.0000 | 0.1100 | 7.1903 | 10.0000 | AID1443980; AID1473738 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 2.4100 | 6.3433 | 10.0000 | AID1473739 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Adiponectin receptor protein 2 | Homo sapiens (human) | Kd | 3.1000 | 3.1000 | 3.1000 | 3.1000 | AID1189230 |
| Adiponectin receptor protein 1 | Homo sapiens (human) | Kd | 1.8000 | 1.8000 | 1.8000 | 1.8000 | AID1189229 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Aminoglycoside 3'-phosphotransferase | Pseudomonas aeruginosa PAO1 | Km | 440.0000 | 10.0000 | 10.0000 | 10.0000 | AID278807 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1739719 | Inhibition of bovine heart mitochondrial complex 1 at 10 uM measured every minute for 2 hrs by microplate reader based assay | 2020 | European journal of medicinal chemistry, Aug-15, Volume: 200 | Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I. |
| AID1739739 | Hypoglycemic activity in 6 hrs fasted normal lean C57BL/6 mouse assessed as reduction in blood glucose level at 100 mg/kg, ig pretreated for 2 hrs followed by glucose challenge and measured up to 90 mins post glucose challenge starting from 120 mins prior | 2020 | European journal of medicinal chemistry, Aug-15, Volume: 200 | Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I. |
| AID1189230 | Binding affinity to AdipoR2 (unknown origin) by surface plasmon resonance analysis | 2015 | Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1 | Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases. |
| AID1739710 | Induction of glucose consumption in mouse C2C12 cells at 10 uM measured after 12 hrs by glucose oxidase method (Rvb = 100 %) | 2020 | European journal of medicinal chemistry, Aug-15, Volume: 200 | Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I. |
| AID1189229 | Binding affinity to AdipoR1 (unknown origin) by surface plasmon resonance analysis | 2015 | Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1 | Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases. |
| AID1739709 | Activation of AMPK in mouse C2C12 cells assessed as increase in AMPK phosphorylation at Thr172 residue at 10 uM measured after 2 hrs by Western blot analysis | 2020 | European journal of medicinal chemistry, Aug-15, Volume: 200 | Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I. |
| AID523513 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3149 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID532169 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii PU55T harboring wild-type GyrA, ParC, GyrB and qnrA genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID1524044 | Antimicrobial activity against Salmonella typhimurium C7731 after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID498815 | Antimicrobial activity against Klebsiella pneumoniae FZ47T expressing IMP-8, TEM-1, CTX-M-14, qnrB2, aac(6')-Ib by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID1273398 | Anti-tubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294T after 7 days by mircodilution method | 2016 | European journal of medicinal chemistry, Jan-01, Volume: 107 | Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis. |
| AID577647 | Antimicrobial activity against Escherichia coli isolate 157 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 3 isolated from urine of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID539121 | Antibacterial activity against Escherichia coli 0157:H07 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID560074 | Antimicrobial activity against Enterobacter cloacae isolate 5420 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID551747 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 12 to 18 hrs by twofold dilution method | 2011 | Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1 | Synthesis and antibacterial activity study of a novel class of cationic anthraquinone analogs. |
| AID533341 | Antibacterial activity against non-gentamicin-resistant Haemophilus influenzae clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID531752 | Antibacterial activity against Pseudomonas aeruginosa 3308 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID373680 | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis, characterization and antimicrobial activity of Co(II), Zn(II) and Cd(II) complexes with N-benzyloxycarbonyl-S-phenylalanine. |
| AID373681 | Antibacterial activity against Klebsiella pneumoniae NCIMB 9111 after 24 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis, characterization and antimicrobial activity of Co(II), Zn(II) and Cd(II) complexes with N-benzyloxycarbonyl-S-phenylalanine. |
| AID529889 | Induction of necrosis in pig LLC-PK1 cells assessed as lactate dehydrogenase release | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Apoptosis induced by aminoglycosides in LLC-PK1 Cells: comparative study of neomycin, gentamicin, amikacin, and isepamicin using electroporation. |
| AID1732052 | Antibacterial activity against Mycobacterium smegmatis VKPM Ac-1339 | 2021 | European journal of medicinal chemistry, Apr-05, Volume: 215 | Discovery of novel N |
| AID278130 | Distribution of Escherichia coli AB1157 IL05 new born cells containing duplicated ori and ter foci at 16 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID533335 | Antibacterial activity against non-gentamicin-resistant Morganella morganii clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1524042 | Antimicrobial activity against Pseudomonas aeruginosa 25349 clinical isolates after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID509870 | Antibacterial activity against Acinetobacter baumannii isolate 5191 isolated from human urine | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID565071 | Antibacterial activity against CTX-M-15 ESBL producing Klebsiella pneumoniae assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID1868118 | Anti-tubercular activity against Mycobacterium tuberculosis CF152 assessed as inhibition of mycobacterial growth incubated for 7 days by resazurin-dye based analysis | 2022 | European journal of medicinal chemistry, Jul-05, Volume: 237 | Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation. |
| AID348091 | Antibacterial activity against Escherichia coli TG1 pET28a plasmid encoded for APH(3')-3a after 12 to 18 hrs | 2008 | Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23 | Surprising alteration of antibacterial activity of 5"-modified neomycin against resistant bacteria. |
| AID533598 | Antibacterial activity against gentamicin-resistant Citrobacter freundii clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID531580 | Antibacterial activity against Citrobacter braakii obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID1524033 | Antimicrobial activity against Escherichia coli UB1005 after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID523490 | Antimicrobial activity against Pseudomonas aeruginosa AHP Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID574587 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 obtained from pus of patient at 1 ug/ml by Bactec MGIT960 modified proportion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID584562 | Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1331878 | Antibacterial activity against Salmonella enterica ATCC 14028 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID1557268 | Antitubercular activity against resistant Mycobacterium tuberculosis harboring rrs A1401G mutant | 2019 | MedChemComm, Aug-01, Volume: 10, Issue:8 | Drug-resistance in |
| AID1449161 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. massiliense isolate 122 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID523488 | Antimicrobial activity against Pseudomonas aeruginosa R70 Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID285658 | Antimicrobial activity against Pseudomonas aeruginosa 19E12 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1474726 | Antibacterial activity against Bacillus subtilis ATCC 11774 after 20 to 24 hrs by broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | Novel bioactive molecules from Lentzea violacea strain AS 08 using one strain-many compounds (OSMAC) approach. |
| AID285159 | Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. |
| AID1442612 | Antibacterial activity against Pseudomonas aeruginosa PA1145 in BALB/c mouse model of lung infection administered as iv bid for 2 to 12 hrs of post-infection measured after 24 hrs | 2017 | Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6 | Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa. |
| AID1449158 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. massiliense isolate 140 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID1224525 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 4 after 7 days by micromethod | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. |
| AID535891 | Antimicrobial activity against aac(6')-Ib-cr-negative Citrobacter freundii JN64 harboring GyrA T83I, wild-type ParC, GyrB and qnrA genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID583240 | Antibacterial activity against Staphylococcus spp. by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID283548 | Antibacterial activity against Pseudomonas aeruginosa FE63 containing inactivated rplY and PA5471 genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID1478545 | Acute toxicity in iv dosed mouse at pH 6.6 administered for 4 days | 2017 | Bioorganic & medicinal chemistry, 06-01, Volume: 25, Issue:11 | Covalently linked kanamycin - Ciprofloxacin hybrid antibiotics as a tool to fight bacterial resistance. |
| AID285622 | Antimicrobial activity against Pseudomonas aeruginosa 8A12 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID510513 | Antibacterial activity against Escherichia coli ATCC 25922 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID523494 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1530c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID535697 | Antimicrobial activity against Azide-resistant Escherichia coli J53 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID1401966 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Synthesis and antimycobacterial activity of triterpeni≿ A-ring azepanes. |
| AID425073 | Antimicrobial activity against Escherichia coli DH10B expressing pCR2.1 in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID1858577 | Antibacterial activity against Mycobacterium Mycobacterium abscessus CIP 104536T infected in mouse RAW264.7 cells assessed as cell viability incubated for 4 to 5 days | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209 | Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery. |
| AID1231413 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as growth inhibition at 30 ug after 24 hrs by disc agar diffusion method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Synthesis and biological evaluation of caracasine acid derivatives. |
| AID535654 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ61 harboring GyrA S83I, GyrA D87A, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID625925 | Antibacterial activity against Pseudomonas aeruginosa by micro-broth dilution method | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Micelles catalyzed chemoselective synthesis 'in water' and biological evaluation of oxygen containing hetero-1,4-naphthoquinones as potential antifungal agents. |
| AID323041 | Antimicrobial activity against extended-spectrum-beta-lactamase producing Proteus mirabilis isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. |
| AID510509 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC4AC9-30 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID571910 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 19 expressing ampC, ompA, adeB, adeM, aacC2 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID540211 | Fraction unbound in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID534361 | Antibacterial activity against Acinetobacter baumannii GIL1 isolate harboring intrinsic blaOXA-51/69-like gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Carbapenem-resistant Acinetobacter baumannii isolates expressing the blaOXA-23 gene associated with ISAba4 in Belgium. |
| AID558052 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S15 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID1890838 | Antimycobacterial activity against Mycobacterium marinum ATCC BAA-535/M assessed as inhibition of mycobacterial growth incubated for 10 to 14 days by resazurin microtiter assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Design, synthesis and antibacterial activity against pathogenic mycobacteria of conjugated hydroxamic acids, hydrazides and O-alkyl/O-acyl protected hydroxamic derivatives. |
| AID534299 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA510 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID545446 | Antimicrobial activity against extended-spectrum beta-lactamase-negative Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID529486 | Antimicrobial activity against Enterobacter cloacae isolate 533 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID1743441 | Antibacterial activity against Mycobacterium aurum measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID528979 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID1463956 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate Praha 1 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID1868117 | Anti-tubercular activity against Mycobacterium tuberculosis CF76 assessed as inhibition of mycobacterial growth incubated for 7 days by resazurin-dye based analysis | 2022 | European journal of medicinal chemistry, Jul-05, Volume: 237 | Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation. |
| AID539129 | Antibacterial activity against vancomycin-intermediate and ciprofloxacin-, gentamicin-resistant Staphylococcus aureus 1269616 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID283398 | Antimicrobial activity against Nocardia carnea after 72 hrs by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. |
| AID733062 | Antitubercular activity against Mycobacterium tuberculosis H37Rv by microdilution alamar Blue broth assay | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents. |
| AID529858 | Ratio of MIC for Pseudomonas aeruginosa N043 to MIC for Pseudomonas aeruginosa PAO1 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID531591 | Antibacterial activity against Salmonella spp. obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID523497 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1529c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID531589 | Antibacterial activity against Proteus vulgaris obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID532187 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae SY26T harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID533334 | Antibacterial activity against non-gentamicin-resistant Serratia marcescens clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID534174 | Antimicrobial activity against armA positive Enterobacter cloacae BEH producing beta lactamase CTX-M-3 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID564016 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA isolated from wound infection of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID1324736 | Antibacterial activity against methicillin-resistant Staphylococcus aureus G14 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID446129 | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID554400 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2933 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID497949 | Antibacterial activity against Pseudomonas aeruginosa PA1054 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID498827 | Antimicrobial activity against Citrobacter freundii SZ63T expressing IMP-4, qnrS1by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID509865 | Antibacterial activity against Acinetobacter baumannii ATCC 17978 isolated from human CSF | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID774214 | Antibacterial activity against Escherichia coli PAZ505H8101 expressing AAC6'-1B after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID1422374 | Antibacterial activity against Escherichia coli PAZ505H8101 harboring AAC6'-1B by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID499066 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ88 deficient in CTX-M-14, ompC/F by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID283536 | Antibacterial activity against Pseudomonas aeruginosa FE53U with inactivated mexZ and galU genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID499055 | Antimicrobial activity against Escherichia coli PU101T expressing CMY-2 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID574806 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 horboring rpoB S531L/G566R/I569L, katG S315T/R463L, gyrA A90V/S95T, rrs A1401G by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID761207 | Antibacterial activity against Escherichia coli expressing defined beta-lactamase by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID1629129 | Antimicrobial activity against Acinetobacter baumannii ATCC 19606 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID542737 | Antimicrobial activity against Klebsiella pneumoniae D24 expressing aac(6')-Ib-cr and CTX-M-9G genes by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals. |
| AID65059 | Concentration required for half maximum rate of enhanced [3H]DHS uptake in Escherichia coli K12 | 1987 | Journal of medicinal chemistry, Feb, Volume: 30, Issue:2 | Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli. |
| AID531750 | Antibacterial activity against Pseudomonas aeruginosa FK06 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID560070 | Antimicrobial activity against Klebsiella pneumoniae isolate 5436 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID567305 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2203 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID520638 | Antimicrobial activity against Escherichia coli MRY04-1060 expressing qepA gene by agar dilution CLSI method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan. |
| AID498806 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ71 deficient in KPC-2, TEM-1, SHV-11, CTX-M-14, ompK35 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID499053 | Antimicrobial activity against carbapenem-resistant Escherichia coli PU96 deficient in TEM-1, CTX-M-14, CMY-2, ompC/F by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID394704 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing AAC(6')-1, ANT(2'')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID531787 | Antibacterial activity against Enterobacter aerogenes obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID250258 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH02; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID65223 | Minimum inhibitory concentration was measured against Escherichia coli OLA 290R5 producing AAD-(2'')-modifying enzyme | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID1324763 | Bacteriostatic activity against methicillin-resistant Staphylococcus aureus S22 at 0.5 times MIC measured up to 3 to 6 hrs by time kill analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID584558 | Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1310592 | Antibacterial activity against Proteus hauseri ATCC 13315 by broth microdilution method | 2016 | European journal of medicinal chemistry, Aug-08, Volume: 118 | Simple avarone mimetics as selective agents against multidrug resistant cancer cells. |
| AID532181 | Antimicrobial activity against aac(6')-Ib-cr-negative Klebsiella pneumoniae SY22T harboring qnrS gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID1449144 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. abscessus rough variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID554432 | Ratio of MIC for Pseudomonas aeruginosa 615R to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID572124 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 29 expressing ampC, ompA, adeM, aadB, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID428270 | Antimicrobial activity against Klebsiella sp. assessed as susceptible isolates by CLSI breakpoint assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID574430 | Antimicrobial activity against Escherichia coli isolate 386T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from wound of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID424858 | Antimicrobial activity against Pseudomonas aeruginosa GY3 producing blaVIM-2 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID404897 | Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB30 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus. |
| AID341595 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID533339 | Antibacterial activity against non-gentamicin-resistant Pseudomonas aeruginosa clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID584325 | Antibacterial activity against wild type Escherichia coli BW25113 | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics. |
| AID583239 | Antibacterial activity against Serratia spp. by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID497948 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID531586 | Antibacterial activity against Morganella morganii obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID278124 | Distribution of Escherichia coli AB1157 IL05 new born cells containing duplicated sister ori foci at 4 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID1232125 | Antimicrobial activity against vancomycin-resistant Enterococcus faecalis ATCC 1299 assessed as inhibition of bacterial growth incubated at 35 degC for 12 to 18 hrs | 2014 | MedChemComm, Aug-01, Volume: 5, Issue:8 | Antifungal Amphiphilic Aminoglycosides. |
| AID1890839 | Antimycobacterial activity against Mycobacterium tuberculosis mc2 6230 assessed as inhibition of mycobacterial growth incubated for 10 to 14 days by resazurin microtiter assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Design, synthesis and antibacterial activity against pathogenic mycobacteria of conjugated hydroxamic acids, hydrazides and O-alkyl/O-acyl protected hydroxamic derivatives. |
| AID65070 | Estimated rate of [3H]DHS (Dihydrostreptomycin) uptake in Escherichia coli K12 (ATCC 25868) [pmol/min (optical density unit)E-1] at the C50 was determined.; OD means optical density | 1987 | Journal of medicinal chemistry, Feb, Volume: 30, Issue:2 | Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli. |
| AID519178 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrZ mutant and MexZ mutant gene selected after 1 ug/ml of tobramycin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID1467546 | Antimicrobial activity against Mycobacterium tuberculosis H37Rv by Alamar blue assay | 2017 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14 | One-pot microwave assisted stereoselective synthesis of novel dihydro-2'H-spiro[indene-2,1'-pyrrolo-[3,4-c]pyrrole]-tetraones and evaluation of their antimycobacterial activity and inhibition of AChE. |
| AID565064 | Antibacterial activity against SHV-12 ESBL producing Enterobacter cloacae assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID499059 | Antimicrobial activity against carbapenem-resistant Enterobacter aerogenes PU41 deficient in CTX-M-14, DHA-1, qnrS1, ompC DEc, ompF by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID523405 | Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 after 3 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID533575 | Antibacterial activity against gentamicin-resistant Klebsiella pneumoniae clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID554387 | Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY operon by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID533763 | Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P122 exhibiting PFGE A pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID532020 | Antibacterial activity against macrolide-lincosamide-streptogramin B-negative, beta-lactamase-positive, methicillin-susceptible Staphylococcus aureus isolate 3 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate. |
| AID394683 | Antibacterial activity against Pseudomonas aeruginosa clinical isolate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID425069 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae M7943 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID564015 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA lung biopsy specimen of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID1322251 | Antibacterial activity against AAC6'-2A expressing Pseudomonas aeruginosa F03 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID508722 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1C3 PTOL1 harboring acquired beta-lactamase OXA-17 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID533338 | Antibacterial activity against non-gentamicin-resistant Acinetobacter calcoaceticus clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID520696 | Antimicrobial activity against Escherichia coli DH10B harboring p041060 carrying qepA gene by agar dilution CLSI method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan. |
| AID332075 | Antibacterial activity against Pseudomonas aeruginosa by agar dilution method | 2008 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11 | Antibacterial activity in serum of the 3,5-diamino-piperidine translation inhibitors. |
| AID535651 | Antimicrobial activity against aac(6')-Ib-cr-positive Escherichia coli FJ3T harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID565280 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID523400 | Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152-M3 expressing rrnA A1408G, rrnB A1408G and rrnC A1408G mutant genes after 3 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID1524123 | Bactericidal activity against Escherichia coli 078 incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID278138 | Distribution of Escherichia coli AB1157 IL05 new born cells containing eight ori foci at 16 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID285614 | Antimicrobial activity against Pseudomonas aeruginosa 3D1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID515176 | Antimicrobial activity against Bacillus subtilis CGMCC 1.1162 after 24 hrs by modified microdilution method | 2010 | European journal of medicinal chemistry, Oct, Volume: 45, Issue:10 | Synthesis and antimicrobial activities of novel 1H-dibenzo[a,c]carbazoles from dehydroabietic acid. |
| AID250257 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH01; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID445286 | Antibacterial activity against Mycobacterium avium 724S by broth dilution method | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22 | Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis. |
| AID373773 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh37 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID499072 | Antimicrobial activity against Citrobacter freundii RJ78 expressing CMY-2, qnrA1, aac(6')-Ib-cr, ompC by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID761216 | Antibacterial activity against Klebsiella pneumoniae 1000-02 by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID531587 | Antibacterial activity against Proteus mirabilis obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID585434 | Antimicrobial activity against Pseudomonas aeruginosa PA14 by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa. |
| AID278125 | Distribution of Escherichia coli AB1157 IL05 new born cells containing duplicated sister ori foci at 8 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID529491 | Antimicrobial activity against Enterobacter cloacae isolate 649 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID283395 | Antimicrobial activity against Nocardia nova after 72 hrs by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. |
| AID533838 | Bactericidal activity against Acinetobacter baumannii ATCC BAA 747 assessed as concentration to achieve 50% of the maximal kill rate for the bacterial population by time-kill study | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. |
| AID1743440 | Antibacterial activity against Mycobacterium smegmatis measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID424857 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pV2GY3 with blaVIM-2 and aac(6)'-32 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID542062 | Antibacterial activity against Klebsiella pneumoniae D expressing CTX-M group 1 beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID285632 | Antimicrobial activity against Pseudomonas aeruginosa 10A9 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID522877 | Antibacterial activity against uropathogenic Escherichia coli UTI89 infected in human 5637 cells assessed as decrease in intracellular bacterial level at 1000 to 2000 ug/ml after 12 hrs by serial dilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. |
| AID533331 | Antibacterial activity against non-gentamicin-resistant Enterobacter aerogenes clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1324745 | Antibacterial activity against methicillin-resistant Staphylococcus aureus USA200 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID283393 | Antimicrobial activity against Nocardia abscessus after 72 hrs by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. |
| AID531766 | Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4677 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID554394 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2715 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID583262 | Antibacterial activity against aminoglycoside-resistant Enterobacter cloacae expressing AAC(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1449145 | Antibacterial activity against non CF patient derived Mycobacterium abscessus subsp. abscessus isolate CIP104536 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID618668 | Antimicrobial activity against Escherichia coli MTCC 4315 at 25 ug/ml | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis, pharmacological evaluation and docking studies of coumarin derivatives. |
| AID554440 | Ratio of MIC for Pseudomonas aeruginosa 2933 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID528983 | Antimicrobial activity against Haemophilus influenzae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID519180 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrW mutant and MexZ mutant gene selected after 1 ug/ml of oflaxacin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID539126 | Antibacterial activity against vancomycin-, ciprofloxacin-, gentamicin-resistant Escherichia coli 1269653 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID1322254 | Antibacterial activity against Acinetobacter lwoffii ATCC 17925 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID533574 | Antibacterial activity against gentamicin-resistant Escherichia coli clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID532166 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii PU55 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB, qnrA genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID519179 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrZ mutant and MexZ mutant gene selected after 4ug/ml of gentamycin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID1463961 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 7357/1998 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID394706 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(3')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID285589 | Antimicrobial activity against Pseudomonas aeruginosa 65.36-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID560060 | Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID574435 | Antimicrobial activity against Escherichia coli isolate 547 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from blood of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID1331879 | Antimycobacterial activity against Mycobacterium smegmatis MC2 155 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID533852 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium abscessus after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID495510 | Antibacterial activity against Acinetobacter baumannii BM4454 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID285618 | Antimicrobial activity against Pseudomonas aeruginosa 5F8 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID570786 | Antimicrobial activity against multidrug-resistant Acinetobacter baumannii by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. |
| AID531745 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID206014 | Minimum inhibitory concentration (MIC) was measured against Staphylococcus aureus. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID583220 | Antibacterial activity against aminoglycoside-resistant Staphylococcus aureus expressing APH(3')-3 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID285606 | Antimicrobial activity against Pseudomonas aeruginosa 2A7 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1426254 | Antibacterial activity against Klebsiella pneumoniae ATCC 13883 | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Synthesis and bioactivity investigation of quinone-based dimeric cationic triazolium amphiphiles selective against resistant fungal and bacterial pathogens. |
| AID531783 | Antibacterial activity against Stenotrophomonas maltophilia obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID394705 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(6')-1, ANT(2'')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID539119 | Antibacterial activity against Escherichia coli ATCC 25922 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID1743445 | Antibacterial activity against Acinetobacter baumannii measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID1232124 | Antimicrobial activity against Escherichia coli ATCC 25922 assessed as inhibition of bacterial growth incubated at 35 degC for 12 to 18 hrs | 2014 | MedChemComm, Aug-01, Volume: 5, Issue:8 | Antifungal Amphiphilic Aminoglycosides. |
| AID1629126 | Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID1224517 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 234/2005 after 7 days by micromethod | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. |
| AID1713722 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth by microdilution alamar blue broth assay | 2016 | Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 | A facile stereoselective synthesis of dispiro-indeno pyrrolidine/pyrrolothiazole-thiochroman hybrids and evaluation of their antimycobacterial, anticancer and AchE inhibitory activities. |
| AID285584 | Antimicrobial activity against Pseudomonas aeruginosa 65.33-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID283543 | Antibacterial activity against Pseudomonas aeruginosa FE57UZ with inactivated rplY, galU and mexZ genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID348090 | Ratio of kcat to Km of Enterococcus APH(3')-3a | 2008 | Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23 | Surprising alteration of antibacterial activity of 5"-modified neomycin against resistant bacteria. |
| AID533853 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium chelonae after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID326550 | Antimicrobial activity against Mycobacterium abscessus V120 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID535897 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JS33 harboring GyrA T83I mutant, wild-type ParC, GyrB, qnrA and qnrB genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID495516 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii AYE by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID1324760 | Antibacterial activity against Salmonella enterica ATCC 14028 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID326533 | Antimicrobial activity against Mycobacterium abscessus after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID533347 | Antibacterial activity against non-gentamicin-resistant Enterobacter cloacae clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID542065 | Antibacterial activity against Klebsiella pneumoniae A expressing CTX-M group 1 beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID761212 | Antibacterial activity against Klebsiella pneumoniae expressing defined beta-lactamase by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID1324755 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID664698 | Antimicrobial activity against Staphylococcus aureus harboring ANT(4')-1 enzyme | 2011 | ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12 | Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue. |
| AID203165 | Minimum inhibitory concentration measured against Serratia marcescens | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID546620 | Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID528984 | Antimicrobial activity against Haemophilus influenzae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID1318910 | Antibacterial activity against amikacin-resistant Escherichia coli isolate CAN-ICU 63074 after 24 hrs by microtitre broth dilution method | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18 | Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux. |
| AID559645 | Antimicrobial activity against Extended-spectrum beta-lactamase producing Escherichia coli clinical isolate assessed as resistant isolate | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular characteristics of travel-related extended-spectrum-beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region. |
| AID564696 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates assessed as resistance isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID533862 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium wolinskyi after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID774219 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID1228698 | Antibacterial activity against Pseudomonas aeruginosa 1145 infected in immunocompetent BALB/c mouse lung infection model assessed as log reduction in colony forming units at 40 mg/kg, iv bid administered at 2 hrs and 12 hrs post-infection measured 24 hrs | 2015 | Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11 | Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents. |
| AID554396 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2721 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID584327 | Antibacterial activity against speE deficient Escherichia coli JW0117-1 | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics. |
| AID508483 | Antimicrobial activity against Pseudomonas aeruginosa isolate K34-7 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID567584 | Antimicrobial activity against Acinetobacter baumannii by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. |
| AID539136 | Antibacterial activity against Staphylococcus epidermidis 1269663 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID1691821 | Antibacterial activity against Pseudomonas aeruginosa PAO1 planktonic cells assessed as reduction in bacterial growth after 18 hrs by resazurin dye based assay | 2020 | European journal of medicinal chemistry, May-15, Volume: 194 | Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1. |
| AID643383 | Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy | 2012 | Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1 | In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. |
| AID531582 | Antibacterial activity against Enterobacter amnigenus obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID1543200 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 15442 assessed as inhibition of microbial growth incubated for 16 hrs by broth microdilution method | |||
| AID554401 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2998 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID285675 | Antimicrobial activity against Pseudomonas aeruginosa 24F4 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID531584 | Antibacterial activity against Escherichia coli obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID1858576 | Antibacterial activity against Mycobacterium abscessus CIP 104536T rough morphotype incubated for 1 to 14 days | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209 | Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery. |
| AID1503231 | Antibacterial activity against Pseudomonas aeruginosa PAO1 after 24 hrs by liquid dilution method | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Structures and Antibacterial Properties of Isorugosins H-J, Oligomeric Ellagitannins from Liquidambar formosana with Characteristic Bridging Groups between Sugar Moieties. |
| AID64908 | Minimum inhibitory concentration was measured against Escherichia coli 76070703 producing AAC-(3)-I modifying enzyme | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID523070 | Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a using ATP/GTP as second substrate by spectrophotometric assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID532413 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C1 isolate AV-13X-28 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1629127 | Antimicrobial activity against Klebsiella pneumoniae ATCC 10031 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID583259 | Antibacterial activity against aminoglycoside-resistant Serratia marcescens expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID565282 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A3 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID278120 | Distribution of Escherichia coli AB1157 IL05 new born cells containing one ori and one ter foci at 4 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID428267 | Antimicrobial activity against carbapenemase producing Enterobacteriaceae assessed as susceptible isolates by CLSI breakpoint assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID1890836 | Antimycobacterial activity against Mycobacterium abscessus CIP104536T with smooth morphotype assessed as inhibition of mycobacterial growth incubated for 3 to 5 days by resazurin microtiter assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Design, synthesis and antibacterial activity against pathogenic mycobacteria of conjugated hydroxamic acids, hydrazides and O-alkyl/O-acyl protected hydroxamic derivatives. |
| AID1524038 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID540237 | Phospholipidosis-positive literature compound observed in rat | |||
| AID508486 | Antimicrobial activity against Pseudomonas aeruginosa isolate BU-36178 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID519177 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrW mutant and MexZ mutant gene selected after 8 ug/ml of amikacin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID1475190 | Antibacterial activity against Pseudomonas aeruginosa clinical isolate after 18 to 24 hrs | 2017 | Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12 | Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC. |
| AID510514 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID278802 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha expressing pBAD in the presence of arabinose | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. |
| AID524914 | Antimicrobial activity against Mycobacterium abscessus 390S assessed as inhibition of planktonic cell growth in replete medium | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID532416 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-11 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID533588 | Antibacterial activity against gentamicin-resistant Staphylococcus epidermidis clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1331870 | Antibacterial activity against Listeria monocytogenes ATCC 19115 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID533587 | Antibacterial activity against gentamicin-resistant Staphylococcus aureus clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID534192 | Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient. |
| AID1324753 | Antibacterial activity against Listeria monocytogenes ATCC 19115 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID533839 | Bactericidal activity against Acinetobacter baumannii ATCC BAA 747 at >16 mg/liter after 2 hrs by time-kill study | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. |
| AID283394 | Antimicrobial activity against Nocardia beijingensis after 72 hrs by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. |
| AID533603 | Antibacterial activity against gentamicin-resistant Staphylococcus aureus clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID533583 | Antibacterial activity against gentamicin-resistant Proteus rettgeri clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID428873 | Antibacterial activity against Escherichia coli JM109 carrying pMCL210 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. |
| AID1467547 | Cytotoxicity against monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14 | One-pot microwave assisted stereoselective synthesis of novel dihydro-2'H-spiro[indene-2,1'-pyrrolo-[3,4-c]pyrrole]-tetraones and evaluation of their antimycobacterial activity and inhibition of AChE. |
| AID1524125 | Bactericidal activity against Escherichia coli K99 incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID567306 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2204 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID533601 | Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1732050 | Antibacterial activity against Bacillus subtilis ATCC 6633 | 2021 | European journal of medicinal chemistry, Apr-05, Volume: 215 | Discovery of novel N |
| AID372854 | Antimicrobial activity against colistin-resistant Acinetobacter baumannii 213 transconjugant with 16S rRNA methylase armA gene expressing Acinetobacter baumannii isolate A | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID1188166 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by microdilution AlamarBlue broth assay | 2014 | European journal of medicinal chemistry, Oct-06, Volume: 85 | Sequential synthesis of amino-1,4-naphthoquinone-appended triazoles and triazole-chromene hybrids and their antimycobacterial evaluation. |
| AID278141 | Sublethal concentration measured by presence of granular bodies in Escherichia coli AB1157 IL05 cells at 4 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID498808 | Antimicrobial activity against Klebsiella pneumoniae ZJ99 expressing KPC-2, CTX-M-3, qnrS1, ompK35 DE by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID534176 | Antimicrobial activity against armA positive Klebsiella pneumoniae DU producing beta lactamase CTX-M-3 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID1294351 | Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 incubated for 7 days by BacTiter-Glo cell viability assay | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9 | Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis. |
| AID1524041 | Antimicrobial activity against Pseudomonas aeruginosa CICC 21625 clinical isolates after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID508725 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E3 PpA2 harboring acquired beta-lactamase OXA-101 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID374113 | Antimicrobial activity against azide-resistant Escherichia coli J53 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1. |
| AID499062 | Antimicrobial activity against carbapenem-resistant Escherichia coli HX74 deficient in TEM-1, CTX-M-14, CTX-M-3, aac(6')-Ibcr, ompC/F by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID498809 | Antimicrobial activity against Klebsiella pneumoniae ZJ99T expressing KPC-2, CTX-M-3, qnrS1 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID571688 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 1 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID576330 | Antibacterial activity against ESBL-producing Klebsiella pneumoniae by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID1474724 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 20 to 24 hrs by broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | Novel bioactive molecules from Lentzea violacea strain AS 08 using one strain-many compounds (OSMAC) approach. |
| AID533830 | Antibacterial activity against Acinetobacter baumannii ATCC BAA 747 after 24 hrs by modified broth macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. |
| AID594855 | Antimicrobial activity against Staphylococcus epidermidis after 24 hrs by microdilution method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID554438 | Ratio of MIC for Pseudomonas aeruginosa 2804 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID531588 | Antibacterial activity against Proteus penneri obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID372855 | Antimicrobial activity against colistin-resistant Acinetobacter baumannii 213 transconjugant with 16S rRNA methylase armA gene expressing Acinetobacter baumannii isolate B | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID542584 | Antimicrobial activity against Acinetobacter radioresistens 251-39C expressing beta-lactamase OXA-133 by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program. |
| AID497944 | Antibacterial activity against Burkholderia cepacia clinical isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID567309 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2207 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID532414 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-02 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID64895 | Minimum inhibitory concentration was measured against Escherichia coli 0000JR66 producing AAD-(2'')-modifying enzyme; Value expressed as 2/4 | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID405090 | Antimicrobial activity against integron carrying Enterobacteriaceae assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome. |
| AID534170 | Antimicrobial activity against armA positive Escherichia coli TOP10 harboring plasmid COP1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID554397 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2729 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID583264 | Antibacterial activity against aminoglycoside-resistant Serratia marcescens expressing AAC(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1363870 | Antibiofilm activity against Staphylococcus aureus ATCC 29213 at 128 ug/ml after 18 hrs by XTT-menadione assay relative to control | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22 | Bile Acid Oligomers and Their Combination with Antibiotics To Combat Bacterial Infections. |
| AID532199 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae WH42T harboring qnrA gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID528831 | Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient wound assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID545425 | Antimicrobial activity against Enterobacter aerogenes obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID1447078 | Antibacterial activity against Acinetobacter baumannii ATCC 17961 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11 | Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo. |
| AID560085 | Bactericidal activity against Pseudomonas aeruginosa isolate 796 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID583218 | Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID530350 | Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID574426 | Antimicrobial activity against Escherichia coli isolate 339T expressing beta-lactamase KPC2 and PFGE cluster 5 isolated from peritoneal fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID283547 | Antibacterial activity against Pseudomonas aeruginosa FE60 containing inactivated mexXY gene by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID533590 | Antibacterial activity against gentamicin-resistant Escherichia coli clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID542769 | Antimicrobial activity against Escherichia coli J53 transformed with pHND1 carrying DHA-1 gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals. |
| AID565293 | Antitubercular activity against Mycobacterium avium infected in C57BL/6J mouse assessed as reduction of CFU counts in spleen at 150 mg/kg, sc administered one month post-infection five times weekly for 1 month (Rvb = 7.4 +/- 1.7 log10CFU) | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | ATP synthase inhibition of Mycobacterium avium is not bactericidal. |
| AID532397 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D isolate VA-06X-69 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID405824 | Antimicrobial activity against Acinetobacter baumannii 696 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID533595 | Antibacterial activity against gentamicin-resistant Proteus mirabilis clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID534097 | Antibacterial activity against Acinetobacter baumannii PFGE type A isolate by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital. |
| AID535755 | Antimicrobial activity against community-acquired Escherichia coli obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob |
| AID583215 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing armA methylase by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID529492 | Antimicrobial activity against Enterobacter cloacae isolate 658 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID515178 | Antimicrobial activity against Escherichia coli CGMCC 1.1571 after 24 hrs by modified microdilution method | 2010 | European journal of medicinal chemistry, Oct, Volume: 45, Issue:10 | Synthesis and antimicrobial activities of novel 1H-dibenzo[a,c]carbazoles from dehydroabietic acid. |
| AID404902 | Antimicrobial activity against Enterococcus faecalis ATCC 29212 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus. |
| AID523397 | Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 3 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID425074 | Antimicrobial activity against Escherichia coli DH10B in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID1324724 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 1 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID373768 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh18 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID531782 | Antibacterial activity against Pseudomonas fluorescens obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID529824 | Antimicrobial activity against Acinetobacter baumannii isolate 853 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. |
| AID1296383 | Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis 234/2005 after 14 days by microdilution method | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. |
| AID583272 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa expressing AAC(6')-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583212 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID498306 | Antibacterial activity against Pseudomonas aeruginosa PA5043 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID533585 | Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID396027 | Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID278123 | Distribution of Escherichia coli AB1157 IL05 new born cells containing one ori and one ter foci at 32 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID577650 | Antimicrobial activity against Escherichia coli isolate 329T expressing beta-lactamase KPC2 and PFGE cluster 2 isolated from blood of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID618669 | Antimicrobial activity against Escherichia coli MTCC 4315 at 50 ug/ml | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis, pharmacological evaluation and docking studies of coumarin derivatives. |
| AID533854 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium peregrinum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID584566 | Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID531780 | Antibacterial activity against Pseudomonas aeruginosa obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID572140 | Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 37 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1331905 | Antibacterial activity against Listeria monocytogenes ATCC 19115 at 0.5 times MIC after 11 serial passages | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID532172 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae SH39 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrA genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID278806 | Antimicrobial activity against Stenotrophomonas maltophilia K279a (aph FS) mutant | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. |
| AID558796 | Antimicrobial activity against extended spectrum beta-lactamase-deficient Escherichia coli assessed as percent susceptible isolates by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID564685 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID774221 | Antibacterial activity against Acinetobacter lwoffii ATCC 17925 after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID560086 | Bactericidal activity against Pseudomonas aeruginosa isolate 956 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID533586 | Antibacterial activity against gentamicin-resistant Pseudomonas spp. clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID424859 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID523498 | Antimicrobial activity against Pseudomonas aeruginosa isolate 14169c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1231412 | Antibacterial activity against Escherichia coli ATCC 35218 assessed as growth inhibition at 30 ug after 24 hrs by disc agar diffusion method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Synthesis and biological evaluation of caracasine acid derivatives. |
| AID510511 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-19 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID1232123 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as inhibition of bacterial growth incubated at 35 degC for 12 to 18 hrs | 2014 | MedChemComm, Aug-01, Volume: 5, Issue:8 | Antifungal Amphiphilic Aminoglycosides. |
| AID1546878 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in microbial growth after 16 hrs by broth microdilution method | 2020 | Journal of natural products, 01-24, Volume: 83, Issue:1 | Reisolation and Configurational Reinvestigation of Cottoquinazolines E-G from an Arthropod-Derived Strain of the Fungus |
| AID574593 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2403 obtained from sputum of patient at 1 ug/ml by Bactec MGIT960 modified proportion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID499068 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ90 deficient in CTX-M-14, ompC/F by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID1322250 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID1324740 | Antibacterial activity against methicillin-resistant Staphylococcus aureus S14 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID533841 | Ratio of Cmax to MIC for Pseudomonas aeruginosa ATCC 27853 in PK/PD model at 2000 mg administered every 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. |
| AID542768 | Antimicrobial activity against Escherichia coli J53 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals. |
| AID558039 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S2 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID1310572 | Antibacterial activity against Kocuria rhizophila ATCC 9341 by broth microdilution method | 2016 | European journal of medicinal chemistry, Aug-08, Volume: 118 | Simple avarone mimetics as selective agents against multidrug resistant cancer cells. |
| AID532399 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-16 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID558042 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID250293 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH18; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID530348 | Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID1254010 | Antibacterial activity against Clostridium sporogenes ATCC 19404 after 24 hrs by microbroth double dilution method | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Synthesis and biological activity of amino acid derivatives of avarone and its model compound. |
| AID584555 | Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID498829 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae RJ94 deficient in IMP-4, TEM-1, CTX-M-3, ompC by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID584564 | Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1524133 | Bactericidal activity against Salmonella typhimurium C7731 incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID560600 | Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid expressing aac(6')-Iaf (TTG-ATG) mutant gene by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID571906 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 17 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1324752 | Antibacterial activity against Vancomycin-resistant Enterococcus measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID774213 | Antibacterial activity against Escherichia coli L58058.1 expressing ANT2''-1A after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID250299 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH24; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID1435651 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 9449/2007 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID520697 | Antimicrobial activity against Escherichia coli DH10B harboring p05283 carrying qepA and rmtB gene by agar dilution CLSI method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan. |
| AID64893 | Minimum inhibitory concentration was measured against Escherichia coli 00000589 producing APH-(3'') modifying enzyme | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID206015 | Minimum inhibitory concentration (MIC) was measured against Staphylococcus aureus ATCC 25923. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID1228697 | Antibacterial activity against Pseudomonas aeruginosa 1145 assessed as bacterial growth inhibition by susceptibility testing assay | 2015 | Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11 | Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents. |
| AID1254008 | Antibacterial activity against Micrococcus luteus ATCC 4698 after 24 hrs by microbroth double dilution method | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Synthesis and biological activity of amino acid derivatives of avarone and its model compound. |
| AID278801 | Antimicrobial activity against recombinant Escherichia coli DH5alpha expressing pBAD | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. |
| AID212903 | Inhibition of human telomerase before assembly using recombinant hTR and hTERT at 50 uM | 2004 | Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13 | Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase. |
| AID528827 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient urine assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID563600 | Antimicrobial activity against Klebsiella pneumoniae isolate 048 expressing beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA. |
| AID373037 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate DL34 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID533576 | Antibacterial activity against gentamicin-resistant Enterobacter cloacae clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID529489 | Antimicrobial activity against Enterobacter cloacae isolate 656 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID571883 | Antibacterial activity against Escherichia coli KAM32 harboring plasmid pUC18 by CLSI broth microdilution method in presence of 25 ug/ml efflux pump inhibitor CCCP | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID373046 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZS5 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID1474725 | Antibacterial activity against Enterococcus faecalis ATCC 51299 after 20 to 24 hrs by broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | Novel bioactive molecules from Lentzea violacea strain AS 08 using one strain-many compounds (OSMAC) approach. |
| AID571884 | Antibacterial activity against Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii. |
| AID532411 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-02 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID285671 | Antimicrobial activity against Pseudomonas aeruginosa 24E2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID283532 | Antibacterial activity against Pseudomonas aeruginosa FE53 with inactivated mexZ gene by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID1732053 | Antibacterial activity against Staphylococcus aureus FDA 209 P | 2021 | European journal of medicinal chemistry, Apr-05, Volume: 215 | Discovery of novel N |
| AID373766 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh14 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID283535 | Antibacterial activity against Pseudomonas aeruginosa FE10U with inactivated nuoG and galU genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID574809 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 horboring rpoB H526Y, katG D329A/R463L, gyrA D94G/S95T, rrs A1401G by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID594846 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus strain 1 TB3G at 100 ug/disc after 24 hrs by disc diffusion method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID761206 | Antibacterial activity against Acinetobacter spp. by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID533342 | Antibacterial activity against non-gentamicin-resistant Haemophilus parainfluenzae clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID533580 | Antibacterial activity against gentamicin-resistant Serratia marcescens clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID285611 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID529498 | Antimicrobial activity against Escherichia coli T-781 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID373757 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1308 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID531788 | Antibacterial activity against Klebsiella oxytoca obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID1503229 | Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OM481 after 24 hrs by liquid dilution method | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Structures and Antibacterial Properties of Isorugosins H-J, Oligomeric Ellagitannins from Liquidambar formosana with Characteristic Bridging Groups between Sugar Moieties. |
| AID529827 | Antimicrobial activity against Acinetobacter baumannii by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. |
| AID565066 | Antibacterial activity against CTX-M-15 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID372857 | Antimicrobial activity against colistin-resistant Acinetobacter baumannii 213 transconjugant with 16S rRNA methylase armA gene expressing Acinetobacter baumannii isolate D | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID373034 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ3-9 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID535903 | Antimicrobial activity against aac(6')-Ib-cr-negative Escherichia coli PU12 harboring GyrA S83L mutant, wild-type GyrB, ParC and qnrS genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID554436 | Ratio of MIC for Pseudomonas aeruginosa 2721 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID529496 | Antimicrobial activity against Escherichia coli T-622 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID1474722 | Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 20 to 24 hrs by broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | Novel bioactive molecules from Lentzea violacea strain AS 08 using one strain-many compounds (OSMAC) approach. |
| AID1322247 | Antibacterial activity against Staphylococcus aureus ATCC 25923 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID1271797 | Antibacterial activity against Escherichia coli 27 after 24 hrs by broth microdilution method | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Synthesis, antibacterial and cytotoxic activities of new biflorin-based hydrazones and oximes. |
| AID1324742 | Antibacterial activity against methicillin-resistant Staphylococcus aureus S22 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID564697 | Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates assessed as resistance isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID341597 | Antibacterial activity against sEscherichia coli GeneHogs harboring blaKPC-encoding plasmids | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID373044 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate CY6 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID524003 | Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-66 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. |
| AID529485 | Antimicrobial activity against Enterobacter cloacae isolate 293 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID533861 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium septicum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID523517 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1665 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID285590 | Antimicrobial activity against Pseudomonas aeruginosa 65.38-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID449435 | Antimycobacterial activity against Mycobacterium tuberculosis XDR infected in MDBK by BACTEC analysis | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Pentacyclo-undecane derived cyclic tetra-amines: synthesis and evaluation as potent anti-tuberculosis agents. |
| AID549332 | Antimicrobial activity against Escherichia coli isolate 86 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID1324727 | Antibacterial activity against methicillin-resistant Staphylococcus aureus C1 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID326534 | Antimicrobial activity against Mycobacterium chelonae after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID533330 | Antibacterial activity against non-gentamicin-resistant Enterobacter cloacae clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID428269 | Antimicrobial activity against Klebsiella sp. by CLSI broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID524916 | Antimicrobial activity against Mycobacterium abscessus 390S assessed as inhibition of planktonic cell growth in depleted medium | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID574439 | Antimicrobial activity against Escherichia coli DH10B by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID394685 | Antibacterial activity against wild type Pseudomonas aeruginosa isolate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID545452 | Antimicrobial activity against extended-spectrum beta-lactamase-positive Proteus mirabilis assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID1422367 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID1474727 | Antibacterial activity against Escherichia coli ATCC 10536 after 20 to 24 hrs by broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | Novel bioactive molecules from Lentzea violacea strain AS 08 using one strain-many compounds (OSMAC) approach. |
| AID574436 | Antimicrobial activity against Escherichia coli isolate 547T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from blood of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID533343 | Antibacterial activity against non-gentamicin-resistant Staphylococcus aureus clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1447090 | Antibacterial activity against Acinetobacter baumannii ARC 5081 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11 | Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo. |
| AID1322944 | Antimycobacterial activity against LuxABCDE expressing Mycobacterium marinum measured after 48 hrs by luminescence based serial dilution assay | 2016 | Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24 | In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA. |
| AID405822 | Antimicrobial activity against Escherichia coli DH5alpha | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID278066 | Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from nondeployed military patient | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID1427357 | Antibacterial activity against Pseudomonas aeruginosa PA7 DSM 24068 after 18 hrs | 2017 | Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6 | New nitrofurans amenable by isocyanide multicomponent chemistry are active against multidrug-resistant and poly-resistant Mycobacterium tuberculosis. |
| AID1449148 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. abscessus isolate 1298 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID446134 | Antibacterial activity against MexEF expressing Pseudomonas aeruginosa PA03 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID584563 | Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID394682 | Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant rate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID583247 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID558071 | Half life in New Zealand White rabbit eye administered as intracameral injection | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Pharmacokinetics of intracameral voriconazole injection. |
| AID523502 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1333c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID532407 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-20 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID64897 | Minimum inhibitory concentration was measured against Escherichia coli 001574-1 producing APH-(3'') modifying enzyme | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1426253 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Synthesis and bioactivity investigation of quinone-based dimeric cationic triazolium amphiphiles selective against resistant fungal and bacterial pathogens. |
| AID539128 | Antibacterial activity against vancomycin-, ciprofloxacin-, gentamicin-resistant Staphylococcus aureus 1269615 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID1524124 | Bactericidal activity against Escherichia coli K88 incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID1071659 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by Alamar Blue staining-based broth microdilution assay | 2014 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4 | Antimycobacterial evaluation of novel hybrid arylidene thiazolidine-2,4-diones. |
| AID1602937 | Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 5 after 7 days by resazurin microtiter assay | 2019 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8 | Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis. |
| AID1482267 | Antibacterial activity against Escherichia coli MG1655 measured every 15 mins for 12 hrs | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure. |
| AID560080 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1037 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID560079 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1019 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID523002 | Cytotoxicity against human 5637 cells assessed as mild induction of cell death by LDH release assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. |
| AID445210 | Antituberculosis activity against Mycobacterium tuberculosis H37Rv by broth dilution method | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22 | Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis. |
| AID65064 | Percent killing of the total Escherichia coli K12 (ATCC 25868) cells at the C50 concentration was determined. | 1987 | Journal of medicinal chemistry, Feb, Volume: 30, Issue:2 | Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli. |
| AID278136 | Distribution of Escherichia coli AB1157 IL05 new born cells containing eight ori foci at 4 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID326549 | Antimicrobial activity against Mycobacterium abscessus R49 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID532394 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-32 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID570787 | Antimicrobial activity against multidrug-resistant Acinetobacter baumannii expressing aac(6')-1b gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. |
| AID497943 | Antibacterial activity against Pseudomonas aeruginosa by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1176931 | Antimicrobial activity against Staphylococcus aureus CGMCC1.1361 after 24 hrs by modified microdilution method | 2015 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3 | Synthesis, in vitro antimicrobial and cytotoxic activities of new carbazole derivatives of ursolic acid. |
| AID534303 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA483 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID278808 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa. |
| AID445288 | Antibacterial activity against Mycobacterium smegmatis by broth dilution method | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22 | Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis. |
| AID1324750 | Antibacterial activity against Enterococcus faecalis ATCC 49533 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID372851 | Antimicrobial activity against azide-resistant Escherichia coli J53 transconjugant with 16S rRNA methylase armA gene expressing Acinetobacter baumannii isolate C | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID497946 | Antibacterial activity against Alcaligenes xylosoxidans by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1435653 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 7357/1998 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID509859 | Antibacterial activity against Acinetobacter baumannii using MHB medium assessed as bacterial growth at 4.5 mg/L after 12 hrs in presence of 30 mg/L efflux pump inhibitor PAbetaN | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID565292 | Antitubercular activity against Mycobacterium avium infected in C57BL/6J mouse assessed as reduction of CFU counts in spleen at 150 mg/kg, sc administered one month post-infection five times weekly for 4 months (Rvb = 8.9 +/- 0.3 log10CFU) | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | ATP synthase inhibition of Mycobacterium avium is not bactericidal. |
| AID152322 | Minimum inhibitory concentration was measured against Providencia stuartii 75082808 producing AAC-(2'') modifying enzyme | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID583234 | Antibacterial activity against Escherichia coli by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID495509 | Antibacterial activity against Acinetobacter baumannii BM4587 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID250262 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH06; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID533329 | Antibacterial activity against non-gentamicin-resistant Klebsiella pneumoniae clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID532908 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID542770 | Antimicrobial activity against Escherichia coli J53 transformed with pHND2 carrying qnrB6 and CTX-M-9G genes by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals. |
| AID1322249 | Antibacterial activity against healthcare-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID1474729 | Antibacterial activity against Klebsiella pneumoniae ATCC BAA-2146 after 20 to 24 hrs by broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | Novel bioactive molecules from Lentzea violacea strain AS 08 using one strain-many compounds (OSMAC) approach. |
| AID1271796 | Antibacterial activity against Proteus vulgaris ATCC 13315 after 24 hrs by broth microdilution method | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Synthesis, antibacterial and cytotoxic activities of new biflorin-based hydrazones and oximes. |
| AID594849 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus strain 2 TB4G at 100 ug/disc after 24 hrs by disc diffusion method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID569270 | Antibacterial activity against drug-sensitive Pseudomonas aeruginosa PAO1 | 2011 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 | Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives. |
| AID1324733 | Antibacterial activity against methicillin-resistant Staphylococcus aureus G1 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID533350 | Antibacterial activity against non-gentamicin-resistant Proteus mirabilis clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID564690 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID542064 | Antibacterial activity against Klebsiella pneumoniae C expressing CTX-M group 1 beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID644960 | Displacement of ethidium bromide from human pre-hsa-mir-155 miRNA after 30 mins | 2012 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4 | Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing. |
| AID531583 | Antibacterial activity against Enterobacter cloacae obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID498085 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1524039 | Antimicrobial activity against Pseudomonas aeruginosa CICC 21630 clinical isolates after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID519185 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY and MexZ mutant gene selected after 0.25 ug/ml of ciprofloxacin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID560591 | Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID424863 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa clinical isolate assessed as resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID374112 | Antimicrobial activity against azide-resistant aac(6')-Ib-cr expressing Escherichia coli J53 qnrA1 bearing pHS6 transconjugant from Escherichia coli 650 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID533332 | Antibacterial activity against non-gentamicin-resistant Citrobacter diversus clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1254009 | Antibacterial activity against Micrococcus flavus ATCC 10240 after 24 hrs by microbroth double dilution method | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Synthesis and biological activity of amino acid derivatives of avarone and its model compound. |
| AID428272 | Antimicrobial activity against carbapenemase producing Enterobacter sp. by CLSI broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID495515 | Antibacterial activity against Acinetobacter baumannii CIP70-10 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID373672 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 10 ug/disk after 24 hrs by agar diffusion method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis, characterization and antimicrobial activity of Co(II), Zn(II) and Cd(II) complexes with N-benzyloxycarbonyl-S-phenylalanine. |
| AID510504 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-2 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID373682 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis, characterization and antimicrobial activity of Co(II), Zn(II) and Cd(II) complexes with N-benzyloxycarbonyl-S-phenylalanine. |
| AID533581 | Antibacterial activity against gentamicin-resistant Morganella morganii clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID405821 | Antimicrobial activity against Acinetobacter baumannii 695 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID555555 | Antimicrobial activity against Pseudomonas aeruginosa isolate 26285 expressing IMP-13 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID497950 | Antibacterial activity against Pseudomonas aeruginosa PA1042 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID542759 | Antimicrobial activity against Escherichia coli Du19 expressing qnrB6 and CTX-M-9G genes by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals. |
| AID529549 | Cmin in human neonate serum after 25 hrs by fluorescence polarization immunoassay | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates. |
| AID1449159 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. massiliense isolate 100 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID588211 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID560088 | Bactericidal activity against Pseudomonas aeruginosa isolate 1037 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID404895 | Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB10 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus. |
| AID279940 | Antibiotic susceptibility by resistance against MDR Pseudomonas aeruginosa from samples collected from patients | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. |
| AID394684 | Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID1422372 | Antibacterial activity against Acinetobacter lwoffii AI.88-483 harboring APH3'-6A by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID529488 | Antimicrobial activity against Enterobacter cloacae isolate 625 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID574432 | Antimicrobial activity against Escherichia coli isolate 543 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID1310594 | Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 by broth microdilution method | 2016 | European journal of medicinal chemistry, Aug-08, Volume: 118 | Simple avarone mimetics as selective agents against multidrug resistant cancer cells. |
| AID1422371 | Antibacterial activity against Acinetobacter lwoffii ATCC 17925 by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID545658 | Antimicrobial activity against Acinetobacter sp. assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID1271383 | Antimicrobial activity against Gram-negative Haemophilus influenzae ATCC 51907 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID278139 | Distribution of Escherichia coli AB1157 IL05 new born cells containing eight ori foci at 32 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID532909 | Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 ST 327 expressing beta-lactamase TEM-1 and CTX-M-2 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID283221 | Antimicrobial activity against Escherichia coli XL1-Blue pPA95S29 | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. |
| AID1426250 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Synthesis and bioactivity investigation of quinone-based dimeric cationic triazolium amphiphiles selective against resistant fungal and bacterial pathogens. |
| AID1435648 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 1 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID565065 | Antibacterial activity against CTX-M-14 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID560059 | Antimicrobial activity against AmpC-depressed Enterobacter cloacae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID522933 | Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a D268N mutant by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID326544 | Antimicrobial activity against Mycobacterium abscessus R50 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID560057 | Antimicrobial activity against ESBL-producing Escherichia coli by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID583241 | Antibacterial activity against Acinetobacter spp. by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583261 | Antibacterial activity against aminoglycoside-resistant Klebsiella pneumoniae expressing AAC(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID533355 | Antibacterial activity against non-gentamicin-resistant Acinetobacter calcoaceticus clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID531590 | Antibacterial activity against Providencia stuartii obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID560092 | Bactericidal activity against Klebsiella pneumoniae isolate 5436 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID1322372 | Antibacterial activity against clinical isolates of Staphylococcus aureus at 0.05 mg after overnight incubation by agar well diffusion method | 2016 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21 | 1H-1,2,3-Triazolyl-substituted 1,3,4-oxadiazole derivatives containing structural features of ibuprofen/naproxen: Their synthesis and antibacterial evaluation. |
| AID486970 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by micro broth dilution method | 2010 | European journal of medicinal chemistry, Jun, Volume: 45, Issue:6 | 'On water' assisted synthesis and biological evaluation of nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents. |
| AID574431 | Antimicrobial activity against Escherichia coli isolate 540 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID1732051 | Antibacterial activity against Mycobacterium smegmatis mc2155 | 2021 | European journal of medicinal chemistry, Apr-05, Volume: 215 | Discovery of novel N |
| AID404901 | Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB41 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus. |
| AID522930 | Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase R92H/D268N mutant by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID565069 | Antibacterial activity against SHV-12 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID1322259 | Antibacterial activity against Klebsiella pneumoniae ATCC 700603 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID574429 | Antimicrobial activity against Escherichia coli isolate 386 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from wound of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID531755 | Antibacterial activity against Pseudomonas aeruginosa 2126 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID446133 | Antibacterial activity against MexCD expressing Pseudomonas aeruginosa PA01 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID510507 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-7 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID583249 | Antibacterial activity against aminoglycoside-resistant Klebsiella pneumoniae expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID201745 | Minimum inhibitory concentration was measured against Serratia marcescens 75022704 producing AAC-(6'')-III modifying enzyme | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID1543199 | Antimicrobial activity against Acinetobacter baumannii ATCC 19606 assessed as inhibition of microbial growth incubated for 16 hrs by broth microdilution method | |||
| AID481447 | Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by macrobroth dilution method | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. |
| AID584326 | Antibacterial activity against tolC deficient Escherichia coli GD100 | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics. |
| AID64907 | Minimum inhibitory concentration was measured against Escherichia coli 73110901 producing AAC-(6')-I) modifying enzyme | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID1602934 | Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 2 after 7 days by resazurin microtiter assay | 2019 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8 | Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis. |
| AID1176933 | Antimicrobial activity against Pseudomonas fluorescens CGMCC1.1828 after 24 hrs by modified microdilution method | 2015 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3 | Synthesis, in vitro antimicrobial and cytotoxic activities of new carbazole derivatives of ursolic acid. |
| AID586086 | Antimicrobial activity against verocytotoxin-producing Escherichia coli isolate O157 obtained from animals and food assessed as percentage of resistant isolates by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26. |
| AID1324746 | Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID535888 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN41T harboring qnrB gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID519186 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY and MexZ mutant gene selected after 4 ug/ml of cefepime exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID405819 | Antimicrobial activity against Acinetobacter sp. 5227 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID372850 | Antimicrobial activity against azide-resistant Escherichia coli J53 transconjugant with 16S rRNA methylase armA gene expressing Acinetobacter baumannii isolate B | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID499056 | Antimicrobial activity against carbapenem-resistant Escherichia coli PU102 deficient in TEM-1, CTX-M-14, CMY-2, aac(6')-Ib, ompC DEc, ompF by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID574800 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 obtained from sputum of patient at 1 ug/ml by Bactec MGIT960 modified proportion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID532019 | Antibacterial activity against macrolide-lincosamide-streptogramin B-positive, beta-lactamase-positive, methicillin-resistant Staphylococcus aureus ATCC 43300 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate. |
| AID285620 | Antimicrobial activity against Pseudomonas aeruginosa 5H6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID571885 | Antibacterial activity against Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene by CLSI broth microdilution method in presence of 25 ug/ml efflux pump inhibitor CCCP | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii. |
| AID523511 | Antimicrobial activity against Pseudomonas aeruginosa isolate 13167 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID644770 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 20 hrs by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | New heterocyclic compounds from 1,2,4-triazole and 1,3,4-thiadiazole class bearing diphenylsulfone moieties. Synthesis, characterization and antimicrobial activity evaluation. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID529736 | Induction of apoptosis in pig LLC-PK1 cells at 6 mM after 2 days by DAPI staining | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Apoptosis induced by aminoglycosides in LLC-PK1 Cells: comparative study of neomycin, gentamicin, amikacin, and isepamicin using electroporation. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID569263 | Antimicrobial activity against drug-sensitive Staphylococcus aureus 209PJC-1 | 2011 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 | Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives. |
| AID499065 | Antimicrobial activity against carbapenem-resistant Enterobacter aerogenes WH85 deficient in TEM-1, CTX-M-3, ompC/F by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID533337 | Antibacterial activity against non-gentamicin-resistant Proteus rettgeri clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID428870 | Antibacterial activity against Escherichia coli CSH-2 carrying Escherichia coli ARS3 pARS3 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. |
| AID481459 | Antibacterial activity against Streptococcus pneumoniae ATCC 13883 after 24 hrs by macrobroth dilution method | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. |
| AID446127 | Antibacterial activity against MexXY expressing Pseudomonas aeruginosa PT629 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID1271794 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by broth microdilution method | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Synthesis, antibacterial and cytotoxic activities of new biflorin-based hydrazones and oximes. |
| AID373762 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii ab1266 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID285160 | Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. |
| AID250297 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH22; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID283391 | Antimicrobial activity against Nocardia farcinica after 72 hrs by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. |
| AID1322945 | Antimicrobial activity against Enterococcus faecalis ATCC 29212 assessed as inhibition of bacterial growth measured after 24 hrs using p-iodonitrotetrazolium violet by broth dilution method | 2016 | Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24 | In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA. |
| AID1422377 | Cytotoxicity against mouse J774 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID761208 | Antibacterial activity against Escherichia coli expressing CTX-M by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID532208 | Antimicrobial activity against Escherichia coli J53 harboring wild-type GyrA, ParC, GyrB genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID534177 | Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid DU by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID571882 | Antibacterial activity against Escherichia coli KAM32 harboring plasmid pUC18 by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii. |
| AID510505 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-4 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID446137 | Antibacterial activity against TriABC expressing MexAB, MexCD, MexEF, MexXY deleted Pseudomonas aeruginosa PA405 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID540213 | Half life in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID250300 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH25; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID533579 | Antibacterial activity against gentamicin-resistant Proteus mirabilis clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID285598 | Antimicrobial activity against Pseudomonas aeruginosa 2C1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID373670 | Antibacterial activity against Escherichia coli ATCC 25922 at 10 ug/disk after 24 hrs by agar diffusion method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis, characterization and antimicrobial activity of Co(II), Zn(II) and Cd(II) complexes with N-benzyloxycarbonyl-S-phenylalanine. |
| AID594861 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus strain 2 TB4G after 24 hrs by microdilution method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID588220 | Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset | 2008 | Toxicology mechanisms and methods, , Volume: 18, Issue:2-3 | Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. |
| AID588213 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID529862 | Ratio of MIC for Pseudomonas aeruginosa N045 to MIC for Pseudomonas aeruginosa PAO1 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID554386 | Antimicrobial activity against mexXY deficient ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID571916 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 22 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID733061 | Antitubercular activity against Mycobacterium tuberculosis H37Rv by BacTiter-Gl Microbial Cell Viability assay | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID558807 | Antimicrobial activity against extended spectrum beta-lactamase-deficient Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID499051 | Antimicrobial activity against carbapenem-resistant Escherichia coli PU60 deficient in TEM-1, CMY-2, ompC/F by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID1071110 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 0.08 ug/ml after 7 days by microplate Alamar blue assay relative to control | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III. |
| AID531767 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4682-1 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID285578 | Antimicrobial activity against Pseudomonas aeruginosa P21.23 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID531777 | Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4663 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID285689 | Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4012 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID554426 | Ratio of MIC for Pseudomonas aeruginosa FE60 transformed with pAGH97 carrying mexXY F1018L mutant to Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID549336 | Antimicrobial activity against Escherichia coli isolate 49 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID1324735 | Antibacterial activity against methicillin-resistant Staphylococcus aureus G12 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID1524127 | Bactericidal activity against Pseudomonas aeruginosa PAO1 incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID1449160 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. massiliense isolate 107 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID1524134 | Bactericidal activity against Salmonella pullorum C7913 incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID533860 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium porcinum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID499047 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ69 deficient in SHV-28, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID560066 | Antimicrobial activity against Escherichia coli isolate 5411 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID257551 | Antibacterial activity against Klebsiella pneumoniae | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23 | Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents. |
| AID562951 | Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID373028 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU86 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID564686 | Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID1324737 | Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS4 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID481457 | Antibacterial activity against Stenotrophomonas maltophilia CAN-ICU 62585 after 24 hrs by macrobroth dilution method | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. |
| AID571908 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 18 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID424879 | Antimicrobial activity against multidrug-resistant Enterobacter cloacae E705 bearing qnrB10 gene with aac(6)-IId-aadA1a integron in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID285643 | Antimicrobial activity against Pseudomonas aeruginosa 15G10 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1331875 | Antibacterial activity against Escherichia coli MC1061 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID539123 | Antibacterial activity against vancomycin-, ciprofloxacin-, gentamicin-resistant Escherichia coli 1269620 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID533578 | Antibacterial activity against gentamicin-resistant Citrobacter diversus clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID323254 | Antimicrobial activity against carbapenem-intermediate or resistant Acinetobacter baumannii isolates by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. |
| AID499060 | Antimicrobial activity against Enterobacter aerogenes PU41T expressing CTX-M-14, DHA-1, qnrS1 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID1322378 | Antibacterial activity against clinical isolates of Escherichia coli at 0.05 mg after overnight incubation by agar well diffusion method | 2016 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21 | 1H-1,2,3-Triazolyl-substituted 1,3,4-oxadiazole derivatives containing structural features of ibuprofen/naproxen: Their synthesis and antibacterial evaluation. |
| AID649219 | Antibacterial activity against Pseudomonas aeruginosa clinical isolates after 16 to 20 hrs by broth microdilution method | 2012 | Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2 | Potent inhibitors of LpxC for the treatment of Gram-negative infections. |
| AID761209 | Antibacterial activity against Escherichia coli expressing ESBL by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID545431 | Antimicrobial activity against Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID560077 | Antimicrobial activity against Pseudomonas aeruginosa isolate 796 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID250291 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH07; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID283390 | Antimicrobial activity against Nocardia cyriacigeorgica after 72 hrs by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. |
| AID532184 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae SY26 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID531768 | Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4696 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID572062 | Antibacterial activity against abeS sigma abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii. |
| AID285608 | Antimicrobial activity against Pseudomonas aeruginosa 3B1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID533589 | Antibacterial activity against gentamicin-resistant Enterococcus faecalis clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID533764 | Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P11 exhibiting PFGE A pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID283537 | Antibacterial activity against Pseudomonas aeruginosa FE57U with inactivated rplY and galU genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID532897 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 ST 340 expressing beta-lactamase TEM-1, SHV-11 and OXA-2 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID324310 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolate | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. |
| AID554442 | Ratio of MIC for Pseudomonas aeruginosa 3066 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID283546 | Antibacterial activity against Pseudomonas aeruginosa KJ7106 with inactivated PA5471 gene by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID285615 | Antimicrobial activity against Pseudomonas aeruginosa 3D10 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID583252 | Antibacterial activity against aminoglycoside-resistant Klebsiella pneumoniae expressing AAC(3)-4 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1324728 | Antibacterial activity against methicillin-resistant Staphylococcus aureus C2 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID278803 | Antimicrobial activity against recombinant Escherichia coli DHalpha expressing pBAD [aph(3')-2] | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. |
| AID1324762 | Antibacterial activity against methicillin-resistant Staphylococcus aureus S22 at 0.5 times MIC measured after 24 hrs by time kill analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID562948 | Antimicrobial activity against Klebsiella pneumoniae PFGE clone E expressing beta-lactamase KPC-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID583236 | Antibacterial activity against Klebsiella spp. by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1524122 | Bactericidal activity against Escherichia coli UB1005 incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID574434 | Antimicrobial activity against Escherichia coli isolate 544 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from abscess of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID1071113 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 1.25 to 5 ug/ml after 7 days by microplate Alamar blue assay relative to control | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III. |
| AID1713730 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth at 3.198 mM by microdilution alamar blue broth assay | 2016 | Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 | A facile stereoselective synthesis of dispiro-indeno pyrrolidine/pyrrolothiazole-thiochroman hybrids and evaluation of their antimycobacterial, anticancer and AchE inhibitory activities. |
| AID373761 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii ab1265 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID533345 | Antibacterial activity against non-gentamicin-resistant Escherichia coli clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID283534 | Antibacterial activity against Pseudomonas aeruginosa FE57 containing inactivated rplY gene with pARAL25 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID369576 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii 06-74 isolate by CLSI microdilution test | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. |
| AID481452 | Antibacterial activity against gentamicin-resistant Escherichia coli ATCC 6174 after 24 hrs by macrobroth dilution method | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. |
| AID1271385 | Antimicrobial activity against Mycobacterium smegmatis MC2-155 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID531781 | Antibacterial activity against Acinetobacter baumannii obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID285640 | Antimicrobial activity against Pseudomonas aeruginosa 13D11 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID528817 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient urine assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID529456 | Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID583267 | Antibacterial activity against aminoglycoside-resistant Staphylococcus aureus expressing APH(2'') + AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID405823 | Antimicrobial activity against Acinetobacter baumannii 9043 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID497945 | Antibacterial activity against Stenotrophomonas maltophilia by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID529481 | Antimicrobial activity against Enterobacter cloacae isolate 18 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID1474723 | Antibacterial activity against Micrococcus luteus ATCC 10240 after 20 to 24 hrs by broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | Novel bioactive molecules from Lentzea violacea strain AS 08 using one strain-many compounds (OSMAC) approach. |
| AID528915 | Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 and other bla gene assessed as susceptible isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. |
| AID508487 | Antimicrobial activity against Pseudomonas aeruginosa isolate BNL-1681 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID555554 | Antimicrobial activity against Pseudomonas aeruginosa isolate M136074 expressing IMP-22 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID545440 | Antimicrobial activity against Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID545434 | Antimicrobial activity against extended-spectrum beta-lactamase-positive Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID498844 | Antimicrobial activity against Klebsiella pneumoniae XJ81T expressing TEM-1, SHV-12, aac(6')-Ib by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID531592 | Antibacterial activity against Serratia marcescens obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID1324741 | Antibacterial activity against methicillin-resistant Staphylococcus aureus S17 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID236835 | Maximum Frel value for binding to 3'-Fl-AM1A-Rhd in Bacillus subtilis tyr | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Fluorescence resonance energy transfer studies of aminoglycoside binding to a T box antiterminator RNA. |
| AID1254012 | Antibacterial activity against Proteus hauseri ATCC 13315 after 24 hrs by microbroth double dilution method | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Synthesis and biological activity of amino acid derivatives of avarone and its model compound. |
| AID285661 | Antimicrobial activity against Pseudomonas aeruginosa 19F2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID508488 | Antimicrobial activity against Pseudomonas aeruginosa isolate OS-210 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID1324758 | Antibacterial activity against Klebsiella pneumoniae ATCC 27736 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID524406 | Antibacterial activity against Enterobacteriaceae by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID582763 | Antimicrobial activity against eaeA positive verocytotoxin-producing non-O157 Escherichia coli isolates obtained from human assessed as percentage of resistant isolates | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26. |
| AID508482 | Antimicrobial activity against Pseudomonas aeruginosa isolate K34-73 producing metallo-beta-lactamase VIM4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID524922 | Bacteriostatic activity against Mycobacterium abscessus 390V infected in human monocyte-derived macrophage at 10 times MIC | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID373040 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ58 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID560065 | Antimicrobial activity against Escherichia coli isolate 5401 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID664700 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus clinical isolate | 2011 | ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12 | Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue. |
| AID1449151 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. abscessus smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID498302 | Antibacterial activity against Pseudomonas aeruginosa PA1054 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID594773 | Antimicrobial activity against Klebsiella pneumoniae at 100 ug/disc after 24 hrs by disc diffusion method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID576331 | Antibacterial activity against plasmid-mediated AmpC beta-Lactamase DHA-1 and ESBL-producing Klebsiella pneumoniae by Etest | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1. |
| AID497947 | Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID510503 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M2AC9-31 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID574811 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis H37Rv by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID1422376 | Antibacterial activity against Klebsiella pneumoniae 700603 by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID1524061 | Bactericidal activity against Escherichia coli ATCC 25922 incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID1743442 | Antibacterial activity against Mycobacterium marinum measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID283549 | Antibacterial activity against Pseudomonas aeruginosa FE64 containing inactivated rplY and mexXY genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID1602935 | Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 3 after 7 days by resazurin microtiter assay | 2019 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8 | Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis. |
| AID572122 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 28 expressing ampC, ompA, adeM, aadB, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID571914 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 21 expressing ampC, ompA, adeB, adeM, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID278132 | Distribution of Escherichia coli AB1157 IL05 new born cells containing four ori foci at 4 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID285609 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID523069 | Activity of Aminoglycoside 2'-phosphotransferase 2a R92H/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID1322257 | Antibacterial activity against AAC6'-IB expressing Escherichia coli PAZ505H8101 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID523503 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1248c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID533340 | Antibacterial activity against non-gentamicin-resistant Pseudomonas spp. clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID499050 | Antimicrobial activity against Klebsiella pneumoniae PU104T expressing TEM-1, CTX-M-15 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID583235 | Antibacterial activity against Enterobacter spp. by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1271381 | Antimicrobial activity against Gram-positive methicillin-resistant Staphylococcus aureus 1 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID1447086 | Antibacterial activity against Acinetobacter baumannii ATCC BAA 1793 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11 | Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo. |
| AID549331 | Antimicrobial activity against Escherichia coli isolate 32 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID1629124 | Antimicrobial activity against Haemophilus influenzae ATCC 49247 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID279815 | Antimicrobial activity against Escherichia coli DH5-alpha with pGEM-T EASY expressing TEM1 gene by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. |
| AID1543198 | Antimicrobial activity against ESBL-producing Escherichia coli ATCC 35218 assessed as inhibition of microbial growth incubated for 16 hrs by broth microdilution method | |||
| AID524917 | Antimicrobial activity against Mycobacterium abscessus 390S assessed as inhibition of biofilm formation at 64 ug/ml after 24 hrs | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID163280 | Minimum inhibitory concentration (MIC) was measured against Pseudomonas aeruginosa. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID557797 | Antimicrobial activity against Escherichia coli J53 transconjugated with Proteus mirabilis pHS10 carrying qnrC gene by CLSI agar dilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis. |
| AID565283 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring plasmid pA1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID446128 | Antibacterial activity against Klebsiella pneumoniae ATCC 700603 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID518816 | Antibacterial activity against Acinetobacter genomosp. 3 isolates by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID498816 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae FZ49 deficient in IMP-8, TEM-1, SHV-11, CTX-M-14, qnrB2, aac(6')-Ib, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID583245 | Antibacterial activity against aminoglycoside-resistant Enterobacter aerogenes expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1310586 | Antibacterial activity against Staphylococcus aureus ATCC 6538 by broth microdilution method | 2016 | European journal of medicinal chemistry, Aug-08, Volume: 118 | Simple avarone mimetics as selective agents against multidrug resistant cancer cells. |
| AID285633 | Antimicrobial activity against Pseudomonas aeruginosa 10B1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID523066 | Antibacterial activity against Escherichia coli JM83 harboring empty pHF022 vector by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID761247 | Antibacterial activity against Pseudomonas aeruginosa from cystic fibrosis patients by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID533357 | Antibacterial activity against non-gentamicin-resistant Pseudomonas spp. clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID582764 | Antimicrobial activity against eaeA negative verocytotoxin-producing non-O157 Escherichia coli isolates obtained from human assessed as percentage of resistant isolates | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26. |
| AID446141 | Antibacterial activity against R-methylase expressing Enterobacter aerogenes 06AB008 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID1447088 | Antibacterial activity against Acinetobacter baumannii ARC 3484 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11 | Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo. |
| AID285364 | Susceptibility of qnr positive Enterobacter cloacae assessed as percentage nonsusceptible isolates | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital. |
| AID554441 | Ratio of MIC for Pseudomonas aeruginosa 2998 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID539125 | Antibacterial activity against vancomycin-, ciprofloxacin-, gentamicin-resistant Escherichia coli 1269652 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID1322258 | Antibacterial activity against ANT2''-IA expressing Escherichia coli L8058.1 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID542047 | Antibacterial activity against Escherichia coli TrC A expressing Klebsiella pneumoniae A blaCTX-M beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID551745 | Antibacterial activity against Escherichia coli ATCC 25922 after 12 to 18 hrs by twofold dilution method | 2011 | Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1 | Synthesis and antibacterial activity study of a novel class of cationic anthraquinone analogs. |
| AID551750 | Antibacterial activity against Enterococcus faecalis ATCC 29212 after 12 to 18 hrs by twofold dilution method | 2011 | Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1 | Synthesis and antibacterial activity study of a novel class of cationic anthraquinone analogs. |
| AID326537 | Antimicrobial activity against Mycobacterium abscessus R31 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID372845 | Antibacterial activity against Acinetobacter baumannii isolate D expressing 16S rRNA methylase armA gene | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID533599 | Antibacterial activity against gentamicin-resistant Proteus rettgeri clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1449150 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. abscessus isolate 2069 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID1449152 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. massiliense isolate 210 rough variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID446125 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID1449167 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. bolletii isolate 114 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID1449164 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. bolletii isolate 108 rough variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID1524036 | Antimicrobial activity against Escherichia coli K99 after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID278119 | Loss of cell viability in Escherichia coli AB1157 IL05 above 16 ug/ml after 8 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID212902 | Inhibition of human telomerase after assembly using recombinant hTR and hTERT at 50 uM | 2004 | Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13 | Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase. |
| AID64906 | Minimum inhibitory concentration was measured against Escherichia coli 72091801 producing AAC-(3)-I modifying enzyme | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID535864 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ47T harboring qnrB gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID531770 | Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4706 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID529457 | Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID583217 | Antibacterial activity against aminoglycoside-resistant Serratia marcescens expressing ANT(2''), AAC(6') by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID532904 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID529855 | Antibacterial activity against Pseudomonas aeruginosa COR6 expressing MexC-MexD-OprJ gene by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID533577 | Antibacterial activity against gentamicin-resistant Enterobacter aerogenes clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID539131 | Antibacterial activity against vancomycin-intermediate and ciprofloxacin-, gentamicin-resistant Staphylococcus aureus 1269618 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID396033 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pBGS18 plasmid by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID529854 | Antibacterial activity against MexA-MexB-OprM-overproducing and OprD-deficient Pseudomonas aeruginosa N041 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID1271798 | Antibacterial activity against Escherichia coli ATCC 10536 after 24 hrs by broth microdilution method | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Synthesis, antibacterial and cytotoxic activities of new biflorin-based hydrazones and oximes. |
| AID524407 | Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID540209 | Volume of distribution at steady state in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID529857 | Antibacterial activity against Pseudomonas aeruginosa N092 expressing MexE-MexD-OprN gene and OprD mutant gene and harboring nfxC mutant gene by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID373332 | Antibacterial activity against Micrococcus luteus ATCC 10240 at 10 ug/disk after 24 hrs by agar diffusion method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis, characterization and antimicrobial activity of Co(II), Zn(II) and Cd(II) complexes with N-benzyloxycarbonyl-S-phenylalanine. |
| AID532400 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-17 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID373763 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh9 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID554385 | Antimicrobial activity against Pseudomonas aeruginosa mutGR1 overexpressing mexXY mutant by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1296384 | Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis 9449/2007 after 14 days by microdilution method | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. |
| AID373031 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU4A22 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID1201501 | Inhibition of FtsZ in Escherichia coli assessed as Z-ring containing cells level at 4 and 8 ug/ml (Rvb = 88%) | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Advances in the discovery of novel antimicrobials targeting the assembly of bacterial cell division protein FtsZ. |
| AID285595 | Antimicrobial activity against Pseudomonas aeruginosa 1B9 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID348089 | Activity of Enterococcus APH(3')-3a | 2008 | Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23 | Surprising alteration of antibacterial activity of 5"-modified neomycin against resistant bacteria. |
| AID434368 | Antibacterial activity against Klebsiella pneumoniae ATCC 27736 after 24 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Design, synthesis and biological evaluation of novel nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents. |
| AID523068 | Activity of Aminoglycoside 2'-phosphotransferase 2a N196D/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID733054 | Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents. |
| AID522932 | Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a N196D mutant by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID1442615 | Antibacterial activity against Pseudomonas aeruginosa PA1145 in BALB/c mouse model of lung infection assessed as reduction in log10CFU per gram of lung at 40 mg/kg, iv bid administered 2 to 12 hrs of post-infection measured after 24 hrs relative to untrea | 2017 | Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6 | Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa. |
| AID583229 | Antibacterial activity against Pseudomonas aeruginosa expressing mexXY operon by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID523508 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1726 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID533836 | Bactericidal activity against Acinetobacter baumannii ATCC BAA 747 assessed as maximal kill rate constant for the bacterial population by time-kill study | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. |
| AID1743446 | Antibacterial activity against Enterobacter aerogenes measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID1271382 | Antimicrobial activity against Gram-positive methicillin-resistant Staphylococcus aureus 2 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID1310590 | Antibacterial activity against Clostridium sporogenes ATCC 19404 by broth microdilution method | 2016 | European journal of medicinal chemistry, Aug-08, Volume: 118 | Simple avarone mimetics as selective agents against multidrug resistant cancer cells. |
| AID561932 | Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate N50 by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii. |
| AID528492 | Antimicrobial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID545443 | Antimicrobial activity against extended-spectrum beta-lactamase-positive Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID508731 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3D2 GM2 harboring acquired beta-lactamase BEL-3 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID529863 | Ratio of MIC for Pseudomonas aeruginosa N041 to MIC for Pseudomonas aeruginosa PAO1 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID446130 | Antibacterial activity against AAC6'-2b expressing Escherichia coli PAZ505H8101 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID532415 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-10 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID533584 | Antibacterial activity against gentamicin-resistant Acinetobacter calcoaceticus clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID567303 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2201 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID1331877 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID532202 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae WH99 harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID556760 | Antimicrobial activity against extended spectrum beta-lactamase CTX-M-2-producing Pseudomonas aeruginosa isolate P6208 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa. |
| AID535873 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JN1 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB and qnrA genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID278131 | Distribution of Escherichia coli AB1157 IL05 new born cells containing duplicated ori and ter foci at 32 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID532412 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-07 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID558043 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S6 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID278065 | Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from deployed military patient | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel. |
| AID285601 | Antimicrobial activity against Pseudomonas aeruginosa 2A3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID65071 | Estimated rate of [3H]DHS uptake in Escherichia coli K12 (ATCC 25868) | 1987 | Journal of medicinal chemistry, Feb, Volume: 30, Issue:2 | Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli. |
| AID372844 | Antibacterial activity against Acinetobacter baumannii isolate C expressing 16S rRNA methylase armA gene | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID574428 | Antimicrobial activity against Escherichia coli isolate 360T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from urine of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID554390 | Antimicrobial activity against Pseudomonas aeruginosa isolate 615S obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID565063 | Antibacterial activity against CTX-M-15 ESBL producing Enterobacter cloacae assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID531758 | Antibacterial activity against Pseudomonas aeruginosa 1956 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID1071104 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate Alamar blue assay | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III. |
| AID285652 | Antimicrobial activity against Pseudomonas aeruginosa 19C7 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID572142 | Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 38 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID373767 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh17 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID534169 | Antimicrobial activity against armB positive Escherichia coli COP producing beta lactamase CTX-M-14 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID531585 | Antibacterial activity against Klebsiella pneumoniae obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID372852 | Antimicrobial activity against azide-resistant Escherichia coli J53 transconjugant with 16S rRNA methylase armA gene expressing Acinetobacter baumannii isolate D | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID446132 | Antibacterial activity against Pseudomonas aeruginosa PAO1 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID373468 | Antibacterial activity against Staphylococcus epidermidis ATCC 12228 at 10 ug/disk after 24 hrs by agar diffusion method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis, characterization and antimicrobial activity of Co(II), Zn(II) and Cd(II) complexes with N-benzyloxycarbonyl-S-phenylalanine. |
| AID529859 | Ratio of MIC for Pseudomonas aeruginosa MR08 to MIC for Pseudomonas aeruginosa PAO1 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID532018 | Antibacterial activity against macrolide-lincosamide-streptogramin B-negative, beta-lactamase-positive, methicillin-susceptible Staphylococcus aureus ATCC 29213 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate. |
| AID535754 | Antimicrobial activity against hospital-acquired Klebsiella pneumoniae expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob |
| AID528823 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient blood assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID498833 | Antimicrobial activity against Klebsiella pneumoniae CY1T expressing SHV-11, DHA-1 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID529850 | Antibacterial activity against OprD-deficient Pseudomonas aeruginosa MR08 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID498813 | Antimicrobial activity against Escherichia coli ZJ87T expressing KPC-2 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID523505 | Antimicrobial activity against Pseudomonas aeruginosa isolate 12142c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1691822 | Antibacterial activity against Pseudomonas aeruginosa PAO1 biofilm cells assessed as reduction in bacterial growth after 2 days by resazurin dye based assay | 2020 | European journal of medicinal chemistry, May-15, Volume: 194 | Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1. |
| AID533348 | Antibacterial activity against non-gentamicin-resistant Enterobacter aerogenes clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1271384 | Antimicrobial activity against Gram-negative Pseudomonas aeruginosa PAO1 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID533344 | Antibacterial activity against non-gentamicin-resistant Staphylococcus epidermidis clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1684104 | Antibacterial activity against Bacillus licheniformis KX785171.1 assessed as reduction in cell viability after 24 hrs by microdilution method | 2020 | Journal of natural products, 12-24, Volume: 83, Issue:12 | Penipyranicins A-C: Antibacterial Methylpyran Polyketides from a Hydrothermal Spring Sediment |
| AID1449165 | Antibacterial activity against non CF patient derived Mycobacterium abscessus subsp. bolletii isolate 17 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID285648 | Antimicrobial activity against Pseudomonas aeruginosa 19B3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1593371 | Inhibition of Pks13 D1644G/N1640K double mutant thioesterase domain in Mycobacterium tuberculosis H37Rv assessed as reduction in bacterial growth by microplate alamar blue assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7 | Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II. |
| AID565279 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A1 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID340732 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase assessed as percent resistant isolates by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID405818 | Antimicrobial activity against Acinetobacter sp. 5248 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID373758 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1254 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID1463959 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 9449/2007 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID583225 | Antibacterial activity against aminoglycoside-resistant Acinetobacter calcoaceticus expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID594854 | Antimicrobial activity against Bacillus subtilis after 24 hrs by microdilution method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID554392 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3020S obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID532398 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D1 isolate VA-06X-63 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID498305 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID542063 | Antibacterial activity against Klebsiella pneumoniae B expressing CTX-M group 1 beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID572059 | Antibacterial activity against Acinetobacter baumannii AC0037 by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii. |
| AID574807 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 horboring rpoB S531L/Q510P, katG S315T/R463L, gyrA D94N/S95T, rrs G1484T by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID761211 | Antibacterial activity against Klebsiella pneumoniae expressing ESBL by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID1629128 | Antimicrobial activity against Escherichia coli ATCC 25922 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID428871 | Antibacterial activity against Escherichia coli CSH-2 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. |
| AID558790 | Antimicrobial activity against Enterobacter cloacae assessed as percent susceptible isolates by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID594779 | Antimicrobial activity against Salmonella Typhimurium at 100 ug/disc after 24 hrs by disc diffusion method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID1449157 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. massiliense isolate 185 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID542060 | Antibacterial activity against Klebsiella pneumoniae expressing CTX-M group 1 beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID422883 | Antimicrobial activity against 8 ug/ml colistin-subcultured Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis and bacteremia by broth microdilution assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex. |
| AID279939 | Antibiotic susceptibility by resistance against Pseudomonas aeruginosa from samples collected from patients | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. |
| AID499046 | Antimicrobial activity against Klebsiella pneumoniae ZJ68T expressing CTX-M-15 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID533597 | Antibacterial activity against gentamicin-resistant Morganella morganii clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID498802 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ18 deficient in KPC-2, SHV-28, DHA-1, ompK35 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID498872 | Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate. |
| AID1426249 | Antibacterial activity against Staphylococcus aureus ATCC 25923 | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Synthesis and bioactivity investigation of quinone-based dimeric cationic triazolium amphiphiles selective against resistant fungal and bacterial pathogens. |
| AID529852 | Antibacterial activity against beta-lactamase-overproducing and OprD-deficient Pseudomonas aeruginosa N044 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID577648 | Antimicrobial activity against Escherichia coli isolate 157T expressing beta-lactamase KPC2 and PFGE cluster 3 isolated from urine of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID583248 | Antibacterial activity against aminoglycoside-resistant Klebsiella oxytoca expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID30395 | Minimum inhibitory concentration (MIC) was measured against Acinetobacter baumanni ATCC 19606. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID207419 | Minimum inhibitory concentration was measured against Staphylococcus aureus ATCC 25923 | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID570782 | Antimicrobial activity against multidrug-resistant Acinetobacter baumannii assessed as resistant isolates by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. |
| AID534194 | Antimicrobial activity against Pseudomonas putida expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient. |
| AID445290 | Antibacterial activity against Escherichia coli by broth dilution method | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22 | Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis. |
| AID539229 | Antibacterial activity against oxymycin-, gentamicin-, levofloxacin-resistant Staphylococcus epidermidis 1269680 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID93906 | Minimum inhibitory concentration (MIC) was measured against Klebsiella pneumoniae. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID278809 | Antibacterial activity against Escherichia coli BL21(DE3) | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa. |
| AID584330 | Antibacterial activity against ygiBC, yjfMC, gspS deficient Escherichia coli GD108 | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics. |
| AID532898 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID257554 | Antibacterial activity against Staphylococcus aureus | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23 | Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents. |
| AID529891 | Induction of apoptosis in pig LLC-PK1 cells upto 9 mM after 2 days by DAPI staining | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Apoptosis induced by aminoglycosides in LLC-PK1 Cells: comparative study of neomycin, gentamicin, amikacin, and isepamicin using electroporation. |
| AID539137 | Antibacterial activity against oxymycin-, gentamicin-, levofloxacin-resistant Staphylococcus epidermidis 1269675 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID560598 | Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID574437 | Antimicrobial activity against Escherichia coli isolate 1679 expressing beta-lactamase KPC2, SHV-12, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID565067 | Antibacterial activity against CTX-M-15 and SHV-27 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID285597 | Antimicrobial activity against Pseudomonas aeruginosa 2A1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID532410 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate CR-04X-14 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID531754 | Antibacterial activity against Pseudomonas aeruginosa 2439 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID495514 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4668 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID285667 | Antimicrobial activity against Pseudomonas aeruginosa 22C5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1684106 | Antibacterial activity against Enterobacter xiangfangensis CP017183.1 assessed as reduction in cell viability after 24 hrs by microdilution method | 2020 | Journal of natural products, 12-24, Volume: 83, Issue:12 | Penipyranicins A-C: Antibacterial Methylpyran Polyketides from a Hydrothermal Spring Sediment |
| AID499073 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae SZ93 deficient in ompC by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID1577331 | Antimycobacterial activity against XDR Mycobacterium tuberculosis Praha 131 after 14 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID558049 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S12 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID373032 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FW-F1 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID529483 | Antimicrobial activity against Enterobacter cloacae isolate 151 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID396026 | Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID1224519 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 9449/2007 after 7 days by micromethod | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. |
| AID529490 | Antimicrobial activity against Enterobacter cloacae isolate 354 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID285337 | Antimicrobial activity against Escherichia coli qnrA1 producing urinary specimen isolate 13.52 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America. |
| AID583223 | Antibacterial activity against aminoglycoside-susceptible Acinetobacter baumannii by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1271795 | Antibacterial activity against Enterococcus faecalis ATCC 4083 after 24 hrs by broth microdilution method | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Synthesis, antibacterial and cytotoxic activities of new biflorin-based hydrazones and oximes. |
| AID761214 | Antibacterial activity against Acinetobacter baumannii AB-3167 by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID533593 | Antibacterial activity against gentamicin-resistant Enterobacter aerogenes clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID519407 | Antibacterial activity against 16S rRNA methylase rmtB and CTX-M-65 ESBL producing rifampin resistant Escherichia coli isolate ECRB1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States. |
| AID278133 | Distribution of Escherichia coli AB1157 IL05 new born cells containing four ori foci at 8 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID498836 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU5 deficient in SHV-12, DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID1684102 | Antibacterial activity against Pseudomonas aeruginosa NR-117678.1 assessed as reduction in cell viability after 24 hrs by microdilution method | 2020 | Journal of natural products, 12-24, Volume: 83, Issue:12 | Penipyranicins A-C: Antibacterial Methylpyran Polyketides from a Hydrothermal Spring Sediment |
| AID323039 | Antimicrobial activity against extended-spectrum-beta-lactamase producing Klebsiella pneumoniae isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. |
| AID528919 | Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-14 and CTX-M-27 gene assessed as susceptible isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. |
| AID285599 | Antimicrobial activity against Pseudomonas aeruginosa 2A2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID428274 | Antimicrobial activity against carbapenemase producing Enterobacter sp. assessed as resistant isolates by CLSI breakpoint assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID1296386 | Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis Praha 1 after 14 days by microdilution method | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. |
| AID508485 | Antimicrobial activity against Pseudomonas aeruginosa isolate BU-43038 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID1324739 | Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS77 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID535876 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JN1T by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID163279 | Minimum inhibitory concentration (MIC) was measured against Pseudomonas aeruginosa ATCC 27853. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID508730 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C9 GM1 harboring acquired beta-lactamase OXA-144 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID583233 | Antibacterial activity against Citrobacter spp. by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID533336 | Antibacterial activity against non-gentamicin-resistant Citrobacter freundii clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID519189 | Antimicrobial activity against mexXY-OprM-overproducing Pseudomonas aeruginosa isolate PA/XY assessed as zone of inhibition by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID588212 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID508478 | Antimicrobial activity against Pseudomonas aeruginosa isolate U9-19005 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID523512 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1240 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID533002 | Antibacterial activity against VEB-1a and OXA-10 producing Pseudomonas aeruginosa isolate P151 exhibiting PFGE I pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID565424 | Antimicrobial activity against beta-lactamase-producing Pseudomonas aeruginosa clinical isolate assessed as susceptible isolates by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil. |
| AID529499 | Antimicrobial activity against Escherichia coli GeneHogs by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID594862 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus strain 4 TB5G after 24 hrs by microdilution method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID1324730 | Antibacterial activity against methicillin-resistant Staphylococcus aureus C14 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID373760 | Antibacterial activity against imipenem-intermediate Acinetobacter baumannii ab1297 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID528922 | Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-14 and CTX-M-27 gene and other bla gene assessed as susceptible isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. |
| AID535882 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN132T harboring qnrB gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID285645 | Antimicrobial activity against Pseudomonas aeruginosa 16D2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID535858 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae GZ40T harboring qnrB gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID584559 | Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID560078 | Antimicrobial activity against Pseudomonas aeruginosa isolate 956 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID481453 | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by macrobroth dilution method | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. |
| AID551744 | Antibacterial activity against Mycobacterium smegmatis ATCC 14468 after 12 to 18 hrs by twofold dilution method | 2011 | Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1 | Synthesis and antibacterial activity study of a novel class of cationic anthraquinone analogs. |
| AID285656 | Antimicrobial activity against Pseudomonas aeruginosa 19E1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID560058 | Antimicrobial activity against ESBL-producing Klebsiella pneumoniae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID583254 | Antibacterial activity against aminoglycoside-resistant Enterobacter aerogenes expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID572132 | Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 33 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID279941 | Antibiotic susceptibility by resistance against non-MDR Pseudomonas aeruginosa from samples collected from patients | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. |
| AID1447079 | Antibacterial activity against Acinetobacter baumannii ARC 3486 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11 | Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo. |
| AID348097 | Antibacterial activity against vancomycin-susceptible and aminoglycosides-resistant Enterococcus faecalis ATCC 29212 after 12 to 18 hrs | 2008 | Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23 | Surprising alteration of antibacterial activity of 5"-modified neomycin against resistant bacteria. |
| AID372856 | Antimicrobial activity against colistin-resistant Acinetobacter baumannii 213 transconjugant with 16S rRNA methylase armA gene expressing Acinetobacter baumannii isolate C | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID567582 | Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolate by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. |
| AID283531 | Antibacterial activity against Pseudomonas aeruginosa FE49 with inactivated galU gene by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID583237 | Antibacterial activity against Proteus mirabilis by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID250284 | Susceptibility testing against Pseudomonas aeruginosa ATCC 27853; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID560090 | Bactericidal activity against Enterobacter cloacae isolate 5420 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID535855 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae GZ40 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID476941 | Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by browth microdilution assay | 2010 | European journal of medicinal chemistry, Apr, Volume: 45, Issue:4 | Synthesis, characterization and biological evaluation of some thiourea derivatives bearing benzothiazole moiety as potential antimicrobial and anticancer agents. |
| AID1577337 | Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 7357/1998 after 21 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID373024 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU4A1 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID510508 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC1AC9-26 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID324311 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. |
| AID534178 | Antimicrobial activity against Escherichia coli TOP10 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID1231411 | Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as growth inhibition at 30 ug after 24 hrs by disc agar diffusion method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Synthesis and biological evaluation of caracasine acid derivatives. |
| AID322318 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID404900 | Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB40 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus. |
| AID498845 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU105 deficient TEM-1, SHV-12, CTX-M-14, DHA-1, qnrB10/B4-like, aac(6')-Ib-cr, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID1890851 | Cytotoxicity against mouse BMDM cells | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Design, synthesis and antibacterial activity against pathogenic mycobacteria of conjugated hydroxamic acids, hydrazides and O-alkyl/O-acyl protected hydroxamic derivatives. |
| AID348098 | Antibacterial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 expressing vanB, ant(6)-1, aac(6')-aph(2') resistant gene after 12 to 18 hrs | 2008 | Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23 | Surprising alteration of antibacterial activity of 5"-modified neomycin against resistant bacteria. |
| AID583209 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID285596 | Antimicrobial activity against Pseudomonas aeruginosa 1C9 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID574810 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 horboring rpoB D516V, katG S315T/R463L, gyrA D94G/S95T/R128S/Y129C, rrs A1401G by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID323037 | Antimicrobial activity against extended-spectrum-beta-lactamase producing Escherichia coli isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. |
| AID519184 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY and MexZ mutant gene selected after 8 ug/ml of amikacin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID565332 | Antibacterial activity against Enterobacter hormaechei isolate UCN62 | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy. |
| AID583242 | Antibacterial activity against Pseudomonas aeruginosa by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID212744 | Inhibition of telomerase before assembly using recombinant Tetraymena thermophilia TR and TERT at 50 uM | 2004 | Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13 | Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase. |
| AID285629 | Antimicrobial activity against Pseudomonas aeruginosa 9B2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID92473 | Denaturation rate constant of IF2 in the presence of aminoglycoside | 2003 | Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6 | Inhibition of bacterial IF2 binding to fMet-tRNA((fMet)) by aminoglycosides. |
| AID238131 | Binding dissociation constant towards 3'-Fl-AM1A-Rhd in Bacillus subtilis tyrS | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Fluorescence resonance energy transfer studies of aminoglycoside binding to a T box antiterminator RNA. |
| AID523500 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1681c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID533352 | Antibacterial activity against non-gentamicin-resistant Morganella morganii clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID323038 | Antimicrobial activity against extended-spectrum-beta-lactamase producing Escherichia coli assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. |
| AID531774 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4703 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID560069 | Antimicrobial activity against Klebsiella pneumoniae isolate 5427 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID533568 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA469 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID283533 | Antibacterial activity against Pseudomonas aeruginosa FE57 with inactivated rplY gene by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID533569 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA475 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID283539 | Antibacterial activity against Pseudomonas aeruginosa FE57G with inactivated rplY and nuoG genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID558050 | Antimicrobial activity against blaKPC-positive Klebsiella oxytoca S13 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID68538 | Minimum inhibitory concentration (MIC) was measured against Enterobacter cloacae. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID476940 | Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 24 hrs by browth microdilution assay | 2010 | European journal of medicinal chemistry, Apr, Volume: 45, Issue:4 | Synthesis, characterization and biological evaluation of some thiourea derivatives bearing benzothiazole moiety as potential antimicrobial and anticancer agents. |
| AID560592 | Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolate IMCJ2S1 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID583250 | Antibacterial activity against aminoglycoside-resistant Serratia liquefaciens expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID761218 | Antibacterial activity against Pseudomonas aeruginosa 1042-06 by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID1743444 | Antibacterial activity against Pseudomonas aeruginosa measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID65061 | Lethal dose required to kill 90% of the Escherichia coli K12 (ATCC 25868) cell population | 1987 | Journal of medicinal chemistry, Feb, Volume: 30, Issue:2 | Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli. |
| AID50539 | Minimum inhibitory concentration (MIC) was measured against Citrobacter freundii. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID535694 | Antimicrobial activity against Azide-resistant Escherichia coli J53 transconjugant harboring Escherichia coli DH5alpha-5825 qnrB2 gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID509851 | Antibacterial activity against Acinetobacter baumannii ATCC 17978 assessed as bacterial growth at 4.5 mg/L in presence of 150 mM NaCl | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID533855 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium fortuitum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID250298 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH23; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID532901 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 ST 376 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID565304 | Antitubercular activity against Mycobacterium avium infected in C57BL/6J mouse assessed as reduction of CFU counts in spleen at 200 mg/kg, po administered one month post-infection five times weekly for 3 months (Rvb = 7.9 +/- 0.7 log10CFU) | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | ATP synthase inhibition of Mycobacterium avium is not bactericidal. |
| AID525041 | Antimicrobial activity against fluoroquinolone-resistant Escherichia coli NorE5 harboring GyrA S83L mutant, ParC S80R mutant, truncated SoxR and constitutively active SoxS by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Constitutive SoxS expression in a fluoroquinolone-resistant strain with a truncated SoxR protein and identification of a new member of the marA-soxS-rob regulon, mdtG. |
| AID1868110 | Anti-tubercular activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of mycobacterial growth incubated for 7 days by resazurin-dye based analysis | 2022 | European journal of medicinal chemistry, Jul-05, Volume: 237 | Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation. |
| AID571696 | Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 5 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID572060 | Antibacterial activity against abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii. |
| AID529482 | Antimicrobial activity against Enterobacter cloacae isolate 140 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID498084 | Antibacterial activity against Pseudomonas aeruginosa PA5043 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID523396 | Antimicrobial activity against amikacin-resistant Nocardia farcinica IFM 10580 after 3 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID532900 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID583213 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(3')-1b by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID322314 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID1524136 | Bactericidal activity against Klebsiella pneumoniae incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID558802 | Antimicrobial activity against extended spectrum beta-lactamase-deficient Klebsiella oxytoca assessed as percent susceptible isolates by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID569267 | Antimicrobial activity against AGs-resistant Enterococcus faecalis ATCC 19434 | 2011 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 | Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives. |
| AID529551 | Drug uptake in human adult CSF at 75 mg, im up to 8.5 hrs by HPLC | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates. |
| AID529860 | Ratio of MIC for Pseudomonas aeruginosa OCR1 to MIC for Pseudomonas aeruginosa PAO1 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID372843 | Antibacterial activity against Acinetobacter baumannii isolate B expressing 16S rRNA methylase armA gene | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID532896 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID1324726 | Antibacterial activity against methicillin-resistant Staphylococcus aureus BRS3 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID535666 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ67 harboring wild-type GyrA S83I and qnrS genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID1819097 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv clinical isolates 4 assessed as reduction in bacterial growth incubated for 7 days by resazurin dye based assay | 2022 | ACS medicinal chemistry letters, Jan-13, Volume: 13, Issue:1 | Structural Rigidification of |
| AID519183 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrW mutant and MexZ mutant gene selected after 4 ug/ml of cefepime exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID1602933 | Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 1 after 7 days by resazurin microtiter assay | 2019 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8 | Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis. |
| AID531751 | Antibacterial activity against Pseudomonas aeruginosa 3308 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID283222 | Antimicrobial activity against Escherichia coli XL1-Blue [pBluescript 2 SK(+) | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. |
| AID285613 | Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID434366 | Antibacterial activity against Escherichia coli after 24 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Design, synthesis and biological evaluation of novel nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents. |
| AID279814 | Antimicrobial activity against Escherichia coli DH5-alpha with pYW2 expressing KPC2 and TEM1 gene by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. |
| AID523067 | Activity of Aminoglycoside 2'-phosphotransferase 2a using ATP/GTP as second substrate by spectrophotometric assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID528980 | Antimicrobial activity against Haemophilus influenzae assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID533762 | Antibacterial activity against OXA-2 and OXA-19 producing Pseudomonas aeruginosa isolate P66 exhibiting PFGE C pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID531581 | Antibacterial activity against Citrobacter freundii obtained from complicated skin and skin structure infections by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. |
| AID1422368 | Antibacterial activity against Pseudomonas aeruginosa FO3 harboring AAC6'-2A by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID1546876 | Antibacterial activity against ESBL-producing Escherichia coli ATCC 35218 assessed as reduction in microbial growth after 16 hrs by broth microdilution method | 2020 | Journal of natural products, 01-24, Volume: 83, Issue:1 | Reisolation and Configurational Reinvestigation of Cottoquinazolines E-G from an Arthropod-Derived Strain of the Fungus |
| AID528818 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID560091 | Bactericidal activity against Klebsiella pneumoniae isolate 5427 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID285679 | Antimicrobial activity against Pseudomonas aeruginosa 29G7 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID522928 | Antibacterial activity against Escherichia coli JM83 producing aminoglycoside 2''-2a phosphotransferase by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID323690 | Antibacterial activity against TEM92 ESBL-producing Acinetobacter baumannii by CLSI method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase. |
| AID373333 | Antibacterial activity against Staphylococcus aureus ATCC 25923 at 10 ug/disk after 24 hrs by agar diffusion method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis, characterization and antimicrobial activity of Co(II), Zn(II) and Cd(II) complexes with N-benzyloxycarbonyl-S-phenylalanine. |
| AID499058 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae GX24 deficient in TEM-1, DHA-1, aac(6')-Ib, ompC by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID1232122 | Antimicrobial activity against Staphylococcus aureus ATCC 25923 assessed as inhibition of bacterial growth incubated at 35 degC for 12 to 18 hrs | 2014 | MedChemComm, Aug-01, Volume: 5, Issue:8 | Antifungal Amphiphilic Aminoglycosides. |
| AID542721 | Antimicrobial activity against ESBL-producing Klebsiella pneumoniae clinical isolate assessed as resistant isolates | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases. |
| AID584331 | Antibacterial activity against tolC, speE deficient Escherichia coli GD106 | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics. |
| AID1422369 | Antibacterial activity against Pseudomonas aeruginosa PA22 harboring surexp MexXY by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID572058 | Ratio of MIC for Escherichia coli KAM32 harboring plasmid pUC18 to MIC for Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii. |
| AID774218 | Antibacterial activity against Pseudomonas aeruginosa F03 expressing AAC6'-2A after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID1071112 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 0.63 ug/ml after 7 days by microplate Alamar blue assay relative to control | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III. |
| AID1743449 | Antibacterial activity against Klebsiella pneumoniae measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID554434 | Ratio of MIC for Pseudomonas aeruginosa 2715 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID571900 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 14 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID533757 | Antibacterial activity against SHV-2a producing Pseudomonas aeruginosa isolate P60 exhibiting PFGE H pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID533333 | Antibacterial activity against non-gentamicin-resistant Proteus mirabilis clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID285605 | Antimicrobial activity against Pseudomonas aeruginosa 2F6 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID348094 | Antibacterial activity against multidrug-resistant Klebsiella pneumoniae ATCC 700603 isolate after 12 to 18 hrs | 2008 | Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23 | Surprising alteration of antibacterial activity of 5"-modified neomycin against resistant bacteria. |
| AID498834 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU3 deficient in DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID1743447 | Antibacterial activity against Enterobacter cloacae measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID567308 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2206 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID571890 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 9 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID594856 | Antimicrobial activity against Klebsiella pneumoniae after 24 hrs by microdilution method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID583232 | Antibacterial activity against Pseudomonas aeruginosa expressing AAC(6')-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID519405 | Antibacterial activity against 16S rRNA methylase RmtB and CTX-M-65 ESBL producing Escherichia coli isolate ECRB1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States. |
| AID558783 | Antimicrobial activity against Enterobacter aerogenes assessed as percent susceptible isolates by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID510510 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-18 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID528793 | Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 and other bla gene assessed as susceptible isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. |
| AID535648 | Antimicrobial activity against aac(6')-Ib-cr-positive Escherichia coli FJ3 harboring GyrA S83L, ParC S80R mutant, wild-type GyrB and qnrB genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID554399 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2858 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID545458 | Antimicrobial activity against Serratia marcescens assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID1577339 | Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 8666/2010 after 14 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID586058 | Antimicrobial activity against Acinetobacter baumannii clinical isolate harboring chromosomally encoded ISAba1-blaOXA-51-like gene with fxsA upstream sequence by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan. |
| AID583216 | Antibacterial activity against aminoglycoside-resistant Providencia stuartii expressing ANT(2')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1254011 | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by microbroth double dilution method | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Synthesis and biological activity of amino acid derivatives of avarone and its model compound. |
| AID563601 | Antimicrobial activity against Escherichia coli isolate CKP048 transconjugant harboring beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA. |
| AID1653391 | Anti-leprotic activity against Mycobacterium leprae infected in BALB/c weanling mouse assessed as bacteria killing at 100 mg/kg, ip administrated for 60 days and measured after 1 year by most probable number technique analysis relative to control | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13 | Insights of synthetic analogues of anti-leprosy agents. |
| AID531749 | Antibacterial activity against Pseudomonas aeruginosa FK06 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID425070 | Antimicrobial activity against multidrug-resistant Escherichia coli M7943-TC2 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID373756 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab20 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID428266 | Antimicrobial activity against carbapenemase producing Enterobacteriaceae by CLSI broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID535691 | Antimicrobial activity against beta-lactamase CTX-M-15-producing fluoroquinolone-resistant Escherichia coli FMV5825 expressing qnrB2 and aac(6')-Ib-cr and harboring gyrA Ser83Ile and Asp87Asn mutant gene and ParC Ser80Ile and Glu84Val mutant gene obtained | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID428268 | Antimicrobial activity against carbapenemase producing Enterobacteriaceae assessed as resistant isolates by CLSI breakpoint assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID564017 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID1449147 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. abscessus isolate 3321 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID560073 | Antimicrobial activity against Enterobacter cloacae isolate 4073 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID555556 | Antimicrobial activity against Pseudomonas aeruginosa isolate 22843 expressing VIM-2 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID560093 | Bactericidal activity against Escherichia coli isolate 5401 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID558045 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S8 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID522931 | Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase R92H mutant by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID322313 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID558810 | Antimicrobial activity against Proteus mirabilis assessed as percent susceptible isolates by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID533566 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA462 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID404896 | Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB28 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus. |
| AID69667 | Minimum inhibitory concentration (MIC) was measured against Escherichia coli ATCC 35218. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID373039 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ32 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID1474728 | Antibacterial activity against Pseudomonas aeruginosa ATCC 10145 after 20 to 24 hrs by broth microdilution method | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11 | Novel bioactive molecules from Lentzea violacea strain AS 08 using one strain-many compounds (OSMAC) approach. |
| AID1449155 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. massiliense isolate 111 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID560087 | Bactericidal activity against Pseudomonas aeruginosa isolate 1019 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID285669 | Antimicrobial activity against Pseudomonas aeruginosa 24D5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID373668 | Antibacterial activity against Enterococcus faecalis ATCC 29212 at 10 ug/disk after 24 hrs by agar diffusion method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis, characterization and antimicrobial activity of Co(II), Zn(II) and Cd(II) complexes with N-benzyloxycarbonyl-S-phenylalanine. |
| AID285651 | Antimicrobial activity against Pseudomonas aeruginosa 19C5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID250296 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH21; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID1447478 | Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by microtiter dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID508726 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1B2 RCA2 harboring acquired beta-lactamase PER-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID250292 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH17; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID531771 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4658 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID571912 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 20 expressing ampC, ompA, adeB, adeM, aacC2 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID761213 | Antibacterial activity against Pseudomonas aeruginosa expressing metallo-beta-lactamase by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID326547 | Antimicrobial activity against Mycobacterium abscessus R65 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID326545 | Antimicrobial activity against Mycobacterium abscessus R54 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID532893 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID533582 | Antibacterial activity against gentamicin-resistant Citrobacter freundii clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID523402 | Antimicrobial activity against amikacin-susceptible Nocardia farcinica isolate IFM 10152-M2 assessed as cell growth at 1024 ug/ml after 24 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID446138 | Antibacterial activity against MexAB, MexCD, MexEF, MexXY, TriABC deleted Pseudomonas aeruginosa PA406 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID481458 | Antibacterial activity against Acinetobacter baumannii CAN-ICU 63169 after 24 hrs by macrobroth dilution method | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. |
| AID1322261 | Cytotoxicity against mouse J774 cells assessed as cell viability at 30 uM after 24 hrs by MTT assay relative to control | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID565419 | Antimicrobial activity against Salmonella enterica serotype Virchow isolate AM23818 expressing rmtC rRNA methyltransferase gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Identification of the aminoglycoside resistance determinants armA and rmtC among non-Typhi Salmonella isolates from humans in the United States. |
| AID322316 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID1868115 | Anti-tubercular activity against Mycobacterium tuberculosis CF16 assessed as inhibition of mycobacterial growth incubated for 7 days by resazurin-dye based analysis | 2022 | European journal of medicinal chemistry, Jul-05, Volume: 237 | Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation. |
| AID250260 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH04; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID521840 | Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA375 containing qnrA1, blaTEM-1, blaSHV-11genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID545422 | Antimicrobial activity against Citrobacter freundii obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID278137 | Distribution of Escherichia coli AB1157 IL05 new born cells containing eight ori foci at 8 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID212743 | Inhibition of telomerase after assembly using recombinant Tetraymena thermophilia TR and TERT at 50 uM | 2004 | Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13 | Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase. |
| AID560590 | Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID533571 | Antibacterial activity against non-gentamicin-resistant Haemophilus parainfluenzae clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1524131 | Bactericidal activity against Pseudomonas aeruginosa 25349 clinical isolates incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID523509 | Antimicrobial activity against Pseudomonas aeruginosa isolate 15107 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID572144 | Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 39 expressing ampC, ompA, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID285680 | Antimicrobial activity against Pseudomonas aeruginosa 29G8 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID94290 | Minimum inhibitory concentration was measured against Klebsiella pneumoniae 760070702 producing AAC-(3)-I modifying enzyme; Value expressed as 0.5/2 | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID283538 | Antibacterial activity against Pseudomonas aeruginosa FE53G with inactivated mexZ and nuoG genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID562813 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID1577327 | Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis Praha 1 after 14 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID761210 | Antibacterial activity against Klebsiella pneumoniae expressing KPC by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID396028 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID540210 | Clearance in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID250294 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH19; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID535682 | Antibacterial activity against 16S rRNA methylase and beta-lactamase producing Enterobacteriaceae by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Plasmid-mediated 16S rRNA methylases in aminoglycoside-resistant Enterobacteriaceae isolates in Shanghai, China. |
| AID532175 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae SH39T harboring qnrA gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID534172 | Antimicrobial activity against armA positive Escherichia coli MEZ producing beta lactamase CTX-M-3 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID529740 | Drug level in human at 4 mg/kg | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Apoptosis induced by aminoglycosides in LLC-PK1 Cells: comparative study of neomycin, gentamicin, amikacin, and isepamicin using electroporation. |
| AID528830 | Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID560593 | Antimicrobial activity against rifampin-resistant Pseudomonas aeruginosa ATCC 27853 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID1322946 | Antivirulence activity against Mycobacterium marinum assessed as Dictyostelium discoideum phagocytic plaque formation at 10 uM preincubated for 2 to 3 hrs followed by Dictyostelium discoideum addition measured after 5 to 9 days in presence of Klebsiella p | 2016 | Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24 | In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA. |
| AID1324749 | Antibacterial activity against Enterococcus faecalis ATCC 29212 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID533328 | Antibacterial activity against non-gentamicin-resistant Escherichia coli clinical isolate after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1324722 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID285624 | Antimicrobial activity against Pseudomonas aeruginosa 8B11 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID498814 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae FZ47 deficient in IMP-8, TEM-1, SHV-11, CTX-M-14, qnrB2, aac(6')-Ib, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID574427 | Antimicrobial activity against Escherichia coli isolate 360 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from urine of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID549330 | Antimicrobial activity against Escherichia coli isolate 16 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID509868 | Antibacterial activity against Acinetobacter baumannii isolate 2898 isolated from human ankle | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID533840 | Ratio of Cmax to MIC for Pseudomonas aeruginosa ATCC 27853 in PK/PD model at 1500 mg administered every 12 hrs | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. |
| AID571896 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 12 expressing ompA, adeB, adeM, aacA4, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID405455 | Antibacterial activity against Escherichia coli 1540 isolate by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID394701 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, ANT(2'')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID554393 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3020R obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1322256 | Antibacterial activity against Escherichia coli ATCC 25922 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID285593 | Antimicrobial activity against Pseudomonas aeruginosa 65.38-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID523404 | Antimicrobial activity against amikacin-resistant Nocardia farcinica IFM 10580 assessed as cell growth at 1024 ug/ml at <12 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID583429 | Antibacterial activity against aminoglycoside-resistant Staphylococcus epidermidis expressing APH(3')-3 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1819098 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv clinical isolates 3 assessed as reduction in bacterial growth incubated for 7 days by resazurin dye based assay | 2022 | ACS medicinal chemistry letters, Jan-13, Volume: 13, Issue:1 | Structural Rigidification of |
| AID279812 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZR01 from patient sputum by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. |
| AID562758 | Antimicrobial activity against Klebsiella pneumoniae PFGE clone A expressing beta-lactamase KPC-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID529493 | Antimicrobial activity against Enterobacter cloacae isolate 781 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID1426251 | Antibacterial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Synthesis and bioactivity investigation of quinone-based dimeric cationic triazolium amphiphiles selective against resistant fungal and bacterial pathogens. |
| AID519406 | Antibacterial activity against Escherichia coli DH10B harboring pBCSK expressing rmtB gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID533565 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA399 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID510502 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate C1AC9-24 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID1524040 | Antimicrobial activity against Pseudomonas aeruginosa 26305 clinical isolates after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID529552 | Cmax in human neonate at 10 mg/kg, iv by HPLC | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates. |
| AID594857 | Antimicrobial activity against Listeria monocytogenes after 24 hrs by microdilution method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID574808 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 horboring rpoB S531L, katG R463L/E217G, gyrA D94N/S95T, rrs A1401G by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID583273 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa expressing ANT(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID326542 | Antimicrobial activity against Mycobacterium abscessus NTU446 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID535852 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ67T harboring qnrS gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID523496 | Antimicrobial activity against Pseudomonas aeruginosa isolate 17145c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1271378 | Antimicrobial activity against Gram-positive Bacillus subtilis 168 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID322315 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID557799 | Antimicrobial activity against Escherichia coli J53 by CLSI agar dilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis. |
| AID535751 | Antimicrobial activity against community-acquired Klebsiella pneumoniae obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID285161 | Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. |
| AID394699 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID560601 | Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID530346 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID528923 | Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-14 and CTX-M-27 gene and other bla gene assessed as susceptible isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. |
| AID1743443 | Antibacterial activity against Mycobacterium bovis BCG measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID499070 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ84 deficient in SHV-11, aac(6')-Ib-cr, ompK35 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID373042 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ49 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID534173 | Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid MEZ by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID283544 | Antibacterial activity against Pseudomonas aeruginosa FE57GZ with inactivated rplY, nuoG and mexZ genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID285626 | Antimicrobial activity against Pseudomonas aeruginosa 9A3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID584332 | Antibacterial activity against tolC, gshB deficient Escherichia coli GD107 | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics. |
| AID495512 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4666 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID534300 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA459 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID396031 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pACYC184 plasmid by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID584329 | Antibacterial activity against gspS deficient Escherichia coli JW2956-1 | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics. |
| AID562472 | Antimicrobial activity against Klebsiella pneumoniae isolate 2641/08 obtained from urine of patient with ischemic cardiomyopathy and several comorbidities by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. |
| AID1732055 | Antibacterial activity against Micrococcus luteus NCTC 8340 | 2021 | European journal of medicinal chemistry, Apr-05, Volume: 215 | Discovery of novel N |
| AID405817 | Antimicrobial activity against Pseudomonas putida 12346 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID523892 | Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-23 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. |
| AID625923 | Antibacterial activity against Staphylococcus aureus ATCC 25923 by micro-broth dilution method | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Micelles catalyzed chemoselective synthesis 'in water' and biological evaluation of oxygen containing hetero-1,4-naphthoquinones as potential antifungal agents. |
| AID1524135 | Bactericidal activity against Acinetobacter baumannii incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID530347 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID583227 | Antibacterial activity against wild type Pseudomonas aeruginosa expressing efflux pump by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID761217 | Antibacterial activity against Pseudomonas aeruginosa 1091-05 by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID565070 | Antibacterial activity against CTX-M-14 ESBL producing Klebsiella pneumoniae assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID563602 | Antimicrobial activity against lacZ-negative, Nalidixic acid-, rifampicin-resistant Escherichia coli EC600 by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA. |
| AID1069174 | Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 7 days by BacTiter-Glo assay | 2014 | European journal of medicinal chemistry, Feb-12, Volume: 73 | Design, synthesis and evaluation of acridine and fused-quinoline derivatives as potential anti-tuberculosis agents. |
| AID323256 | Antimicrobial activity against carbapenem-intermediate or resistant Acinetobacter baumannii assessed as percent susceptible isolates | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. |
| AID524913 | Antimicrobial activity against Mycobacterium abscessus 390S | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID67885 | Minimum inhibitory concentration (MIC) was measured against Enterococcus faecalis ATCC 29212. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID348093 | Antibacterial activity against ampicillin-resistant and aminoglycosides-susceptible Klebsiella pneumoniae ATCC 13883 after 12 to 18 hrs | 2008 | Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23 | Surprising alteration of antibacterial activity of 5"-modified neomycin against resistant bacteria. |
| AID1629123 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID1331898 | Antibacterial activity against Listeria monocytogenes ATCC 19115 at 0.5 times MIC after 15 serial passages | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID515177 | Antimicrobial activity against Staphylococcus aureus CGMCC 1.1361 after 24 hrs by modified microdilution method | 2010 | European journal of medicinal chemistry, Oct, Volume: 45, Issue:10 | Synthesis and antimicrobial activities of novel 1H-dibenzo[a,c]carbazoles from dehydroabietic acid. |
| AID523071 | Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a N196D/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID508480 | Antimicrobial activity against Pseudomonas aeruginosa isolate AK5493 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID530321 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SD2 harboring blaVIM-1 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID1592958 | Antibacterial activity against multi-drug resistant Escherichia coli NMI 3898/15 assessed as reduction in microbial growth incubated for 20 hrs | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. |
| AID476943 | Antibacterial activity against Enterococcus faecalis ATCC 25923 after 24 hrs by browth microdilution assay | 2010 | European journal of medicinal chemistry, Apr, Volume: 45, Issue:4 | Synthesis, characterization and biological evaluation of some thiourea derivatives bearing benzothiazole moiety as potential antimicrobial and anticancer agents. |
| AID1713723 | Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 | A facile stereoselective synthesis of dispiro-indeno pyrrolidine/pyrrolothiazole-thiochroman hybrids and evaluation of their antimycobacterial, anticancer and AchE inhibitory activities. |
| AID373049 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate JN45 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID524915 | Antimicrobial activity against Mycobacterium abscessus 390S assessed as inhibition of resuspended biofilm formation in replete medium | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID664696 | Antimicrobial activity against Staphylococcus aureus ATCC 29213 | 2011 | ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12 | Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue. |
| AID1732054 | Antibacterial activity against Staphylococcus aureus INA 00761 | 2021 | European journal of medicinal chemistry, Apr-05, Volume: 215 | Discovery of novel N |
| AID1055941 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 16 hrs | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain. |
| AID565418 | Antimicrobial activity against Salmonella enterica serotype Stanley isolate AM04864 expressing armA rRNA methyltransferase gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Identification of the aminoglycoside resistance determinants armA and rmtC among non-Typhi Salmonella isolates from humans in the United States. |
| AID583257 | Antibacterial activity against aminoglycoside-resistant Klebsiella oxytoca expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID278805 | Antimicrobial activity against Stenotrophomonas maltophilia K279a mutant | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. |
| AID533592 | Antibacterial activity against gentamicin-resistant Enterobacter cloacae clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1473740 | Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID533353 | Antibacterial activity against non-gentamicin-resistant Citrobacter freundii clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1868116 | Anti-tubercular activity against Mycobacterium tuberculosis CF61 assessed as inhibition of mycobacterial growth incubated for 7 days by resazurin-dye based analysis | 2022 | European journal of medicinal chemistry, Jul-05, Volume: 237 | Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation. |
| AID529837 | Bactericidal activity against Acinetobacter baumannii isolate 1198 at 16 ug/ml after 24 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. |
| AID30415 | Minimum inhibitory concentration (MIC) was measured against Acinetobacter lwoffi ATCC 17986. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID539135 | Antibacterial activity against Staphylococcus capitis 1269682 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID567580 | Antimicrobial activity against Acinetobacter baumannii assessed as resistant isolate by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. |
| AID498840 | Antimicrobial activity against Klebsiella pneumoniae GZ66T expressing SHV-11, DHA-1 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID558046 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S9 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID571693 | Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 2 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID285649 | Antimicrobial activity against Pseudomonas aeruginosa 19B6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID532390 | Antibacterial activity against VIM-1 producing Pseudomonas putida isolate RM-11X-11 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID373765 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh13 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID285637 | Antimicrobial activity against Pseudomonas aeruginosa 12B2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID583224 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID499052 | Antimicrobial activity against Escherichia coli PU60T expressing CMY-2 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID499071 | Antimicrobial activity against Klebsiella pneumoniae WH97 expressing SHV-33, aac(6')-Ib, ompK35 DE by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID1443980 | Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch | 2010 | Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2 | Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. |
| AID542771 | Antimicrobial activity against Escherichia coli J53 transformed with pHND3 carrying qnrB6 gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals. |
| AID1602928 | Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by resazurin microtiter assay | 2019 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8 | Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis. |
| AID285664 | Antimicrobial activity against Pseudomonas aeruginosa 22D9 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID540212 | Mean residence time in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID326541 | Antimicrobial activity against Mycobacterium abscessus R51 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID528816 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID535879 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN132 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID530329 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pGEM-T carrying aacA4 Ala108Thr mutant gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID285657 | Antimicrobial activity against Pseudomonas aeruginosa 19E2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1324729 | Antibacterial activity against methicillin-resistant Staphylococcus aureus C7 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID523487 | Antimicrobial activity against Pseudomonas aeruginosa M1251 by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID326548 | Antimicrobial activity against Mycobacterium abscessus R53 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID1310588 | Antibacterial activity against Micrococcus luteus ATCC 10240 by broth microdilution method | 2016 | European journal of medicinal chemistry, Aug-08, Volume: 118 | Simple avarone mimetics as selective agents against multidrug resistant cancer cells. |
| AID562760 | Antimicrobial activity against Klebsiella pneumoniae PFGE clone C expressing beta-lactamase KPC-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID499064 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae GX56 deficient in ompC and expressing low levels of ompF DE by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID283530 | Antibacterial activity against Pseudomonas aeruginosa FE10 with inactivated nuoG gene by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID529737 | Induction of apoptosis in pig LLC-PK1 cells at 6 mM after 3 days by DAPI staining | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Apoptosis induced by aminoglycosides in LLC-PK1 Cells: comparative study of neomycin, gentamicin, amikacin, and isepamicin using electroporation. |
| AID560599 | Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid expressing aac(6')-Iaf wild type gene by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID66097 | Minimum inhibitory concentration was measured against Enterobacter cloacae ATCC 23355 | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID583221 | Antibacterial activity against aminoglycoside-resistant Staphylococcus aureus expressing APH(2'') + AAC(6') by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID394702 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(6')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID285691 | Antimicrobial susceptibility of Citrobacter freundii CF6010 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID1324761 | Antibacterial activity against Staphylococcus epidermidis ATCC 12228 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID481455 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by macrobroth dilution method | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. |
| AID531757 | Antibacterial activity against Pseudomonas aeruginosa 1956 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID498826 | Antimicrobial activity against Citrobacter freundii SZ63 expressing IMP-4, qnrS1by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID375076 | Binding affinity to A-site RNA | 2009 | Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12 | Design and implementation of an ribonucleic acid (RNA) directed fragment library. |
| AID583214 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(3)-4a by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1310589 | Antibacterial activity against Micrococcus luteus ATCC 4698 by broth microdilution method | 2016 | European journal of medicinal chemistry, Aug-08, Volume: 118 | Simple avarone mimetics as selective agents against multidrug resistant cancer cells. |
| AID532219 | Antibacterial activity against macrolide-lincosamide-streptogramin B-negative, beta-lactamase-positive, methicillin-susceptible Staphylococcus aureus isolate 4 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate. |
| AID554395 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2716 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID545461 | Antimicrobial activity against Pasteurella sp. assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID1449162 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. massiliense isolate 120 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID542773 | Antimicrobial activity against Escherichia coli J53 transformed with pHNPA1 carrying qnrB6 gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals. |
| AID571684 | Antimicrobial activity against ESBL producing Escherichia coli isolated from patient bloodstream assessed as resistant isolate by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. |
| AID531772 | Antimicrobial activity against Pseudomonas aeruginosa pleural fluid isolate 4679 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID257552 | Antibacterial activity against Escherichia coli | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23 | Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents. |
| AID508729 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C8 GM1 harboring acquired beta-lactamase OXA-144 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID326535 | Antimicrobial activity against Mycobacterium fortuitum after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID531746 | Antibacterial activity against Pseudomonas aeruginosa FE60 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID285665 | Antimicrobial activity against Pseudomonas aeruginosa 22E1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID558048 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S11 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID535885 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN41 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID583269 | Antibacterial activity against aminoglycoside-resistant Acinetobacter baumannii expressing AAC(3')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID69666 | Minimum inhibitory concentration (MIC) was measured against Escherichia coli ATCC 25922. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID372848 | Antibacterial activity against armA knockout Acinetobacter baumannii 231 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID1324725 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 2 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID499048 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ83 deficient in SHV-11, CTX-M-14, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID572061 | Ratio of MIC for Acinetobacter baumannii AC0037 to MIC for abeS-deficient Acinetobacter baumannii AC0037 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii. |
| AID373045 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZS15 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID561931 | Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate VA-566/00 by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii. |
| AID285592 | Antimicrobial activity against Pseudomonas aeruginosa 65.38-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID535752 | Antimicrobial activity against hospital-acquired Klebsiella pneumoniae obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob |
| AID508479 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA66 producing metallo-beta-lactamase VIM4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID1449168 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. bolletii isolate 116 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID532404 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone F isolate RM-11X-09 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1713731 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth at 0.17 mM by microdilution alamar blue broth assay relative to control | 2016 | Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 | A facile stereoselective synthesis of dispiro-indeno pyrrolidine/pyrrolothiazole-thiochroman hybrids and evaluation of their antimycobacterial, anticancer and AchE inhibitory activities. |
| AID499063 | Antimicrobial activity against Escherichia coli HX74T expressing CTX-M-3 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID445289 | Antibacterial activity against Staphylococcus aureus by broth dilution method | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22 | Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis. |
| AID533604 | Antibacterial activity against gentamicin-resistant Staphylococcus epidermidis clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID565337 | Antibacterial activity against Enterobacter hormaechei isolate UCN63 after 3 weeks of treatment | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy. |
| AID278129 | Distribution of Escherichia coli AB1157 IL05 new born cells containing duplicated ori and ter foci at 8 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID348096 | Antibacterial activity against aminoglycosides-resistant Pseudomonas aeruginosa ATCC 27853 expressing APH(3')-2b after 12 to 18 hrs | 2008 | Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23 | Surprising alteration of antibacterial activity of 5"-modified neomycin against resistant bacteria. |
| AID528785 | Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli assessed as resistant isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. |
| AID529861 | Ratio of MIC for Pseudomonas aeruginosa N044 to MIC for Pseudomonas aeruginosa PAO1 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID1463960 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 234/2005 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID1322943 | Inhibition of recombinant Mycobacterium tuberculosis InhA expressed in Escherichia coli Rosetta (DE3) pLysS using 2-trans-decenoyl-N-acetylcyste-amine as substrate in presence of NADH by spectrophotometric method | 2016 | Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24 | In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA. |
| AID1524132 | Bactericidal activity against Salmonella typhimurium ATCC 14028 incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID1435654 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 8666/2010 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID425071 | Antimicrobial activity against Escherichia coli J53-AzR in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID533605 | Antibacterial activity against gentamicin-resistant Enterococcus faecalis clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID532903 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 ST 376 expressing beta-lactamase SHV-1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID1322255 | Antibacterial activity against APH3'-VIA expressing Acinetobacter lwoffii AI.88-483 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID584560 | Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID554435 | Ratio of MIC for Pseudomonas aeruginosa 2716 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID546618 | Antimicrobial activity against Pseudomonas aeruginosa isolate 243-31C expressing beta-lactamase VIM-18 isolated from sputum of patient by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID1449146 | Antibacterial activity against non CF patient derived Mycobacterium abscessus subsp. abscessus isolate CIP104536 rough variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID533759 | Antibacterial activity against OXA-10, PSE-1, VIM-2 and PER-1 producing Pseudomonas aeruginosa isolate P22 exhibiting PFGE F pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID326551 | Antimicrobial activity against Mycobacterium fortuitum V13 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID583238 | Antibacterial activity against indole positive Proteae by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID562809 | Antimicrobial activity against Escherichia coli J53 | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID1629135 | Selectivity ratio, ratio of IC50 for cytosolic eukaryotic translation in rabbit reticulocyte S30 extract to IC50 for 16S rRNA A-site in Escherichia coli S30 extract | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID560089 | Bactericidal activity against Enterobacter cloacae isolate 4073 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID1629130 | Antimicrobial activity against aminoglycoside-resistant Burkholderia cepacia ATCC 25416 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID519408 | Antibacterial activity against 16S rRNA methylase RmtB and CTX-M-65 ESBL producing Escherichia coli DH10B by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States. |
| AID1324754 | Antibacterial activity against Mycobacterium smegmatis MC2-155 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID1331874 | Antibacterial activity against Enterobacter cloacae ATCC 13047 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID1501982 | Antibacterial activity against ESBL-producing Escherichia coli ATCC 35218 after 16 hrs by broth microdilution method | 2017 | Journal of natural products, 09-22, Volume: 80, Issue:9 | Bioassay-Guided Isolation of Antibacterial Metabolites from Emericella sp. TJ29. |
| AID1271799 | Antibacterial activity against Staphylococcus aureus 358 after 24 hrs by broth microdilution method | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Synthesis, antibacterial and cytotoxic activities of new biflorin-based hydrazones and oximes. |
| AID533600 | Antibacterial activity against gentamicin-resistant Acinetobacter calcoaceticus clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID285641 | Antimicrobial activity against Pseudomonas aeruginosa 13E1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID539230 | Antibacterial activity against Staphylococcus warneri 1269686 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID1254007 | Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hrs by microbroth double dilution method | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Synthesis and biological activity of amino acid derivatives of avarone and its model compound. |
| AID498807 | Antimicrobial activity against Klebsiella pneumoniae ZJ71T expressing KPC-2 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID528820 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID1524034 | Antimicrobial activity against Escherichia coli 078 after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID498820 | Antimicrobial activity against Klebsiella pneumoniae WH76 expressing IMP-4, TEM-1, SHV-14, CTX-M-3, qnrS1 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID285660 | Antimicrobial activity against Pseudomonas aeruginosa 19F1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID285579 | Antimicrobial activity against Pseudomonas aeruginosa IA5 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID534305 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA507 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID532907 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 ST 376 expressing beta-lactamase SHV-1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID571922 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 25 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1524129 | Bactericidal activity against Pseudomonas aeruginosa 26305 clinical isolates incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID523489 | Antimicrobial activity against Pseudomonas aeruginosa R20 Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID498837 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU8 deficient in SHV-11, DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID404898 | Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB33 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus. |
| AID584557 | Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID529741 | Drug uptake in human at 15 mg/kg | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Apoptosis induced by aminoglycosides in LLC-PK1 Cells: comparative study of neomycin, gentamicin, amikacin, and isepamicin using electroporation. |
| AID1449166 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. bolletii isolate 97 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID498805 | Antimicrobial activity against Klebsiella pneumoniae ZJ70T expressing KPC-2 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID519181 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrZ mutant and MexZ mutant gene selected after 1 ug/ml of Norfloxacin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID571894 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 11 expressing ompA, adeB, adeM, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID508728 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C1 VAL6 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID1322376 | Antibacterial activity against clinical isolates of Pseudomonas aeruginosa at 0.05 mg after overnight incubation by agar well diffusion method | 2016 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21 | 1H-1,2,3-Triazolyl-substituted 1,3,4-oxadiazole derivatives containing structural features of ibuprofen/naproxen: Their synthesis and antibacterial evaluation. |
| AID373770 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh26 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID1296388 | Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis Praha 131 after 14 days by microdilution method | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. |
| AID531765 | Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4667 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID571924 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 26 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1322248 | Antibacterial activity against NorA expressing Staphylococcus aureus 1 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID279816 | Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. |
| AID570788 | Antimicrobial activity against multidrug-resistant Acinetobacter baumannii expressing aph(3')-Vla gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. |
| AID523492 | Antimicrobial activity against Pseudomonas aeruginosa 2779-con by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1310587 | Antibacterial activity against Bacillus subtilis ATCC 6633 by broth microdilution method | 2016 | European journal of medicinal chemistry, Aug-08, Volume: 118 | Simple avarone mimetics as selective agents against multidrug resistant cancer cells. |
| AID1543201 | Antimicrobial activity against Klebsiella pneumoniae ATCC 700603 assessed as inhibition of microbial growth incubated for 16 hrs by broth microdilution method | |||
| AID1435650 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 131 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID1271376 | Antimicrobial activity against Gram-positive Bacillus anthracis str. Sterne after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID1232126 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of bacterial growth incubated at 35 degC for 12 to 18 hrs | 2014 | MedChemComm, Aug-01, Volume: 5, Issue:8 | Antifungal Amphiphilic Aminoglycosides. |
| AID422882 | Antimicrobial activity against Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis by broth microdilution assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex. |
| AID285678 | Antimicrobial activity against Pseudomonas aeruginosa 29G6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID554439 | Ratio of MIC for Pseudomonas aeruginosa 2858 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID532913 | Antimicrobial activity against Escherichia coli Genehogs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID1449141 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. abscessus isolate 2524 rough variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID1324734 | Antibacterial activity against methicillin-resistant Staphylococcus aureus G6 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID572126 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 30 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID554384 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID529548 | Drug uptake in human neonate CSF after 25 hrs by HPLC | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates. |
| AID528981 | Antimicrobial activity against Haemophilus influenzae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID428869 | Antibacterial activity against Escherichia coli isolate ARS3 carrying pARS3 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. |
| AID1524126 | Bactericidal activity against Pseudomonas aeruginosa ATCC 27853 incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID594776 | Antimicrobial activity against Listeria monocytogenes at 100 ug/disc after 24 hrs by disc diffusion method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID562810 | Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID583231 | Antibacterial activity against Pseudomonas aeruginosa expressing AAC(3)-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID571920 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 24 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1331894 | Antibacterial activity against methicillin-resistant Staphylococcus aureus at 0.5 times MIC after 12 serial passages | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID558047 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S10 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID545655 | Antimicrobial activity against Stenotrophomonas maltophilia assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID554398 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2804 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID523004 | Antibacterial activity against uropathogenic Escherichia coli UTI89 assessed as degradation of preexisting biofilm after 24 hrs by microscopy | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. |
| AID373027 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA6 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID533761 | Antibacterial activity against OXA-28 producing Pseudomonas aeruginosa isolate P174 exhibiting PFGE E pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID374111 | Antimicrobial activity against azide-resistant aac(6')-Ib-cr deficient Escherichia coli J53 qnrA1 bearing pHS5 transconjugant from Enterobacter cloacae 641 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1. |
| AID294720 | Antibacterial activity against Pseudomonas aeruginosa at 30 ug/ml by agar plate diffusion technique | 2007 | European journal of medicinal chemistry, Jun, Volume: 42, Issue:6 | Studies on synthesis and pharmacological activities of 3,6-disubstituted-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and their dihydro analogues. |
| AID285676 | Antimicrobial activity against Pseudomonas aeruginosa 24G1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID583256 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID530345 | Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID373036 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ52 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID1324720 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 6538 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID1449154 | Antibacterial activity against Addison's disease patient derived Mycobacterium abscessus subsp. massiliense isolate CIP108297 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID529856 | Antibacterial activity against Pseudomonas aeruginosa N091 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID285610 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID523072 | Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a R92H/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID565300 | Antitubercular activity against Mycobacterium avium infected in C57BL/6J mouse assessed as reduction of CFU counts in spleen at 25 mg/kg, po administered one month post-infection five times weekly for 2 months (Rvb = 9.4 +/- 0.2 log10CFU) | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | ATP synthase inhibition of Mycobacterium avium is not bactericidal. |
| AID572128 | Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 31 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID394700 | Antibacterial activity against MexXY-OprM pump-independent aminoglycoside-resistant Pseudomonas aeruginosa isolate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID523515 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1253 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID534166 | Antimicrobial activity against rmtB positive Escherichia coli VOG producing beta lactamase CTX-M-14 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID523401 | Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152-M2 expressing wild type rrnB gene and plasmid encoded rrnA A1408G and rrnC A1408G mutant genes after 3 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID584554 | Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1653586 | Anti-leprotic activity against Mycobacterium leprae infected in BALB/c weanling mouse assessed as bacteria killing at 100 mg/kg, ip administrated for 60 days and measured after 1 year by Spearman-Karber technique analysis relative to control | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13 | Insights of synthetic analogues of anti-leprosy agents. |
| AID523001 | Cytotoxicity against human 5637 cells assessed as mild induction of cell death by trypan blue exclusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. |
| AID571902 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 15 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID584556 | Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1324744 | Antibacterial activity against methicillin-resistant Staphylococcus aureus USA100 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID326539 | Antimicrobial activity against Mycobacterium abscessus NTU445 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID564018 | Antibacterial activity against Pseudomonas aeruginosa isolated from wound infection of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID531773 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4688 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID1435649 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 4 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID285635 | Antimicrobial activity against Pseudomonas aeruginosa 12A3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID278987 | Antimycobacterial activity in Mycobacterium ulcerans Cu001 infected BALB/c mouse assessed as mean number of CFU per foot-pad at 150 mg, sc after 2 weeks | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin. |
| AID373048 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FZ84 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID446126 | Antibacterial activity against AAC6'-2a expressing Pseudomonas aeruginosa F03 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID510962 | Antimicrobial activity against Escherichia coli assessed as nonsusceptible isolates by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada. |
| AID545428 | Antimicrobial activity against Enterobacter cloacae obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID1426252 | Antibacterial activity against Escherichia coli ATCC 25922 | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Synthesis and bioactivity investigation of quinone-based dimeric cationic triazolium amphiphiles selective against resistant fungal and bacterial pathogens. |
| AID625836 | Antibacterial activity against Escherichia coli by micro-broth dilution method | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Micelles catalyzed chemoselective synthesis 'in water' and biological evaluation of oxygen containing hetero-1,4-naphthoquinones as potential antifungal agents. |
| AID499049 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU104 deficient in TEM-1, SHV-11, CTX-M-15, qnrS1, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID1629132 | Antimicrobial activity against aminoglycoside-resistant Klebsiella pneumoniae ATCC BAA-2470 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID533859 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium smegmatis after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID285582 | Antimicrobial activity against Pseudomonas aeruginosa 65.33-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1684105 | Antibacterial activity against Staphylococcus aureus CP011526.1 assessed as reduction in cell viability after 24 hrs by microdilution method | 2020 | Journal of natural products, 12-24, Volume: 83, Issue:12 | Penipyranicins A-C: Antibacterial Methylpyran Polyketides from a Hydrothermal Spring Sediment |
| AID498838 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae SZ61 deficient in TEM-1, SHV-1a, CMY-2, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID1524043 | Antimicrobial activity against Salmonella typhimurium ATCC 14028 after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID562950 | Antimicrobial activity against Klebsiella oxytoca expressing beta-lactamase KPC-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID348095 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 after 12 to 18 hrs | 2008 | Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23 | Surprising alteration of antibacterial activity of 5"-modified neomycin against resistant bacteria. |
| AID373030 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU78 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID532895 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID1524047 | Antimicrobial activity against Klebsiella pneumoniae after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID283545 | Antibacterial activity against Pseudomonas aeruginosa FE57GUZ with inactivated rplY, nuoG, galU and mexZ genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID404903 | Antibacterial activity against Streptococcus bovis ATCC 33317 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus. |
| AID528821 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient wound assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID285638 | Antimicrobial activity against Pseudomonas aeruginosa 13D3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID69665 | Minimum inhibitory concentration (MIC) was measured against Escherichia coli. | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23 | Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. |
| AID561934 | Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate RUH134 harboring plasmid ABVA01 by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii. |
| AID341594 | Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 469 transformants producing KPC2, OXA4 and CTX-M-10 carbapenemases | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID509867 | Antibacterial activity against Acinetobacter baumannii isolate 2824 isolated from human urine | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID534302 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA479 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID774217 | Antibacterial activity against Pseudomonas aeruginosa PA22 (PT629) expressing MexXY after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID1463957 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate Praha 4 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID498842 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae CY75 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID285577 | Antimicrobial activity against Pseudomonas aeruginosa 65.18-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1524032 | Antimicrobial activity against Escherichia coli ATCC 25922 after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID326536 | Antimicrobial activity against Mycobacterium abscessus CH10 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID529480 | Antimicrobial activity against Enterobacter cloacae isolate 1 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID1176932 | Antimicrobial activity against Escherichia coli CGMCC1.1571 after 24 hrs by modified microdilution method | 2015 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3 | Synthesis, in vitro antimicrobial and cytotoxic activities of new carbazole derivatives of ursolic acid. |
| AID533856 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium mucogenicum after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID572130 | Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 32 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID285162 | Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. |
| AID283400 | Antimicrobial activity against Nocardia sp. after 72 hrs by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. |
| AID529484 | Antimicrobial activity against Enterobacter cloacae isolate 185 containing PFGE genetic clone A expressing qnrB2 aac(6')-Ib-cr and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID285612 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID551749 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 12 to 18 hrs by twofold dilution method | 2011 | Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1 | Synthesis and antibacterial activity study of a novel class of cationic anthraquinone analogs. |
| AID285654 | Antimicrobial activity against Pseudomonas aeruginosa 19D9 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID498818 | Antimicrobial activity against Klebsiella pneumoniae GZ64 expressing IMP-4, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID152320 | Minimum inhibitory concentration was measured against Providencia stuartii 00000164 producing AAC-(2'') modifying enzyme | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID557795 | Antimicrobial activity against Proteus mirabilis 06-489 isolated from infected human urinary tract by CLSI agar dilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis. |
| AID257553 | Antibacterial activity against Pseudomonas aeruginosa | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23 | Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents. |
| AID498822 | Antimicrobial activity against Klebsiella pneumoniae WH77 expressing IMP-4, TEM-1, SHV-14, CTX-M-3, qnrS1 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID285627 | Antimicrobial activity against Pseudomonas aeruginosa 9A7 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID278811 | Ratio of km to kcat for PH(3')-2b activity | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa. |
| AID532405 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone G isolate NA-14X-13 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID212742 | Inhibition of purified telomerase of Euplotes aediculatus at 50 uM | 2004 | Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13 | Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase. |
| AID481451 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 24 hrs by macrobroth dilution method | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. |
| AID1422370 | Antibacterial activity against Pseudomonas aeruginosa PA406 harboring triABC deletion mutant by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID570785 | Antimicrobial activity against multidrug-resistant Acinetobacter baumannii expressing armA gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. |
| AID571892 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 10 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID539134 | Antibacterial activity against oxymycin-sensitive Staphylococcus aureus 1269670 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID569268 | Antimicrobial activity against drug-sensitive Escherichia coli JM109 | 2011 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 | Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives. |
| AID1546877 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 assessed as reduction in microbial growth after 16 hrs by broth microdilution method | 2020 | Journal of natural products, 01-24, Volume: 83, Issue:1 | Reisolation and Configurational Reinvestigation of Cottoquinazolines E-G from an Arthropod-Derived Strain of the Fungus |
| AID94287 | Minimum inhibitory concentration was measured against Klebsiella pneumoniae 75012101 producing AAD-(2'')-modifying enzyme; Value expressed as 0.5/1 | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID283220 | Antimicrobial activity against Pseudomonas aeruginosa PA0905 | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. |
| AID1324732 | Antibacterial activity against methicillin-resistant Staphylococcus aureus C19 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID531748 | Antibacterial activity against Pseudomonas aeruginosa EryR harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID285573 | Antimicrobial activity against Pseudomonas aeruginosa P21.21 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID533758 | Antibacterial activity against PER-1 producing Pseudomonas aeruginosa isolate P170 exhibiting PFGE G pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID405089 | Antibacterial activity against blaVIM2-harboring integrons containing Pseudomonas aeruginosa 42 isolate from ventilator-associated pneumonia patient | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | blaVIM-2-harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3' conserved sequence. |
| AID499067 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ89 deficient in CTX-M-14, ompC/F by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID509866 | Antibacterial activity against Acinetobacter baumannii isolate 510 isolated from human sputum | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID285646 | Antimicrobial activity against Pseudomonas aeruginosa 16D5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID285600 | Antimicrobial activity against Pseudomonas aeruginosa 2C2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1463962 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 8666/2010 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID529848 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID542772 | Antimicrobial activity against Escherichia coli J53 transformed with pHNDU1 carrying qnrB6 gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals. |
| AID562474 | Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase SHV-12 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. |
| AID532163 | Antimicrobial activity against aac(6')-Ib-cr-negative Escherichia coli PU12T harboring wild-type GyrA, GyrB, ParC and qnrS genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID519314 | Antimicrobial activity against mexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID549333 | Antimicrobial activity against Escherichia coli isolate 36 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID1322252 | Antibacterial activity against MexXY expressing Pseudomonas aeruginosa PA22 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID532196 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae WH42 harboring wild-type GyrA, ParC, GyrB and qnrA genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID565074 | Antibacterial activity against CTX-M-14 ESBL producing Proteus mirabilis assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID1254006 | Antibacterial activity against Kocuria rhizophila ATCC 9341 after 24 hrs by microbroth double dilution method | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Synthesis and biological activity of amino acid derivatives of avarone and its model compound. |
| AID529495 | Antimicrobial activity against Enterobacter cloacae isolate 4469 containing PFGE genetic clone C expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID428872 | Antibacterial activity against Escherichia coli JM109 carrying pMCL-BE by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. |
| AID533351 | Antibacterial activity against non-gentamicin-resistant Serratia marcescens clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID446135 | Antibacterial activity against MexAB expressing Pseudomonas aeruginosa PA21 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID1858575 | Antibacterial activity against Mycobacterium abscessus CIP 104536T smooth morphotype incubated for 1 to 14 days | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209 | Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery. |
| AID1592957 | Antibacterial activity against multi-drug resistant Escherichia coli NMI 3548/14 assessed as reduction in microbial growth incubated for 20 hrs | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. |
| AID446139 | Antibacterial activity against R-methylase expressing Citrobacter amalonaticus 06AB0010 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID542585 | Antimicrobial activity against plasmid encoded beta-lactamase OXA-58 deficient Acinetobacter radioresistens by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program. |
| AID283392 | Antimicrobial activity against Nocardia otitidiscaviarum after 72 hrs by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. |
| AID567304 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2202 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID201257 | Minimum inhibitory concentration was measured against Staphylococcus aureus 76080401 producing AAD-(4')) modifying enzyme; Value expressed as 8/2 | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID523493 | Antimicrobial activity against Pseudomonas aeruginosa 1405-con D2 by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID498824 | Antimicrobial activity against Citrobacter freundii SZ62 expressing IMP-4, TEM-1, CMY-2, qnrS1, aac(6')-Ib-cr by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID486969 | Antibacterial activity against Escherichia coli after 24 hrs by micro broth dilution method | 2010 | European journal of medicinal chemistry, Jun, Volume: 45, Issue:6 | 'On water' assisted synthesis and biological evaluation of nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents. |
| AID533572 | Antibacterial activity against non-gentamicin-resistant Staphylococcus aureus clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1271377 | Antimicrobial activity against Gram-positive Bacillus cereus ATCC 17788 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID425072 | Antimicrobial activity against Escherichia coli DH10B expressing pCRQB10 in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID498817 | Antimicrobial activity against Klebsiella pneumoniae FZ49T expressing IMP-8, TEM-1, CTX-M-14, qnrB2, aac(6')-Ib by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID285690 | Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4036 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID524408 | Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. |
| AID583226 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID535753 | Antimicrobial activity against community-acquired Klebsiella pneumoniae expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob |
| AID529735 | Induction of apoptosis in pig LLC-PK1 cells at 6 mM after 1 day by DAPI staining | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Apoptosis induced by aminoglycosides in LLC-PK1 Cells: comparative study of neomycin, gentamicin, amikacin, and isepamicin using electroporation. |
| AID583230 | Antibacterial activity against Pseudomonas aeruginosa expressing ANT(4')-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID588208 | Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset | 2010 | Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5 | Predicting phospholipidosis using machine learning. |
| AID495517 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4675 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID574794 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 obtained from sputum of patient at 1 ug/ml by Bactec MGIT960 modified proportion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID1176930 | Antimicrobial activity against Bacillus subtilis CGMCC1.1162 after 24 hrs by modified microdilution method | 2015 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3 | Synthesis, in vitro antimicrobial and cytotoxic activities of new carbazole derivatives of ursolic acid. |
| AID533857 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium mageritense after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID523501 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1352c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID396032 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP3 plasmid containing Enterobacter aerogenes acrR gene by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID542044 | Antibacterial activity against Escherichia coli TrC B expressing Klebsiella pneumoniae B blaCTX-M beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID531776 | Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4680 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID545449 | Antimicrobial activity against extended-spectrum beta-lactamase-positive Klebsiella oxytoca assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID509869 | Antibacterial activity against Acinetobacter baumannii isolate 4860 isolated from human urine | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID1422364 | Antibacterial activity against Staphylococcus aureus ATCC 25923 by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID1546879 | Antibacterial activity against Klebsiella pneumoniae ATCC BAA2146 assessed as reduction in microbial growth after 16 hrs by broth microdilution method | 2020 | Journal of natural products, 01-24, Volume: 83, Issue:1 | Reisolation and Configurational Reinvestigation of Cottoquinazolines E-G from an Arthropod-Derived Strain of the Fungus |
| AID583270 | Antibacterial activity against aminoglycoside-resistant Acinetobacter baumannii expressing ANT(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID373669 | Antibacterial activity against Bacillus subtilis ATCC 6633 at 10 ug/disk after 24 hrs by agar diffusion method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis, characterization and antimicrobial activity of Co(II), Zn(II) and Cd(II) complexes with N-benzyloxycarbonyl-S-phenylalanine. |
| AID92477 | Maximal inhibition of the aminoglycoside on Staphylococcus aureus IF-2 binding to fMet-tRNA(fMet) | 2003 | Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6 | Inhibition of bacterial IF2 binding to fMet-tRNA((fMet)) by aminoglycosides. |
| AID583246 | Antibacterial activity against aminoglycoside-resistant Enterobacter cloacae expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID323040 | Antimicrobial activity against extended-spectrum-beta-lactamase producing Klebsiella pneumoniae assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. |
| AID1890837 | Antimycobacterial activity against Mycobacterium abscessus CIP104536T with rough morphotype assessed as inhibition of mycobacterial growth incubated for 3 to 5 days by resazurin microtiter assay | 2022 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 64 | Design, synthesis and antibacterial activity against pathogenic mycobacteria of conjugated hydroxamic acids, hydrazides and O-alkyl/O-acyl protected hydroxamic derivatives. |
| AID583265 | Antibacterial activity against aminoglycoside-resistant Staphylococcus aureus expressing ANT(4',4'')-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID528819 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID545464 | Antimicrobial activity against Pseudomonas fluorescens assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID523516 | Antimicrobial activity against Pseudomonas aeruginosa isolate 13120 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID574438 | Antimicrobial activity against Escherichia coli isolate 1679T expressing beta-lactamase KPC2, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID509860 | Antibacterial activity against Acinetobacter baumannii using MHB medium with 150 mM assessed as bacterial growth at 4.5 mg/L after 12 hrs in presence of 30 mg/L efflux pump inhibitor PAbetaN | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID664699 | Antimicrobial activity against Staphylococcus aureus harboring APH(2'''') and AAC(6') enzymes | 2011 | ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12 | Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue. |
| AID534301 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA460 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID94284 | Minimum inhibitory concentration was measured against Klebsiella pneumoniae 00GT3020 producing AAD-(2'')-modifying enzyme | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID534306 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA509 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID285623 | Antimicrobial activity against Pseudomonas aeruginosa 8C4 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1322253 | Antibacterial activity against triABC deficient Pseudomonas aeruginosa PA406 by microdilution method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID528834 | Antimicrobial activity against CTX-M ESBL producing Escherichia coli assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID534771 | Antimicrobial activity against Acinetobacter baumannii-calcoaceticus obtained from war-wounded patient assessed as susceptible isolates | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center. |
| AID558041 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S4 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID394708 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing AAC(6')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID523499 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1247c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID531775 | Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4659 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID583244 | Antibacterial activity against aminoglycoside-resistant Citrobacter freundii expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID542719 | Antimicrobial activity against ESBL-producing Klebsiella pneumoniae clinical isolate by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases. |
| AID498828 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae SZ92 deficient in IMP-4, TEM-1, CTX-M-14, DHA-1, qnrB10/B4-like, aac(6')-Ib, ompC by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID373025 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU73 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID373769 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh20 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID532389 | Antibacterial activity against VIM-1 producing Enterobacter cloacae isolate TO-16X-51 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID533356 | Antibacterial activity against non-gentamicin-resistant Pseudomonas aeruginosa clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1524035 | Antimicrobial activity against Escherichia coli K88 after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID283396 | Antimicrobial activity against Nocardia veterana after 72 hrs by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. |
| AID571695 | Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 4 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID285339 | Antimicrobial activity against streptomycin-resistant Escherichia coli J53 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America. |
| AID583210 | Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID554388 | Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY F29S mutant by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID533596 | Antibacterial activity against gentamicin-resistant Serratia marcescens clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID533001 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa isolate P67 exhibiting PFGE J pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID373759 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1316 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID523506 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1712c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID285634 | Antimicrobial activity against Pseudomonas aeruginosa 10B3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID373035 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ55 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID1503228 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus 209P after 24 hrs by liquid dilution method | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Structures and Antibacterial Properties of Isorugosins H-J, Oligomeric Ellagitannins from Liquidambar formosana with Characteristic Bridging Groups between Sugar Moieties. |
| AID283397 | Antimicrobial activity against Nocardia transvalensis after 72 hrs by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. |
| AID532409 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-38 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID558040 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S3 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID518817 | Antibacterial activity against Acinetobacter genomosp. 3 isolates assessed as percent of resistance isolates by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID520639 | Antimicrobial activity against Escherichia coli MRY05-3283 expressing qepA and rmtB gene by agar dilution CLSI method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan. |
| AID519182 | Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrW mutant and MexZ mutant gene selected after 0.25 ug/ml of ciprofloxacin exposure | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID618608 | Antimicrobial activity against Escherichia coli MTCC 4315 at 10 ug/ml | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis, pharmacological evaluation and docking studies of coumarin derivatives. |
| AID584561 | Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID1324757 | Antibacterial activity against Escherichia coli MC1061 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID603179 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus 22 at 20 ug/ml after 24 hrs by cup plate method | 2011 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13 | Practical synthesis, anticonvulsant, and antimicrobial activity of N-allyl and N-propargyl di(indolyl)indolin-2-ones. |
| AID1592960 | Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 3081/09 assessed as reduction in microbial growth incubated for 20 hrs | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. |
| AID530349 | Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID532906 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID1577329 | Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis Praha 4 after 14 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID529303 | Antimicrobial activity against Acinetobacter genospecies 3 isolate Ac057 expressing beta-lactamase Oxa-58 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. |
| AID594770 | Antimicrobial activity against Staphylococcus epidermidis at 100 ug/disc after 24 hrs by disc diffusion method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID495518 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4676 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID499045 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ68T deficient in CTX-M-15, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID341107 | Antibacterial activity against Escherichia coli transconjugant carrying pEC28 isolate eby Etest | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID583263 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing AAC(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID278127 | Distribution of Escherichia coli AB1157 IL05 new born cells containing duplicated sister ori foci at 32 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID373772 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh36 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID532905 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 ST 376 expressing beta-lactamase SHV-1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID498304 | Antibacterial activity against Pseudomonas aeruginosa PA5063 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID545455 | Antimicrobial activity against Pseudomonas aeruginosa assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID1463958 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate Praha 131 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID428273 | Antimicrobial activity against carbapenemase producing Enterobacter sp. assessed as susceptible isolates by CLSI breakpoint assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID533756 | Antibacterial activity against SHV-2a producing Pseudomonas aeruginosa isolate P102 exhibiting PFGE H pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID532193 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii TJ15T harboring wild-type GyrA, ParC, GyrB genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID285644 | Antimicrobial activity against Pseudomonas aeruginosa 15H5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID535756 | Antimicrobial activity against hospital-acquired Escherichia coli obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob |
| AID1819093 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv clinical isolates 1 assessed as reduction in bacterial growth incubated for 7 days by resazurin dye based assay | 2022 | ACS medicinal chemistry letters, Jan-13, Volume: 13, Issue:1 | Structural Rigidification of |
| AID586085 | Antimicrobial activity against verocytotoxin-producing Escherichia coli isolate O157 obtained from human assessed as percentage of resistant isolates by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26. |
| AID1231410 | Antibacterial activity against Bacillus cereus ATCC 14579 assessed as growth inhibition at 30 ug after 24 hrs by disc agar diffusion method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Synthesis and biological evaluation of caracasine acid derivatives. |
| AID583271 | Antibacterial activity against aminoglycoside-resistant Acinetobacter baumannii expressing APH(3')-6 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID533760 | Antibacterial activity against OXA-30, PSE-1, VIM-2 and PER-1 producing Pseudomonas aeruginosa isolate P19 exhibiting PFGE F pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID498804 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ70 deficient in KPC-2, SHV-11, CTX-M-14, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID322317 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID285338 | Antimicrobial activity against streptomycin-resistant Escherichia coli J53 transconjugant with qnrA1 producing urinary specimen isolate 13.52 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America. |
| AID510506 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-6 expressing KPC beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID644767 | Antibacterial activity against Escherichia coli ATCC 25922 after 20 hrs by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | New heterocyclic compounds from 1,2,4-triazole and 1,3,4-thiadiazole class bearing diphenylsulfone moieties. Synthesis, characterization and antimicrobial activity evaluation. |
| AID539133 | Antibacterial activity against oxymycin-sensitive Staphylococcus aureus 1269669 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID583222 | Antibacterial activity against aminoglycoside-resistant Acinetobacter spp. expressing APH(3')-6 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID201750 | Minimum inhibitory concentration was measured against Serratia marcescens S20. | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID558793 | Antimicrobial activity against extended spectrum beta-lactamase-expressing Escherichia coli assessed as percent susceptible isolates by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID574788 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 obtained from sputum of patient at 1 ug/ml by Bactec MGIT960 modified proportion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID562475 | Antimicrobial activity against rifampicin-resistant Escherichia coli A15 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. |
| AID1324747 | Antibacterial activity against methicillin-resistant Staphylococcus aureus USA600 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID529864 | Ratio of MIC for Pseudomonas aeruginosa COR6 to MIC for Pseudomonas aeruginosa PAO1 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID532418 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C3 isolate PG-12X-03 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID278810 | Antibacterial activity against Escherichia coli BL21(DE3) expressing Pseudomonas aeruginosa APH(3')-2b | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa. |
| AID594852 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus strain 4 TB5G at 100 ug/disc after 24 hrs by disc diffusion method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID562812 | Antimicrobial activity against Escherichia coli DH5[alpha] | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID644765 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 20 hrs by broth microdilution method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | New heterocyclic compounds from 1,2,4-triazole and 1,3,4-thiadiazole class bearing diphenylsulfone moieties. Synthesis, characterization and antimicrobial activity evaluation. |
| AID562949 | Antimicrobial activity against Klebsiella pneumoniae PFGE clone F expressing beta-lactamase KPC-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID583208 | Antibacterial activity against Klebsiella pneumoniae ATCC 10031 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID774215 | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID436367 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 14 days by serial dilution technique | 2009 | European journal of medicinal chemistry, Oct, Volume: 44, Issue:10 | Design, synthesis and antimycobacterial activity of some novel imidazo[1,2-c]pyrimidines. |
| AID572136 | Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 35 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID535660 | Antimicrobial activity against aac(6')-Ib-cr-positive Enterobacter cloacae FJ63 harboring GyrA S83I, GyrA D87A, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID285688 | Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA2404 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID499061 | Antimicrobial activity against carbapenem-resistant Escherichia coli PU43 deficient in TEM-1, CTX-M-14, aac(6')-Ib, ompC/F by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID523518 | Antimicrobial activity against Pseudomonas aeruginosa isolate 17112 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID250259 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH03; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID1172530 | Antimicrobial activity against Bacillus subtilis | 2014 | European journal of medicinal chemistry, Nov-24, Volume: 87 | Synthetic derivatives of aromatic abietane diterpenoids and their biological activities. |
| AID1473738 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID285655 | Antimicrobial activity against Pseudomonas aeruginosa 19D10 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID519188 | Antimicrobial activity against mexXY-OprM-overproducing Pseudomonas aeruginosa clinical isolate | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. |
| AID1331873 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID1449170 | Antibacterial activity against Mycobacterium abscessus subsp. bolletii isolate CIP108541 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID532588 | Antibacterial activity against metallo-beta-lactamase positive Pseudomonas aeruginosa assessed as percent susceptible isolates by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID583253 | Antibacterial activity against aminoglycoside-resistant Citrobacter freundii expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1449149 | Antibacterial activity against non CF patient derived Mycobacterium abscessus subsp. abscessus isolate 2587 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID532220 | Antibacterial activity against macrolide-lincosamide-streptogramin B-negative, beta-lactamase-positive, methicillin-susceptible Staphylococcus aureus isolate 5 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate. |
| AID1324743 | Antibacterial activity against methicillin-resistant Staphylococcus aureus S24 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID529550 | Cmax in human neonate serum after 25 hrs by fluorescence polarization immunoassay | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates. |
| AID508724 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E2 PpA1 harboring acquired beta-lactamase OXA-144 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID1324756 | Antibacterial activity against Enterobacter cloacae ATCC 13047 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID285631 | Antimicrobial activity against Pseudomonas aeruginosa 10A6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID498823 | Antimicrobial activity against Klebsiella pneumoniae WH77T expressing IMP-4, TEM-1, CTX-M-3, qnrS1 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID521834 | Antibacterial activity against Klebsiella pneumoniae isolate VA367 with blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, blaSHV-12, aac(6')-1b genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID1324721 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID1324723 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID508727 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1D5 SA1 harboring acquired beta-lactamase VIM-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID436368 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 21 days by serial dilution technique | 2009 | European journal of medicinal chemistry, Oct, Volume: 44, Issue:10 | Design, synthesis and antimycobacterial activity of some novel imidazo[1,2-c]pyrimidines. |
| AID594764 | Antimicrobial activity against Escherichia coli at 100 ug/disc after 24 hrs by disc diffusion method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID562811 | Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID278140 | Assembly of Z-ring in Escherichia coli AB1157 IL05 new born cells at 4 ug/ml | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID278135 | Distribution of Escherichia coli AB1157 IL05 new born cells containing four ori foci at 32 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID554391 | Antimicrobial activity against Pseudomonas aeruginosa isolate 615R obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID405820 | Antimicrobial activity against Acinetobacter baumannii 501 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID508490 | Antimicrobial activity against Pseudomonas aeruginosa isolate K45-32 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID372853 | Antimicrobial activity against azide-resistant Escherichia coli J53 transconjugant with 16S rRNA methylase armA gene expressing Acinetobacter baumannii isolate E | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID533594 | Antibacterial activity against gentamicin-resistant Citrobacter diversus clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID533591 | Antibacterial activity against gentamicin-resistant Klebsiella pneumoniae clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID594858 | Antimicrobial activity against Salmonella Typhimurium after 24 hrs by microdilution method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID1503230 | Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OM505 after 24 hrs by liquid dilution method | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Structures and Antibacterial Properties of Isorugosins H-J, Oligomeric Ellagitannins from Liquidambar formosana with Characteristic Bridging Groups between Sugar Moieties. |
| AID341593 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 469 isolate producing KPC2, OXA4 and CTX-M-10 carbapenemases | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID532902 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID508723 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E1 PpA1 harboring acquired beta-lactamase OXA-144 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID495511 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4665 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID522929 | Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase N196D/D268N mutant by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin. |
| AID583268 | Antibacterial activity against aminoglycoside-resistant Staphylococcus epidermidis expressing APH(2'') + AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID528833 | Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient blood assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID348092 | Ratio of MIC for Escherichia coli TG1 to MIC for Escherichia coli TG1 pET28a plasmid encoded for APH(3')-3a | 2008 | Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23 | Surprising alteration of antibacterial activity of 5"-modified neomycin against resistant bacteria. |
| AID535867 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ51 harboring qnrA gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID564691 | Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID373753 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab4 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID528829 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID285630 | Antimicrobial activity against Pseudomonas aeruginosa 9B5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1324751 | Antibacterial activity against Enterococcus faecium BM4105-RF measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID373033 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ3-23 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID495513 | Antibacterial activity against Acinetobacter baumannii BM4467 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID534304 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA494 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID1310593 | Antibacterial activity against Salmonella enterica subsp. enterica serovar Enteritidis ATCC 13076 by broth microdilution method | 2016 | European journal of medicinal chemistry, Aug-08, Volume: 118 | Simple avarone mimetics as selective agents against multidrug resistant cancer cells. |
| AID1629133 | Binding affinity to 16S rRNA A-site in Escherichia coli S30 extract assessed as inhibition of translation measured after 30 mins by coupled transcription/translation-based luciferase reporter gene assay | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID542106 | Antibacterial activity against Escherichia coli TrC C expressing Klebsiella pneumoniae C blaCTX-M beta-lactamase by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID1447085 | Antibacterial activity against Acinetobacter baumannii ATCC BAA 1710 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11 | Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo. |
| AID424862 | Antimicrobial activity against carbapenem-susceptible Pseudomonas aeruginosa clinical isolate assessed as resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID285625 | Antimicrobial activity against Pseudomonas aeruginosa 9A1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID498841 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae SX67 deficient in SHV-2, CTX-M-14, DHA-1, qnrB6/S1, aac(6')-Ib-cr, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID534167 | Antimicrobial activity against Escherichia coli TOP10 harboring plasmid VOG1 expressing RmtB, TEM-1, and QepA gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID1629125 | Antimicrobial activity against Haemophilus influenzae ATCC 10211 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID283399 | Antimicrobial activity against Nocardia brasiliensis after 72 hrs by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. |
| AID498835 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU4 deficient in SHV-1, DHA-1, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID508489 | Antimicrobial activity against Pseudomonas aeruginosa isolate K44-24 producing metallo-beta-lactamase IMP14 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID534168 | Antimicrobial activity against Escherichia coli TOP10 harboring plasmid VOG2 expressing CTX-M-14 and AAC(6 )-Ib gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID532401 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D3 isolate VA-06X-65 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1254005 | Antibacterial activity against Staphylococcus aureus ATCC 6538 after 24 hrs by microbroth double dilution method | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Synthesis and biological activity of amino acid derivatives of avarone and its model compound. |
| AID583219 | Antibacterial activity against aminoglycoside-resistant Staphylococcus aureus expressing ANT(4')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID373774 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh39 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID523514 | Antimicrobial activity against Pseudomonas aeruginosa isolate 12102 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID539124 | Antibacterial activity against vancomycin-, ciprofloxacin-, gentamicin-resistant Escherichia coli 1269621 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID1868119 | Anti-tubercular activity against Mycobacterium tuberculosis CF161 assessed as inhibition of mycobacterial growth incubated for 7 days by resazurin-dye based analysis | 2022 | European journal of medicinal chemistry, Jul-05, Volume: 237 | Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation. |
| AID481456 | Antibacterial activity against Pseudomonas aeruginosa CAN-ICU 62308 after 24 hrs by macrobroth dilution method | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. |
| AID1296387 | Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis Praha 4 after 14 days by microdilution method | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. |
| AID533765 | Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P9 exhibiting PFGE A pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID574581 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 obtained from sputum of patient at 1 ug/ml by Bactec MGIT960 modified proportion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID534296 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA477 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID434367 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by broth microdilution method | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Design, synthesis and biological evaluation of novel nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents. |
| AID532221 | Antibacterial activity against macrolide-lincosamide-streptogramin B-positive, beta-lactamase-positive, methicillin-resistant Staphylococcus aureus isolate 6 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate. |
| AID583251 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing AAC(3)-4 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID571698 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 6 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID558786 | Antimicrobial activity against Citrobacter freundii assessed as percent susceptible isolates by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID528828 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID528822 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolated from ICU patient urine assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID561933 | Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate RUH134 by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii. |
| AID285591 | Antimicrobial activity against Pseudomonas aeruginosa 65.38-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID285619 | Antimicrobial activity against Pseudomonas aeruginosa 5G3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID594859 | Antimicrobial activity against Staphylococcus aureus after 24 hrs by microdilution method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID571898 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 13 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID532894 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID341108 | Antibacterial activity against Escherichia coli 26R793 by Etest | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12. |
| AID533602 | Antibacterial activity against gentamicin-resistant Pseudomonas spp. clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID1524130 | Bactericidal activity against Pseudomonas aeruginosa CICC 21625 clinical isolates incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID372847 | Antibacterial activity against Escherichia coli DH10B expressing Acinetobacter baumannii isolate B 16S rRNA methylase armA gene | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID498825 | Antimicrobial activity against Citrobacter freundii SZ62T expressing IMP-4, qnrS1by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID569265 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus MF490 | 2011 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 | Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives. |
| AID394707 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(6')-1, AAC(3')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID498831 | Antimicrobial activity against Escherichia coli C600 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID285616 | Antimicrobial activity against Pseudomonas aeruginosa 3E2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID554389 | Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY F1018L mutant by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID584565 | Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. |
| AID529849 | Antibacterial activity against beta-lactamase-overproducing Pseudomonas aeruginosa N043 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID529494 | Antimicrobial activity against Enterobacter cloacae isolate 837 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID285617 | Antimicrobial activity against Pseudomonas aeruginosa 5F2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID523398 | Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 5 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID534171 | Antimicrobial activity against beta lactamase CTX-M-14 producing Escherichia coli TOP10 harboring plasmid COP2 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID558038 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S1 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID532395 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate NA-14X-34 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1422366 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID532190 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii TJ15 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB, qnrB genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID571886 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 7 expressing ampC, ompA, adeB, adeM, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1322260 | Cytotoxicity against mouse J774 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues. |
| AID594767 | Antimicrobial activity against Bacillus subtilis at 100 ug/disc after 24 hrs by disc diffusion method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID498803 | Antimicrobial activity against Klebsiella pneumoniae ZJ18T expressing KPC-2, DHA-1 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID285670 | Antimicrobial activity against Pseudomonas aeruginosa 24E1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID532178 | Antimicrobial activity against aac(6')-Ib-cr-negative Klebsiella pneumoniae SY22 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID499054 | Antimicrobial activity against carbapenem-resistant Escherichia coli PU101 deficient in TEM-1, CTX-M-14, CMY-2, ompC by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID285607 | Antimicrobial activity against Pseudomonas aeruginosa 2A9 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID278804 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha expressing pBAD [aph(3')-2] in the presence of arabinose | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. |
| AID1071102 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by broth microdilution assay | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III. |
| AID530322 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SL2 harboring blaVIM-13 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID523406 | Antimicrobial activity against amikacin-susceptible Nocardia farcinica isolate IFM 10152-M2 assessed as cell growth at 1024 ug/ml at <12 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID326553 | Antimicrobial activity against Mycobacterium fortuitum V146 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID510963 | Antimicrobial activity against ESBL producing Escherichia coli assessed as nonsusceptible isolates by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada. |
| AID285673 | Antimicrobial activity against Pseudomonas aeruginosa 24E6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID523403 | Antimicrobial activity against amikacin-susceptible Nocardia farcinica isolate IFM 10152-M3 assessed as cell growth at 1024 ug/ml at <12 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID535894 | Antimicrobial activity against aac(6')-Ib-cr-negative Citrobacter freundii JN64T harboring qnrA gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID533573 | Antibacterial activity against non-gentamicin-resistant Staphylococcus epidermidis clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID278128 | Distribution of Escherichia coli AB1157 IL05 new born cells containing duplicated ori and ter foci at 4 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID532406 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B1 isolate SS-09X-45 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID498821 | Antimicrobial activity against Klebsiella pneumoniae WH76T expressing IMP-4, TEM-1, CTX-M-3, qnrS1 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID285663 | Antimicrobial activity against Pseudomonas aeruginosa 22D6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID532205 | Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae WH99T harboring qnrB gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID498843 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae XJ81 deficient in TEM-1, SHV-12, DHA-1, aac(6')-Ib, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID326546 | Antimicrobial activity against Mycobacterium abscessus R61 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID554437 | Ratio of MIC for Pseudomonas aeruginosa 2729 to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID326538 | Antimicrobial activity against Mycobacterium abscessus R39 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID551746 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 12 to 18 hrs by twofold dilution method | 2011 | Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1 | Synthesis and antibacterial activity study of a novel class of cationic anthraquinone analogs. |
| AID285653 | Antimicrobial activity against Pseudomonas aeruginosa 19C12 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID594860 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus strain 1 TB3G after 24 hrs by microdilution method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID373041 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ36 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID551751 | Antibacterial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 after 12 to 18 hrs by twofold dilution method | 2011 | Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1 | Synthesis and antibacterial activity study of a novel class of cationic anthraquinone analogs. |
| AID558044 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S7 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID1524046 | Antimicrobial activity against Acinetobacter baumannii after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID1254014 | Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 after 24 hrs by microbroth double dilution method | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Synthesis and biological activity of amino acid derivatives of avarone and its model compound. |
| AID531769 | Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4698 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID498832 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae CY1 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID529497 | Antimicrobial activity against Escherichia coli T-625 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID64905 | Minimum inhibitory concentration was measured against Escherichia coli 71120101 producing AAD-(4')) modifying enzyme | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID257550 | Antibacterial activity against Streptococcus faecalis | 2005 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23 | Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents. |
| AID285659 | Antimicrobial activity against Pseudomonas aeruginosa 19E9 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID565281 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A2 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID535861 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ47 harboring qnrB and qnrS genes by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID560094 | Bactericidal activity against Escherichia coli isolate 5411 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID285674 | Antimicrobial activity against Pseudomonas aeruginosa 23C5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1447453 | Antibacterial activity against amikacin-resistant Escherichia coli isolate CAN-ICU 63074 after 18 hrs by microtiter dilution assay | 2017 | Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9 | Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. |
| AID539227 | Antibacterial activity against oxymycin-, gentamicin-, levofloxacin-resistant Staphylococcus epidermidis 1269676 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID531747 | Antibacterial activity against Pseudomonas aeruginosa EryR by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID283529 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID542720 | Antimicrobial activity against ESBL-producing Klebsiella pneumoniae clinical isolate assessed as susceptible isolates | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases. |
| AID532911 | Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 ST 327 expressing beta-lactamase TEM-1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID528825 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID1331897 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 0.5 times MIC after 5 serial passages | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID574425 | Antimicrobial activity against Escherichia coli isolate 339 expressing beta-lactamase KPC2, TEM and PFGE cluster 5 isolated from peritoneal fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID1422375 | Antibacterial activity against Escherichia coli L8058.1 harboring ANT2'-1A by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID394714 | Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as susceptible rate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID664697 | Antimicrobial activity against Staphylococcus aureus harboring APH(3'/5'''')-3 enzyme | 2011 | ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12 | Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue. |
| AID532408 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-28 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID285621 | Antimicrobial activity against Pseudomonas aeruginosa 8A2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1422365 | Antibacterial activity against Staphylococcus aureus SA-1 expressing NorA pump by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID523399 | Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152-M2 expressing rrnA A1408G and rrnC A1408G mutant genes after 3 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic. |
| AID445287 | Antibacterial activity against Mycobacterium avium SmO by broth dilution method | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22 | Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis. |
| AID481449 | Antibacterial activity against Staphylococcus epidermidis ATCC 1490 after 24 hrs by macrobroth dilution method | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. |
| AID583258 | Antibacterial activity against aminoglycoside-resistant Klebsiella pneumoniae expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID521838 | Antibacterial activity against Klebsiella pneumoniae isolate VA375 with blaKPC-3, qnrA1, blaTEM-1, blaSHV-11 genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID571694 | Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 3 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID446131 | Antibacterial activity against ANT2'-2a expressing Escherichia coli L58058.1 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID520698 | Antimicrobial activity against Escherichia coli isolate DH10B by agar dilution CLSI method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan. |
| AID1449142 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. abscessus isolate 2648 rough variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID250295 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH20; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID529825 | Antimicrobial activity against Acinetobacter baumannii isolate 1198 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. |
| AID481450 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis ATCC 14990 after 24 hrs by macrobroth dilution method | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. |
| AID285588 | Antimicrobial activity against Pseudomonas aeruginosa 65.36-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID539122 | Antibacterial activity against vancomycin-, ciprofloxacin-, gentamicin-sensitive Escherichia coli 1269640 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID583243 | Antibacterial activity against aminoglycoside-resistant Klebsiella pneumoniae expressing AAC(3)-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID373752 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab3 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID1473739 | Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID285604 | Antimicrobial activity against Pseudomonas aeruginosa 2A6 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID92475 | Inhibitory activity of the aminoglycoside on Staphylococcus aureus IF-2 binding to fMet-tRNA(fMet) | 2003 | Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6 | Inhibition of bacterial IF2 binding to fMet-tRNA((fMet)) by aminoglycosides. |
| AID584328 | Antibacterial activity against gshB deficient Escherichia coli JW2914-1 | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics. |
| AID565073 | Antibacterial activity against CTX-M-14 ESBL producing Morganella morganii assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID1322380 | Antibacterial activity against clinical isolates of Klebsiella pneumoniae at 0.05 mg after overnight incubation by agar well diffusion method | 2016 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21 | 1H-1,2,3-Triazolyl-substituted 1,3,4-oxadiazole derivatives containing structural features of ibuprofen/naproxen: Their synthesis and antibacterial evaluation. |
| AID372846 | Antibacterial activity against Acinetobacter baumannii isolate E expressing 16S rRNA methylase armA gene | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID1271380 | Antimicrobial activity against Gram-positive Staphylococcus aureus ATCC 29213 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID285662 | Antimicrobial activity against Pseudomonas aeruginosa 22D2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1296385 | Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis 8666/2010 after 14 days by microdilution method | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. |
| AID1447091 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11 | Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo. |
| AID571904 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 16 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1271379 | Antimicrobial activity against Gram-positive Listeria monocytogenes ATCC 19115 after 16 to 24 hrs by micro-dilution method | 2015 | ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11 | Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides. |
| AID373038 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate NJ59 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID1254013 | Antibacterial activity against Salmonella enterica ATCC 13076 after 24 hrs by microbroth double dilution method | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21 | Synthesis and biological activity of amino acid derivatives of avarone and its model compound. |
| AID529304 | Antimicrobial activity against Acinetobacter baumannii isolate Ac058 expressing beta-lactamase Oxa-58 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. |
| AID1449163 | Antibacterial activity against non CF patient derived Mycobacterium abscessus subsp. bolletii isolate 19 rough variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID774220 | Antibacterial activity against Acinetobacter lwoffii AI.88-483 expressing APH3'-6A after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID529830 | Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolates by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. |
| AID534297 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA481 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID625924 | Antibacterial activity against Klebsiella pneumoniae ATCC 27736 by micro-broth dilution method | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Micelles catalyzed chemoselective synthesis 'in water' and biological evaluation of oxygen containing hetero-1,4-naphthoquinones as potential antifungal agents. |
| AID583260 | Antibacterial activity against aminoglycoside-resistant Enterobacter gergoviae expressing AAC(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1629122 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 47085 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID1743439 | Antitubercular activity against Mycobacterium tuberculosis H37Rv measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID533858 | Antibacterial activity against nonpigmented rapidly growing Mycobacterium alvei after 3 days by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. |
| AID1447087 | Antibacterial activity against Acinetobacter baumannii ATCC BAA 1800 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11 | Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo. |
| AID551748 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 after 12 to 18 hrs by twofold dilution method | 2011 | Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1 | Synthesis and antibacterial activity study of a novel class of cationic anthraquinone analogs. |
| AID535663 | Antimicrobial activity against aac(6')-Ib-cr-positive Enterobacter cloacae FJ63T harboring qnrS gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID323042 | Antimicrobial activity against extended-spectrum-beta-lactamase producing Proteus mirabilis assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. |
| AID278121 | Distribution of Escherichia coli AB1157 IL05 new born cells containing one ori and one ter foci at 8 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID531756 | Antibacterial activity against Pseudomonas aeruginosa 2126 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID373771 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh29 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID528824 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID445285 | Antibacterial activity against Mycobacterium bovis BCG str. Tokyo 172 by broth dilution method | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22 | Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis. |
| AID436369 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 30 days by serial dilution technique | 2009 | European journal of medicinal chemistry, Oct, Volume: 44, Issue:10 | Design, synthesis and antimycobacterial activity of some novel imidazo[1,2-c]pyrimidines. |
| AID534419 | Antibacterial activity against Mycobacterium bovis BCG-Connaught | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. |
| AID396029 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID565068 | Antibacterial activity against CTX-M-15 and SHV-12 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID394703 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing ANT(2'')-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID1324731 | Antibacterial activity against methicillin-resistant Staphylococcus aureus C16 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID1422378 | Cytotoxicity against mouse J774 cells assessed as cell viability at 30 uM after 24 hrs by MTT assay relative to control | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID1071111 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 0.16 to 0.31 ug/ml after 7 days by microplate Alamar blue assay relative to control | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III. |
| AID372842 | Antibacterial activity against Acinetobacter baumannii isolate A expressing 16S rRNA methylase armA gene | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID92476 | Maximal inhibition against the displacement of Picogreen from fMet-tRNA(fMet) by the aminoglycoside | 2003 | Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6 | Inhibition of bacterial IF2 binding to fMet-tRNA((fMet)) by aminoglycosides. |
| AID285672 | Antimicrobial activity against Pseudomonas aeruginosa 24E5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID285647 | Antimicrobial activity against Pseudomonas aeruginosa 19B1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID532417 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-12 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1743448 | Antibacterial activity against Staphylococcus aureus measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID532899 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 ST 340 expressing beta-lactamase TEM-1 and SHV-11 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID285668 | Antimicrobial activity against Pseudomonas aeruginosa 24D1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1819099 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv clinical isolates 2 assessed as reduction in bacterial growth incubated for 7 days by resazurin dye based assay | 2022 | ACS medicinal chemistry letters, Jan-13, Volume: 13, Issue:1 | Structural Rigidification of |
| AID1224523 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 1 after 7 days by micromethod | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. |
| AID528786 | Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae assessed as resistant isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. |
| AID535757 | Antimicrobial activity against community-acquired Escherichia coli expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob |
| AID534298 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA500 expressing VIM-1 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID481454 | Antibacterial activity against Escherichia coli CAN-ICU 63074 after 24 hrs by macrobroth dilution method | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. |
| AID562473 | Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase KPC-2/TEM-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. |
| AID1331869 | Antibacterial activity against Bacillus subtilis 168 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID539127 | Antibacterial activity against Staphylococcus aureus ATCC 292213 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID341106 | Antibacterial activity against metallo-beta-lactamase VIM12 expressing Escherichia coli 28 isolate from decubitus ulcer infection patient by Etest | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12. |
| AID577649 | Antimicrobial activity against Escherichia coli isolate 329 expressing beta-lactamase KPC2, CTX-M-2, TEM and PFGE cluster 2 isolated from blood of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID564019 | Antibacterial activity against Pseudomonas aeruginosa isolated from lung biopsy specimen of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID1524045 | Antimicrobial activity against Salmonella pullorum C7913 after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID533832 | Bactericidal activity against Acinetobacter baumannii ATCC BAA 747 assessed as growth rate constant for the bacterial population by time-kill study | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. |
| AID569264 | Antimicrobial activity against drug-sensitive Staphylococcus aureus RN4220 | 2011 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 | Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives. |
| AID373047 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FZ4A18 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID509856 | Antibacterial activity against Acinetobacter baumannii using MHB medium assessed as bacterial growth at 4.5 mg/L in presence of 150 mM of KCl | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID481448 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 after 24 hrs by macrobroth dilution method | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. |
| AID510512 | Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate W2AC8-S10 expressing OXA-51 | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Detection of KPC in Acinetobacter spp. in Puerto Rico. |
| AID533346 | Antibacterial activity against non-gentamicin-resistant Klebsiella pneumoniae clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID542735 | Antimicrobial activity against Klebsiella pneumoniae D10 expressing aac(6')-Ib-cr, qnrB4, CTX-M-1G and DHA-1 genes by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals. |
| AID373755 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab12 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID201751 | Minimum inhibitory concentration was measured against Serratia marcescens S69. | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID546619 | Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-18 by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID524910 | Antimicrobial activity against Mycobacterium abscessus 390R after 96 hrs | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. |
| AID532403 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone E isolate VA-06X-29 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1324764 | Bacteriostatic activity against methicillin-resistant Staphylococcus aureus S22 at MIC measured up to 3 to 6 hrs by time kill analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID549334 | Antimicrobial activity against Escherichia coli isolate 100 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID594853 | Antimicrobial activity against Escherichia coli after 24 hrs by microdilution method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID583266 | Antibacterial activity against aminoglycoside-resistant Staphylococcus epidermidis expressing ANT(4',4'')-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID533570 | Antibacterial activity against non-gentamicin-resistant Haemophilus influenzae clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID283542 | Antibacterial activity against Pseudomonas aeruginosa FE57GU with inactivated rplY, nuoG and galU genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID446124 | Antibacterial activity against APH30-VIa expressing Acinetobacter lwoffii AI.88-483 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID508481 | Antimicrobial activity against Pseudomonas aeruginosa isolate B4-25753 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID1447089 | Antibacterial activity against Acinetobacter baumannii ARC 5079 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11 | Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo. |
| AID539132 | Antibacterial activity against vancomycin-sensitive and oxymycin-, ciprofloxacin-, gentamicin-resistant Staphylococcus aureus 9269619 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID1449156 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. massiliense isolate 212 smooth variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID373987 | Antimicrobial activity against azide-resistant aac(6')-Ib-cr deficient Escherichia coli J53 qnrA1 bearing pHS4 transconjugant from Enterobacter cloacae 91 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1. |
| AID539228 | Antibacterial activity against oxymycin and gentamicin-resistant Staphylococcus epidermidis 1269677 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID94294 | Minimum inhibitory concentration was measured against Klebsiella pneumoniae 7608271 producing AAC-(3)-II modifying enzyme; Value expressed as 8/2 | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID278134 | Distribution of Escherichia coli AB1157 IL05 new born cells containing four ori foci at 16 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID498810 | Antimicrobial activity against carbapenem-resistant Escherichia coli ZJ86 deficient in KPC-2, TEM-1, ompC by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID558813 | Antimicrobial activity against Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID533567 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA465 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID572138 | Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 36 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID532402 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D4 isolate VA-06X-47 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID558792 | Antimicrobial activity against extended spectrum beta-lactamase-expressing Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID1524037 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by NCCLS-protocol based assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID515179 | Antimicrobial activity against Pseudomonas fluorescens CGMCC 1.1828 after 24 hrs by modified microdilution method | 2010 | European journal of medicinal chemistry, Oct, Volume: 45, Issue:10 | Synthesis and antimicrobial activities of novel 1H-dibenzo[a,c]carbazoles from dehydroabietic acid. |
| AID542742 | Antimicrobial activity against Citrobacter freundii D26 expressing qnrB6 and CTX-M-9G genes by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals. |
| AID1447092 | Antibacterial activity against Acinetobacter baumannii ATCC BAA 1797 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11 | Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo. |
| AID428271 | Antimicrobial activity against Klebsiella sp. assessed as resistant isolates by CLSI breakpoint assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID521836 | Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA367 containing blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, aac(6')-1b genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID278122 | Distribution of Escherichia coli AB1157 IL05 new born cells containing one ori and one ter foci at 16 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID1224527 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 131 after 7 days by micromethod | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. |
| AID201744 | Minimum inhibitory concentration was measured against Serratia marcescens 75012711 producing AAD-(2'')+AAC(6'') modifying enzyme | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID1473741 | Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID283540 | Antibacterial activity against Pseudomonas aeruginosa FE57Z with inactivated rplY and mexZ genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID283218 | Antimicrobial susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patient assessed as percent susceptible isolates | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. |
| AID1602936 | Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 4 after 7 days by resazurin microtiter assay | 2019 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8 | Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis. |
| AID1331871 | Antibacterial activity against methicillin-resistant Staphylococcus aureus | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID1324759 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID1224521 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 8666/2010 after 7 days by micromethod | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. |
| AID528826 | Antimicrobial activity against ESBL producing Klebsiella pneumoniae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID569269 | Antibacterial activity against drug-sensitive Klebsiella pneumoniae ATCC BAA-1705 | 2011 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 | Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives. |
| AID326543 | Antimicrobial activity against Mycobacterium abscessus R47 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID569266 | Antimicrobial activity against AGs-resistant Enterococcus faecalis ATCC 19433 | 2011 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3 | Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives. |
| AID1331896 | Antibacterial activity against vancomycin-resistant Enterococcus at 0.5 times MIC after 3 serial passages | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID542049 | Antibacterial activity against rifampicin resistant Escherichia coli J53-2 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. |
| AID555557 | Antimicrobial activity against Pseudomonas aeruginosa isolate 27135 expressing VIM-2 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID562759 | Antimicrobial activity against Klebsiella pneumoniae PFGE clone B expressing beta-lactamase KPC-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID1449143 | Antibacterial activity against non CF patient derived Mycobacterium abscessus subsp. abscessus isolate 3022 rough variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID542766 | Antimicrobial activity against Escherichia coli PA11 expressing aac(6')-Ib-cr, qnrS1 and qepA genes by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals. |
| AID545437 | Antimicrobial activity against extended-spectrum beta-lactamase-negative Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). |
| AID532912 | Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID530328 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pGEM-T carrying aacA4 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID574433 | Antimicrobial activity against Escherichia coli isolate 543T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID486971 | Antibacterial activity against Klebsiella pneumoniae ATCC 27736 after 24 hrs by micro broth dilution method | 2010 | European journal of medicinal chemistry, Jun, Volume: 45, Issue:6 | 'On water' assisted synthesis and biological evaluation of nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents. |
| AID373026 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA1 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID1310591 | Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method | 2016 | European journal of medicinal chemistry, Aug-08, Volume: 118 | Simple avarone mimetics as selective agents against multidrug resistant cancer cells. |
| AID285681 | Antimicrobial activity against Pseudomonas aeruginosa 29H1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID539130 | Antibacterial activity against vancomycin-, ciprofloxacin-, gentamicin-resistant Staphylococcus aureus 1269617 | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria. |
| AID572134 | Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 34 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID562947 | Antimicrobial activity against Klebsiella pneumoniae PFGE clone D expressing beta-lactamase KPC-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. |
| AID285677 | Antimicrobial activity against Pseudomonas aeruginosa 29F6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID603180 | Antibacterial activity against Escherichia coli K12 at 20 ug/ml after 24 hrs by cup plate method | 2011 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13 | Practical synthesis, anticonvulsant, and antimicrobial activity of N-allyl and N-propargyl di(indolyl)indolin-2-ones. |
| AID373986 | Antimicrobial activity against azide-resistant aac(6')-Ib-cr expressing Escherichia coli J53 qnrA1 bearing pHS3 transconjugant from Citrobacter freundii 64 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1. |
| AID499069 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ91 deficient in CTX-M-14, ompC/F by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID373764 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh11 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID498839 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ66 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID529487 | Antimicrobial activity against Enterobacter cloacae isolate 622 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID508721 | Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1C2 PTOL1 harboring beta-lactamase OXA-17 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID583255 | Antibacterial activity against aminoglycoside-resistant Enterobacter cloacae expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID373754 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab8 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID528832 | Antimicrobial activity against CTX-M ESBL producing Escherichia coli isolated from ICU patient urine assessed as resistant isolates by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. |
| AID533834 | Bactericidal activity against Acinetobacter baumannii ATCC BAA 747 assessed as maximum population size by time-kill study | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. |
| AID532396 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate FG-17X-08 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID285666 | Antimicrobial activity against Pseudomonas aeruginosa 22E3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1592959 | Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 2697/14 assessed as reduction in microbial growth incubated for 20 hrs | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. |
| AID554428 | Ratio of MIC for Pseudomonas aeruginosa mutGR1 overexpressing mexXY mutant to Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID532391 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A1 isolate FG-17X-14 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID446123 | Antibacterial activity against Acinetobacter lwoffii ATCC 17925 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID523507 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1495c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID554402 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3066 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID525040 | Antimicrobial activity against fluoroquinolone-susceptible Escherichia coli PS5 harboring GyrA S83L mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Constitutive SoxS expression in a fluoroquinolone-resistant strain with a truncated SoxR protein and identification of a new member of the marA-soxS-rob regulon, mdtG. |
| AID373029 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA7 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID404899 | Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB34 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus. |
| AID396030 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP2 plasmid containing Enterobacter cloacae acrA gene by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1577333 | Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 9449/2007 after 21 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID1435652 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 234/2005 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID549337 | Antimicrobial activity against Escherichia coli ATCC 25922 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID546621 | Antimicrobial activity against Escherichia coli harboring plasmid pPCRScript by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID583211 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID476942 | Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 hrs by browth microdilution assay | 2010 | European journal of medicinal chemistry, Apr, Volume: 45, Issue:4 | Synthesis, characterization and biological evaluation of some thiourea derivatives bearing benzothiazole moiety as potential antimicrobial and anticancer agents. |
| AID1449153 | Antibacterial activity against Addison's disease patient derived Mycobacterium abscessus subsp. massiliense isolate CIP108297 rough variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID529851 | Antibacterial activity against MexA-MexB-OprM-overproducing Pseudomonas aeruginosa OCR1 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID1629134 | Inhibition of cytosolic eukaryotic translation in rabbit reticulocyte S30 extract measured after 60 mins by coupled transcription/translation-based luciferase reporter gene assay | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID535657 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ61T harboring qnrS gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID424861 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pGTAAC-32 with cloned aac(6)'-32 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID549335 | Antimicrobial activity against Escherichia coli isolate Z1 harboring bla CTX-M-3a gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. |
| AID571918 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 23 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, aphA6 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID521842 | Antibacterial activity against Escherichia coli J53 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID558799 | Antimicrobial activity against extended spectrum beta-lactamase-expressing Klebsiella oxytoca assessed as percent susceptible isolates by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. |
| AID1684103 | Antibacterial activity against Escherichia fergusonii CU928158.2 assessed as reduction in cell viability after 24 hrs by microdilution method | 2020 | Journal of natural products, 12-24, Volume: 83, Issue:12 | Penipyranicins A-C: Antibacterial Methylpyran Polyketides from a Hydrothermal Spring Sediment |
| AID326552 | Antimicrobial activity against Mycobacterium fortuitum V61 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID774216 | Antibacterial activity against Klebsiella pneumoniae ATCC 700603 after 24 hrs by geometric microdilution method | 2013 | Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19 | Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. |
| AID92474 | Inhibitory activity against the displacement of Picogreen from fMet-tRNA(fMet) by the aminoglycoside | 2003 | Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6 | Inhibition of bacterial IF2 binding to fMet-tRNA((fMet)) by aminoglycosides. |
| AID372849 | Antimicrobial activity against azide-resistant Escherichia coli J53 transconjugant with 16S rRNA methylase armA gene expressing Acinetobacter baumannii isolate A | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID529853 | Antibacterial activity against beta-lactamase and MexA-MexB-OprM-overproducing Pseudomonas aeruginosa N045 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID583228 | Antibacterial activity against efflux pump deficient Pseudomonas aeruginosa by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID510964 | Antimicrobial activity against CTX-M15/CTX-M14 ESBL producing Escherichia coli ST131 clonal complex isolate assessed as nonsusceptible isolates by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID533349 | Antibacterial activity against non-gentamicin-resistant Citrobacter diversus clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID558051 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID373043 | Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate CY7 by CLSI agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. |
| AID499057 | Antimicrobial activity against Escherichia coli PU102T expressing TEM-1, CTX-M-14, CMY-2 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID565072 | Antibacterial activity against SHV-12 ESBL producing Klebsiella pneumoniae assessed as resistant isolates by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali. |
| AID528789 | Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 gene assessed as susceptible isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. |
| AID529865 | Ratio of MIC for Pseudomonas aeruginosa N092 to MIC for Pseudomonas aeruginosa PAO1 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. |
| AID498812 | Antimicrobial activity against Escherichia coli ZJ87 expressing KPC-2, TEM-1, ompC by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID283541 | Antibacterial activity against Pseudomonas aeruginosa FE53GU with inactivated mexZ, nuoG and galU genes by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. |
| AID528918 | Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-14 and CTX-M-27 gene assessed as susceptible isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. |
| AID1331872 | Antibacterial activity against vancomycin-resistant Enterococcus | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID1331876 | Antibacterial activity against Klebsiella pneumoniae ATCC 27736 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID523495 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1693c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1449169 | Antibacterial activity against CF patient derived Mycobacterium abscessus subsp. bolletii isolate 112 rough variant after 3 to 5 days by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections. |
| AID532393 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-26 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID372858 | Antimicrobial activity against colistin-resistant Acinetobacter baumannii 213 transconjugant with 16S rRNA methylase armA gene expressing Acinetobacter baumannii isolate E | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. |
| AID498811 | Antimicrobial activity against Escherichia coli ZJ86T expressing KPC-2 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID250261 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH05; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID523510 | Antimicrobial activity against Pseudomonas aeruginosa isolate 16008 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID533000 | Antibacterial activity against IMP-18 producing Pseudomonas aeruginosa isolate P85 exhibiting PFGE K pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID498830 | Antimicrobial activity against carbapenem-resistant Enterobacter cloacae WH103 deficient in IMP-4, TEM-1, CTX-M-3, qnrS1, ompC by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID572120 | Antimicrobial activity against Acinetobacter baumannii lambda clonal group isolate 27 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID326540 | Antimicrobial activity against Mycobacterium abscessus NTU459 isolate after 3 to 5 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. |
| AID70617 | Minimum inhibitory concentration was measured against Escherichia coli ATCC 25992. | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID1324738 | Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS51 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID498819 | Antimicrobial activity against Klebsiella pneumoniae GZ64T expressing IMP-4 by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. |
| AID534175 | Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid BEH by Etest method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates. |
| AID405816 | Antimicrobial activity against Escherichia coli DH5alpha harboring recombinant pIMPAR31 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID535900 | Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JS33T harboring qnrA gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID497951 | Antibacterial activity against Pseudomonas aeruginosa PA5063 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID529826 | Antimicrobial activity against Acinetobacter baumannii isolate 1826 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. |
| AID761215 | Antibacterial activity against Klebsiella pneumoniae 1487-07 by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID533354 | Antibacterial activity against non-gentamicin-resistant Proteus rettgeri clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. |
| AID278126 | Distribution of Escherichia coli AB1157 IL05 new born cells containing duplicated sister ori foci at 16 ug/ml after 14 hrs incubation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. |
| AID373671 | Antibacterial activity against Klebsiella pneumoniae NCIMB 9111 at 10 ug/disk after 24 hrs by agar diffusion method | 2009 | European journal of medicinal chemistry, Apr, Volume: 44, Issue:4 | Synthesis, characterization and antimicrobial activity of Co(II), Zn(II) and Cd(II) complexes with N-benzyloxycarbonyl-S-phenylalanine. |
| AID1324748 | Antibacterial activity against Staphylococcus epidermidis ATCC 35984 measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID528790 | Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 gene assessed as susceptible isolates by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. |
| AID1577335 | Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 234/2005 after 14 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID285639 | Antimicrobial activity against Pseudomonas aeruginosa 13D6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID152321 | Minimum inhibitory concentration was measured against Providencia stuartii 72052305 producing AAC-(2'') modifying enzyme | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 | New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6". Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation. |
| AID278807 | Activity against Pseudomonas aeruginosa APH(3')-2b expressed in Escherichia coli BL21(DE3) assessed as phosphorylation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa. |
| AID572146 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii unique clonal group isolate 40 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID585435 | Antimicrobial activity against Pseudomonas aeruginosa PA14 mutS gene hypermutant by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa. |
| AID285642 | Antimicrobial activity against Pseudomonas aeruginosa 15G2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID446140 | Antibacterial activity against R-methylase expressing Escherichia coli 06AB003 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID1422373 | Antibacterial activity against Escherichia coli ATCC 25922 by microdilution assay | 2018 | European journal of medicinal chemistry, Sep-05, Volume: 157 | Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines. |
| AID285636 | Antimicrobial activity against Pseudomonas aeruginosa 12A7 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID586057 | Antimicrobial activity against Acinetobacter baumannii clinical isolate harboring plasmid encoded ISAba1-blaOXA-51-like gene with nuc upstream sequence by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan. |
| AID508484 | Antimicrobial activity against Pseudomonas aeruginosa isolate BU-20287 producing metallo-beta-lactamase VIM2 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. |
| AID1172529 | Antimicrobial activity against Staphylococcus aureus | 2014 | European journal of medicinal chemistry, Nov-24, Volume: 87 | Synthetic derivatives of aromatic abietane diterpenoids and their biological activities. |
| AID1524128 | Bactericidal activity against Pseudomonas aeruginosa CICC 21630 clinical isolates incubated for 4 hrs followed by culture spread on agar plates and cultured overnight | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria. |
| AID297186 | Antibacterial activity against multidrug resistant Staphylococcus aureus 49589 | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms. |
| AID424860 | Antimicrobial activity against Escherichia coli XL1-Blue by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID508741 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent nonsusceptible isolates by broth microdilution assay | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID571888 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 8 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID594843 | Antimicrobial activity against Staphylococcus aureus at 100 ug/disc after 24 hrs by disc diffusion method | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation. |
| AID523491 | Antimicrobial activity against Pseudomonas aeruginosa Z799/61 by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID405091 | Antimicrobial activity against non-integron carrying Enterobacteriaceae assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome. |
| AID532392 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-21 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1324785 | Antibacterial activity against methicillin-resistant Staphylococcus aureus S22 using 1 10'6CFU/ml measured after overnight incubation by broth double-dilution method | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus. |
| AID446136 | Antibacterial activity against MexXY expressing Pseudomonas aeruginosa PA22 after 24 hrs by geometric microdilution method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID530330 | Antimicrobial activity against Escherichia coli XL1-Blue by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID498303 | Antibacterial activity against Pseudomonas aeruginosa PA1042 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID532910 | Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID405825 | Antimicrobial activity against Acinetobacter baumannii 694 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID1629131 | Antimicrobial activity against aminoglycoside-resistant Escherichia coli ATCC BAA-2452 measured after 24 hrs by double-dilution method | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation. |
| AID523504 | Antimicrobial activity against Pseudomonas aeruginosa isolate 15110c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID554433 | Ratio of MIC for Pseudomonas aeruginosa 3020R to MIC for Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID531753 | Antibacterial activity against Pseudomonas aeruginosa 2439 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID535758 | Antimicrobial activity against hospital-acquired Escherichia coli expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob |
| AID285628 | Antimicrobial activity against Pseudomonas aeruginosa 9A10 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID567307 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2205 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID341596 | Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID285650 | Antimicrobial activity against Pseudomonas aeruginosa 19C2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID535870 | Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ51T harboring qnrA gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. |
| AID279813 | Antimicrobial activity against Escherichia coli DH5-alpha pYW1 transformants expressing KPC2 gene by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1384 (30.48) | 18.7374 |
| 1990's | 808 (17.79) | 18.2507 |
| 2000's | 817 (17.99) | 29.6817 |
| 2010's | 1069 (23.54) | 24.3611 |
| 2020's | 463 (10.20) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (96.79) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (22.22%) | 5.53% |
| Trials | 0 (0.00%) | 5.53% |
| Trials | 485 (10.23%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Reviews | 6 (6.06%) | 6.00% |
| Reviews | 195 (4.11%) | 6.00% |
| Case Studies | 2 (22.22%) | 4.05% |
| Case Studies | 0 (0.00%) | 4.05% |
| Case Studies | 666 (14.05%) | 4.05% |
| Observational | 1 (11.11%) | 0.25% |
| Observational | 0 (0.00%) | 0.25% |
| Observational | 30 (0.63%) | 0.25% |
| Other | 4 (44.44%) | 84.16% |
| Other | 93 (93.94%) | 84.16% |
| Other | 3,363 (70.96%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Patient Satisfaction and Long-term Safety of Intravesical Aminoglycoside Instillations in UTI Prevention [NCT05376670] | 44 participants (Actual) | Observational | 2022-04-20 | Completed | |||
| Probability of Optimal Target Attainment of Amikacin in Patients With Febrile Neutropenia During Treatment for a Hematological Disorder: a Prospective, Single-centre Study and PKPD-analysis [NCT05689450] | 50 participants (Anticipated) | Observational | 2022-12-21 | Recruiting | |||
| The Effect of Colistin Inhalation on the Clinical Outcome of Patients With Ventilator Associated Pneumonia [NCT03622450] | Phase 2/Phase 3 | 40 participants (Actual) | Interventional | 2016-01-02 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact [NCT04677569] | Phase 3 | 250 participants (Anticipated) | Interventional | 2021-04-01 | Recruiting | ||
| Role of Prophylactic Antibiotics in Preventing Neonatal Sepsis in Neonates Born Through Meconium Stained Amniotic Fluid - A Randomized Controlled Trial [NCT01290003] | 250 participants (Actual) | Interventional | 2010-06-30 | Completed | |||
| Raja Isteri Pengiran Anak Saleha Appendicitis Treatment Without Operation - Antibiotic Non-operative Management Strategy Versus Surgery Management Strategy, a Non-Inferiority Randomised Controlled Trial. [NCT03169114] | 81 participants (Actual) | Interventional | 2017-11-01 | Terminated(stopped due to Poor recruitment and terminated during COVID-19 pandemic) | |||
| A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease [NCT01315236] | Phase 2 | 90 participants (Actual) | Interventional | 2012-04-19 | Completed | ||
| Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikace™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa [NCT01315691] | Phase 3 | 0 participants (Actual) | Interventional | Withdrawn | |||
| Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240] | Early Phase 1 | 11 participants (Actual) | Interventional | 2014-03-06 | Terminated(stopped due to Not enough patient enrollment and lack of staffing) | ||
| Comparison of the Impact on Digestive Portage of Broad Spectrum Beta-Lactamase-Producing Enterobacteriaceae (E-ESBLs) of Proposed Treatments in Outbreaks of Childhood Urinary Tract Infection [NCT03825874] | 200 participants (Anticipated) | Observational | 2019-01-18 | Recruiting | |||
| Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis [NCT03625739] | 800 participants (Anticipated) | Observational [Patient Registry] | 2018-07-01 | Recruiting | |||
| Randomized Phase II Study of Antibiotic Prophylaxis With Fosfomycin vs Amikacin in Transurethral Resection of Bladder [NCT04209192] | Phase 2 | 75 participants (Actual) | Interventional | 2020-01-01 | Completed | ||
| Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock [NCT04178148] | 180 participants (Actual) | Interventional | 2019-11-25 | Completed | |||
| [NCT02201082] | 15 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| In Vitro Comparison of Continuous and Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation: Analysis of Inhaled and Lost Doses. [NCT02084043] | 3 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum [NCT00042289] | 1,578 participants (Actual) | Observational | 2003-06-09 | Completed | |||
| Evaluation of the Safety and Efficacy of Nebulized Amikacin as Adjunctive Therapy in Hospital Acquired and Ventilator Associated Bacterial Pneumonia in Surgical Intensive Care Units [NCT02728518] | 133 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| Which Apparatus for Inhaled Pentamidine? A Comparison of Drug Delivery to the Lung Between Two Nebulizers: The Respirgard II and the Isoneb. [NCT02277808] | Early Phase 1 | 10 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| Evaluation of the Incidence of Necrotizing Enterocolitis in Preterm Infants With Respiratory Distress Syndrome Undergoing Caffeine Therapy [NCT06097767] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2023-10-19 | Active, not recruiting | ||
| Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) [NCT04310930] | Phase 2/Phase 3 | 300 participants (Anticipated) | Interventional | 2020-03-02 | Recruiting | ||
| "Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis (Stake) Amendment to Study Protocol: All-oral Shorter Treatment Regimen for Multidrug- and Rifampicin-resistant Tub [NCT05555303] | Phase 2 | 20 participants (Anticipated) | Interventional | 2023-03-01 | Recruiting | ||
| Long Term Safety and Tolerability Study of Open-Label Liposomal Amikacin for Inhalation (ARIKACE™) in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa [NCT01316276] | Phase 3 | 206 participants (Actual) | Interventional | 2012-10-05 | Completed | ||
| A Double-Blind, Placebo-controlled Parallel Group, Phase II Dose-Ranging Study of Nebulized Amikacin Delivered Via the Pulmonary Drug Delivery System (PDDS) in Ventilated Patients With Nosocomial Pneumonia Due to Gram Negative Organisms [NCT01004445] | Phase 2 | 69 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Prospective Randomised Trial of 'Area Under the Curve' (AUC) Dosing Strategy for Intravenous Tobramycin Versus Standard Trough Dosing for Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis (CF) [NCT02489955] | 0 participants | Interventional | 2015-02-28 | Recruiting | |||
| Antibiotic Dosing in Pediatric Intensive Care [NCT02456974] | 640 participants (Anticipated) | Observational [Patient Registry] | 2012-05-31 | Recruiting | |||
| Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia [NCT04948463] | Phase 4 | 312 participants (Anticipated) | Interventional | 2021-11-15 | Recruiting | ||
| Impact of Imipenem With Amikacin Pharmacokinetic and Pharmacodynamic [NCT00950222] | 70 participants (Actual) | Interventional | 2009-06-30 | Completed | |||
| Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) in Cystic Fibrosis Patients With Chronic Infections Due to Pseudomonas Aeruginosa [NCT03905642] | Phase 2 | 49 participants (Actual) | Interventional | 2009-01-08 | Completed | ||
| Assessment of Efficiency of Nebulized Ceftazidime and Amikacin in Treatment of Ventilator Associated Pneumonia Caused by Pseudomonas Aeruginosa [NCT00786305] | Phase 2 | 40 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| [NCT02535130] | 15 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | |||
| A Randomized Double-Blind, Placebo-Controlled, Crossover to Open Label, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow® AFIS Inline System in Mechanically Ventilated Patients With Gram-negative and/or Gram-pos [NCT02218359] | Phase 2 | 0 participants (Actual) | Interventional | 2014-10-31 | Withdrawn(stopped due to No Participants Enrolled) | ||
| Inhaled Amikacin in Preventing Acute Exacerbation of Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD): a Multicenter Clinical Study [NCT05213507] | Phase 3 | 136 participants (Anticipated) | Interventional | 2022-03-31 | Not yet recruiting | ||
| A Randomized, Parallel, Controlled, Exploratory Study: the Efficacy and Safety of Taking Probiotics, Inhaled Antibiotics or Combined Vaccination to Prevent Acute Exacerbation in Subjects With Moderate to Severe COPD and Decolonize Bacteria in Lower Respir [NCT03449459] | Early Phase 1 | 144 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
| Dose Optimization by PK/PD of Antibiotics to Improve Clinical Outcome of CRKP Bloodstream Infections in Critically Ill Patients and in Vitro Study of Monotherapy, Combination Therapy and Molecular Biology of Drug Resistance at Phramongkutklao Hospital: Pr [NCT05862402] | Phase 4 | 76 participants (Anticipated) | Interventional | 2023-05-07 | Recruiting | ||
| Phase 2a Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) In Cystic Fibrosis Patients With Chronic Infections Due To Pseudomonas Aeruginosa. [NCT00777296] | Phase 1/Phase 2 | 66 participants (Actual) | Interventional | 2007-02-22 | Completed | ||
| Prospective Study Evaluating Plasma Exposure of Optimized Antibiotic Therapy According to TDM in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC) [NCT04132115] | 104 participants (Anticipated) | Observational | 2019-10-01 | Recruiting | |||
| An Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the PARI Investigational eFlow Nebulizer System or the PARI LC Sprint Nebulizer in Healthy Volunteers [NCT02709265] | Phase 1 | 30 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Comparison of Amukin Versus Biseptine Use for Dressing Application of Epicutaneocavous Catheters for Nosocomial Infection Prevention [NCT00389558] | Phase 4 | 453 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Amikacin Pharmacokinetic Profile in Plasma and Tissue After an Administration Using Impregnated Dressings in Burned Patient Population [NCT02872272] | Phase 4 | 75 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | ||
| Phase II Study of High Dose Nebulized Amikacin in Patients With Pneumonia Undergoing Mechanical Ventilation [NCT00861315] | Phase 2/Phase 3 | 24 participants (Anticipated) | Interventional | 2009-01-31 | Recruiting | ||
| A Placebo Controlled, Randomized, Parallel Cohort, Safety And Tolerability Study Of 2 Dose Levels Of Liposomal Amikacin For Inhalation (Arikayce™) In Patients With Bronchiectasis Complicated By Chronic Infection Due To Pseudomonas Aeruginosa. [NCT00775138] | Phase 2 | 64 participants (Actual) | Interventional | 2008-06-24 | Completed | ||
| Clinical Outcome of Newborn Infants With Suspected Nosocomial Coagulase-negative Staphylococcal Sepsis Treated With Cefazolin or Vancomycin. A Non-inferiority, Randomized, Controlled Trial [NCT01867138] | Phase 3 | 109 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| An Open-Label, Multicenter, Multinational Study to Assess the Safety,Tolerability and Pharmacokinetics of Aerosolized Amikacin Delivered Via the Pulmonary Drug Delivery System (NKTR-061) in Intubated and Mechanically- Ventilated Patients With Nosocomial P [NCT01021436] | Phase 2 | 30 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Single Dose Amikacin for Uncomplicated Cystitis in the Emergency Department (ED): A Feasibility Study [NCT05227937] | 75 participants (Anticipated) | Observational | 2022-09-21 | Recruiting | |||
| Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria [NCT02574130] | 60 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| Pharmacokinetic Evaluation and Local Tolerability of Dry Powder Amikacin Via the Cyclops™ in Patients With Drug Susceptible Tuberculosis [NCT04249531] | Phase 1 | 8 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | ||
| A Single-center, Open-label, Two Sequence, Crossover Study to Investigate the Interaction Between Amikacin and POL7080 in Healthy Subjects [NCT02897869] | Phase 1 | 14 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment [NCT02628600] | Phase 3 | 163 participants (Actual) | Interventional | 2016-02-05 | Completed | ||
| Inhaled Amikacin for Treatment of Intractable Nontuberculous Mycobacterial Lung Disease [NCT01528930] | Phase 2 | 0 participants (Actual) | Interventional | 2012-02-29 | Withdrawn(stopped due to Although this study was approved at the Institutional Review Board, Korea Food & Drug Administration (KFDA) did not approve this study due to safety concern.) | ||
| Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa [NCT01315678] | Phase 3 | 302 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care [NCT01431326] | 3,520 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| A Randomized, Controlled Study of Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis [NCT02081963] | Phase 4 | 178 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Comparison of Efficacy, Safety and Economic Outcomes Between Once-Daily Versus Twice-Daily Amikacin in Combination With Cloxacillin in Febrile Neutropenic Children [NCT00129688] | 166 participants | Interventional | 2002-04-30 | Completed | |||
| A Gamma Scintigraphy Study to Investigate the Lung Deposition of Inhaled Amikacin-Loaded Liposomes in Healthy Male Volunteers [NCT05999942] | Phase 1 | 6 participants (Actual) | Interventional | 2004-06-02 | Completed | ||
| Observed Pharmacokinetic of Piperacillin/Tazobactam in ICU Patients Compared to Therapeutic Drug Monitoring of Amikacin [NCT03990467] | 60 participants (Anticipated) | Interventional | 2021-01-28 | Recruiting | |||
| A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia [NCT01799993] | Phase 3 | 725 participants (Actual) | Interventional | 2013-04-13 | Completed | ||
| Impact of 30 mg/kg Amikacin and 8 mg/kg Gentamicin on Serum Concentrations in Critically Ill Patients With Severe Sepsis [NCT02898961] | Phase 4 | 63 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit [NCT00445094] | Phase 4 | 120 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals. [NCT00000641] | Phase 2 | 90 participants | Interventional | Completed | |||
| Platelet Rich Fibrin in Combination With Topical Antibiotics or Antiseptics in the Treatment of Chronic Wounds - a Prospective, Randomized, Active Controlled, Double Blind Pilot Trial With an Observer-blinded Control Group [NCT02652169] | 120 participants (Anticipated) | Interventional | 2014-06-30 | Recruiting | |||
| Standard vs. Biofilm Susceptibility Testing in CF [NCT00153634] | 75 participants (Actual) | Interventional | 2004-03-31 | Completed | |||
| Clinical Efficacy and Safety of Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis:An Open-label Randomized Parallel Controlled Study [NCT02509091] | Phase 4 | 100 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| Evaluation of Directed Antimicrobial Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy (TRUSP) [NCT01659866] | Phase 4 | 563 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avi [NCT04677543] | Phase 3 | 99 participants (Actual) | Interventional | 2020-12-22 | Completed | ||
| Double-blinded Multicenter Randomized Controlled Trial Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia [NCT03149640] | Phase 3 | 850 participants (Actual) | Interventional | 2017-07-19 | Completed | ||
| A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in [NCT00000796] | 525 participants | Interventional | Completed | ||||
| Amikacin Pharmacokinetics to Optimize Dosing Recommendations and Patho(Physiological) Considerations in Neonates With Perinatal Asphyxia Treated With Hypothermia [NCT04867993] | 80 participants (Anticipated) | Interventional | 2018-08-28 | Recruiting | |||
| A Randomized, Open Label, Multicentre Phase Iv Study To Evaluate The Efficacy And Safety Of Magnex (Cefoperazone-Sulbactam) In Comparison With Ceftazidime Plus Amikacin And Metronidazole In The Treatment Of Intra-Abdominal Infections [NCT00360607] | Phase 4 | 307 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Amikacin Penetration Into the Cerebrospinal Fluid: Pharmacokinetic/Pharmacodynamic Analysis in Adults With Hospital Acquired Gram-negative Meningitis Associated With Intracranial Pressure Monitoring and Draining Devices [NCT00362245] | Phase 4 | 0 participants (Actual) | Interventional | 2006-09-30 | Withdrawn(stopped due to lack of participants) | ||
| Population Pharmacokinetics of Amikacin in Suspected Cases of Neonatal Sepsis: Multicenter Study [NCT04867135] | 138 participants (Actual) | Observational | 2019-12-01 | Completed | |||
| Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Amikacin in Patients With Severe Sepsis or Septic Shock Admitted at the Emergency Department(ED) [NCT02365272] | Phase 4 | 100 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Metabolic Potentiation of Aminoglycosides: a Novel Antimicrobial Strategy to Prevent Urinary Tract Infections (UROPOT TRIAL). [NCT05761405] | Early Phase 1 | 90 participants (Anticipated) | Interventional | 2023-10-16 | Not yet recruiting | ||
| Safety and Efficacy of Fixed-low-dose Amikacin for Urinary Tract Infection on the Elderly Patient [NCT04197739] | Phase 4 | 200 participants (Anticipated) | Interventional | 2019-12-31 | Not yet recruiting | ||
| A Randomized Blinded, Placebo-Controlled, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow® Inline System in Mechanically Ventilated Patients With Gram-negative Bacterial Pneumonia (IASIS) [NCT01969799] | Phase 2 | 143 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Population Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Septic Patients Admitted to the ICU or the ED [NCT04470973] | 40 participants (Anticipated) | Observational | 2020-07-15 | Recruiting | |||
| A Randomized, Open-label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment [NCT02344004] | Phase 3 | 336 participants (Actual) | Interventional | 2015-05-27 | Completed | ||
| Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Hospitalized Subjects With Pneumonia Requiring Mechanical Ventilation [NCT01570192] | Phase 2 | 43 participants (Actual) | Interventional | 2010-09-30 | Terminated(stopped due to NIAID terminated the study due to low subject enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||